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The critical role of the microbiology laboratory in infectious disease diagnosis calls for a close, positive working
relationship between the physician and the microbiologists who provide enormous value to the health care
team. This document, developed by both laboratory and clinical experts, provides information on which tests
are valuable and in which contexts, and on tests that add little or no value for diagnostic decisions. Sections are
divided into anatomic systems, including Bloodstream Infections and Infections of the Cardiovascular System,
Central Nervous System Infections, Ocular Infections, Soft Tissue Infections of the Head and Neck, Upper Re-
spiratory Infections, Lower Respiratory Tract infections, Infections of the Gastrointestinal Tract, Intraabdomi-
nal Infections, Bone and Joint Infections, Urinary Tract Infections, Genital Infections, and Skin and Soft
Tissue Infections; or into etiologic agent groups, including Tickborne Infections, Viral Syndromes, and Blood
and Tissue Parasite Infections. Each section contains introductory concepts, a summary of key points, and de-
tailed tables that list suspected agents; the most reliable tests to order; the samples (and volumes) to collect in
order of preference; specimen transport devices, procedures, times, and temperatures; and detailed notes on
specific issues regarding the test methods, such as when tests are likely to require a specialized laboratory or
have prolonged turnaround times. There is redundancy among the tables and sections, as many agents and
assay choices overlap. The document is intended to serve as a reference to guide physicians in choosing tests
that will aid them to diagnose infectious diseases in their patients.
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Common abbreviations used throughout the text:
CSF, cerebrospinal fluid; DFA, direct fluorescent antibody;
EIA, enzyme immunoassay; GI, gastrointestinal; IFA, indirect
fluorescent antibody; IIF, indirect immunofluorescence; MRSA,
methicillin-resistant Staphylococcus aureus; NAAT, nucleic acid
amplification test; PMN, polymorphonuclear neutrophil; RPR,
rapid plasma reagin (test for syphilis); RT, room temperature;
VRE, vancomycin-resistant enterococcus; WBC, white blood cell
EXECUTIVE SUMMARY
Introduction
Unlike other areas of the diagnostic laboratory, clinical microbi-
ology is a science of interpretive judgment that is becoming
more complex, not less. Even with the advent of laboratory auto-
mation and the integration of genomics and proteomics in mi-
crobiology, interpretation of results still depends on the quality
of the specimens received for analysis. Prokaryotic microorgan-
isms, while genetically less complex than multicellular eukary-
otes, are uniquely suited to adapt to environments where
antibiotics and host responses apply pressures that encourage
their survival. A laboratory instrument may or may not detect
those mutations, so a specialist in microbiology is needed to facil-
itate microbiology laboratory result interpretation. Clearly, all
microbes grow, multiply, and die very quickly. If any of those
events occur during specimen collection, transport, or storage,
the results of analysis will be compromised and interpretation
could be misleading. Therefore, attention to preanalytical speci-
men management in microbiology is critical to accuracy.
Physicians need confidence that the results provided by the
microbiology laboratory are accurate, significant, and clinically
relevant. Anything less is below the community standard of care.
In order to provide that level of quality, however, the laboratory
requires that all microbiology specimens be properly selected, col-
lected, and transported to optimize analysis and interpretation.
Because result interpretation in microbiology depends entirely on
the quality of the specimen submitted for analysis, specimen
management cannot be left to chance, and those that collect spec-
imens for microbiologic analysis must be aware of what the phy-
sician needs as well as what the laboratory needs, including
ensuring that specimens arrive at the laboratory for analysis as
quickly as possible after collection (Introduction-Table 1).
At an elementary level, the physician needs answers to 3 very
basic questions from the laboratory: Is my patient’s illness
caused by a microbe? If so, what is it? What is the susceptibility
profile of the organism so therapy can be targeted? To meet
those needs, the laboratory requires very different information.
The microbiology laboratory needs a specimen that has been
appropriately selected, collected, and transported to the
laboratory for analysis. Caught in the middle, between the phy-
sician and laboratory, are those who select and collect the speci-
men and who may not know or understand what the physician
or the laboratory needs to do their work. Enhancing the quality
of the specimen is everyone’s job, so communication between
the physicians, nurses, and laboratory staff should be encour-
aged and open with no punitive motive or consequences.
The diagnosis of infectious disease is best achieved by apply-
ing in-depth knowledge of both medical and laboratory science
along with principles of epidemiology and pharmacokinetics of
antibiotics and by integrating a strategic view of host-parasite













































device, RT, 2 h




Swab – flocked swabs
are recommended
Virus swab transport
device, RT, 2 h
Suspected agent
of bioterrorism




Serology 5 mL serum Clot tube, RT, 2 h






NAAT 5 mL plasma EDTA tube, RT, 2 h
Other specimen Closed container,
RT, 2 h
Abbreviations: AFB, acid-fast bacillus; NAAT, nucleic acid amplification test;
RT, Room Temperature.
a Contact the microbiology laboratory regarding appropriate collection and
transport devices and procedures since transport media such as Cary-Blair or
parasite preservative transport for stool specimens, boric acid for urines,
specialized containers for Mycobacterium tuberculosis are often critical for
successful examination. The time from collection to transport listed will
optimize results; longer times may compromise results.
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interactions. Clearly, the best outcomes for patients are the
result of strong partnerships between the clinician and the lab-
oratorian specialist. This document illustrates this partnership
and emphasizes the importance of appropriate specimen man-
agement to clinical relevance of the results. One of the most
valuable laboratory partners in infectious disease diagnosis is
the certified microbiology specialist, particularly a specialist
certified as a Diplomate by the American Board of Medical Mi-
crobiology (ABMM), the American Board of Pathology (ABP),
or the American Board of Medical Laboratory Immunology
(ABMLI) or their equivalent certified by other organizations.
Clinicians should recommend and medical institutions should
provide this kind of leadership for the microbiology laboratory
or provide formal access to this level of laboratory expertise
through consultation.
Impact of Specimen Management
Microbiology specimen selection and collection are the respon-
sibility of the medical staff, not usually the laboratory, although
the certified specialist may be called upon for consultation or
assistance. The impact of proper specimen management on
patient care is enormous. It is the key to accurate laboratory di-
agnosis and confirmation, it directly affects patient care and
patient outcomes, it influences therapeutic decisions, it impacts
hospital infection control, it impacts patient length of stay, hos-
pital costs, and laboratory costs, and influences laboratory effi-
ciency. Clinicians should consult the laboratory to ensure that
selection, collection, transport, and storage of patient speci-
mens are performed properly.
Tenets of Specimen Management
Throughout the text, there will be caveats that are relevant to
specific specimens and diagnostic protocols for infectious
disease diagnosis. However, there are some strategic tenets of
specimen management and testing in microbiology that stand
as community standards of care and that set microbiology
apart from other laboratory departments such as chemistry or
hematology. Ten points of importance are:
1. Specimens of poor quality must be rejected. Microbiolo-
gists act correctly and responsibly when they call physicians to
clarify and resolve problems with specimen submissions.
2. Physicians should not demand that the laboratory report
“everything that grows,” thus providing irrelevant information
that could result in inaccurate diagnosis and inappropriate
therapy.
3. “Background noise” must be avoided where possible.
Many body sites have normal microbiota that can easily con-
taminate the specimen. Therefore, specimens from sites such as
lower respiratory tract (sputum), nasal sinuses, superficial
wounds, fistulae, and others require care in collection.
4. The laboratory requires a specimen, not a swab of a speci-
men. Actual tissue, aspirates, and fluids are always specimens of
choice, especially from surgery. A swab is not the specimen of
choice for many specimens because swabs pick up extraneous mi-
crobes, hold extremely small volumes of the specimen (0.05 mL),
make it difficult to get bacteria or fungi away from the swab fibers
and onto media, and the inoculum from the swab is often not
uniform across several different agar plates. Swabs are expected
from nasopharyngeal and viral respiratory infections. Flocked
swabs have become a valuable tool for specimen collection and
have been shown to be more effective than Dacron, rayon, and
cotton swabs in many situations. The flocked nature of the swab
allows for more efficient release of contents for evaluation.
5. The laboratory must follow its procedure manual or face
legal challenges. These manuals are usually supported by the
literature.
6. A specimen should be collected prior to administration of
antibiotics. Once antibiotics have been started, the flora
changes, leading to potentially misleading culture results.
7. Susceptibility testing should be performed on clinically
significant isolates, not on all microorganisms recovered in
culture.
8. Microbiology laboratory results that are reported should
be accurate, significant, and clinically relevant.
9. The laboratory should be allowed to set technical policy;
this is not the purview of the medical staff. Good communica-
tion and mutual respect will lead to collaborative policies.
10. Specimens must be labeled accurately and completely so
that interpretation of results will be reliable. Labels such as
“eye” and “wound” are not helpful to the interpretation of
results without more specific site and clinical information (eg,
dog bite wound right forefinger).
The microbiology laboratory policy manual should be avail-
able at all times for all medical staff to review or consult and it
would be particularly helpful to encourage the nursing staff to
review the specimen collection and management portion of the
manual. This can facilitate collaboration between the laborato-
ry, with the microbiology expertise, and the specimen collec-
tion personnel, who may know very little about microbiology
or what the laboratory needs in order to establish or confirm a
diagnosis.
Welcome and engage the microbiology laboratory as an inte-
gral part of the healthcare team and encourage the hospital or
the laboratory facility to have board-certified laboratory special-
ists on hand or available to optimize infectious disease labora-
tory diagnosis.
How to Use This Document
The full text of this document, available online, is organized by
body system, although many organisms are capable of causing
disease in more than one body system. There may be a
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redundant mention of some organisms because of their pro-
pensity to infect multiple sites. One of the unique features of
this document is its ability to assist clinicians who have specific
suspicions regarding possible etiologic agents causing a specific
type of disease. Another unique feature is that in most sections,
there are targeted recommendations and precautions regarding
selecting and collecting specimens for analysis for a disease
process. Within each section, there is a table describing the
specimen needs regarding a variety of etiologic agents that one
may suspect as causing the illness. The test methods in the
tables are listed in priority order according to the recommenda-
tions of the authors and reviewers.
When room temperature (RT) is specified for a certain time
period, such as 2 hours, it is expected that the sample should be
refrigerated after that time unless specified otherwise in that
section. Almost all specimens for virus detection should be
transported on wet ice and frozen at −80°C if testing is delayed
>48 hours, although specimens in viral transport media may be
transported at room temperature when rapid (<2 hours) deliv-
ery to the laboratory is assured.
History and Update
The document has been endorsed by the Infectious Diseases
Society of America (IDSA) and the American Society for
Microbiology (ASM). Future modifications are to be expected,
as diagnostic microbiology is a dynamic and rapidly changing
discipline.
I. BLOODSTREAM INFECTIONS AND
INFECTIONS OF THE CARDIOVASCULAR
SYSTEM
A. Bloodstream Infections and Infective Endocarditis
The diagnosis of bloodstream infections (BSIs) is one of the
most critical functions of clinical microbiology laboratories. For
the great majority of etiologic agents of BSIs, conventional blood
culture methods provide results within 48 hours; incubation for
more than 5 days seldom is required when modern automated
continuous-monitoring blood culture systems and media are
used [1, 2]. This includes recovery of historically fastidious or-
ganisms such as HACEK [1] (Haemophilus, Aggregatibacter,
Cardiobacterium, Eikenella, and Kingella) bacteria and Brucella
spp [3, 4]. Some microorganisms, such as mycobacteria and di-
morphic fungi, require longer incubation periods; others may
require special culture media or non-culture-based methods.
Although filamentious fungi often require special broth media or
lysis-centrifugation vials for detection, Candida spp tend to grow
very well in standard blood culture broths unless the patient has
been on antifungal therapy. Unfortunately, blood cultures from
patients with suspected candidemia do not yield positive results
in almost half of patients. Table I-1 below provides a summary of
diagnostic methods for most BSIs.
For most etiologic agents of infective endocarditis, conven-
tional blood culture methods will suffice [3–5]. However, some
less common etiologic agents cannot be detected with current
blood culture methods. The most common etiologic agents of
culture-negative endocarditis, Bartonella spp and Coxiella bur-
netii, often can be detected by conventional serologic testing.
However, molecular amplification methods may be needed for
detection of these organisms as well as others (eg, Tropheryma
whipplei). In rare instances of culture-negative endocarditis,
16S polymerase chain reaction (PCR) and DNA sequencing of
valve tissue may help determine an etiologic agent.
The volume of blood that is obtained for each blood culture
request (also known as a blood culture set, consisting of all
bottles procured from a single venipuncture or during one cathe-
ter draw) is the most important variable in recovering bacteria
and fungi from patients with bloodstream infections [1, 2, 5, 6].
For adults, 20–30 mL of blood per culture set (depending on the
manufacturer of the instrument) is recommended and may
require more than 2 bottles depending on the system. For chil-
dren, an age- and weight-appropriate volume of blood should be
cultured (see Table I-1a for recommended volumes). A second
important determinant is the number of blood culture sets per-
formed during a given septic episode. Generally, in adults with a
suspicion of BSI, 2–4 blood culture sets should be obtained in
the evaluation of each septic episode [5, 7].
The timing of blood culture orders should be dictated by
patient acuity. In urgent situations, 2 or more blood culture sets
can be obtained sequentially over a short time interval, after
which empiric therapy can be initiated. In less urgent situa-
tions, obtaining blood culture sets may be spaced over several
hours or more.
Contaminated blood culture bottles are common, very costly
to the healthcare system, and frequently confusing to clinicians.
To minimize the risk of contamination of the blood culture with
commensal skin flora, meticulous care should be taken in skin
preparation prior to venipuncture. Consensus guidelines [2] and
expert panels [1] recommend peripheral venipuncture as the pre-
ferred technique for obtaining blood for culture based on data
showing that blood obtained in this fashion is less likely to be
contaminated than blood obtained from an intravascular cathe-
ter or other device. Several studies have documented that iodine
tincture, chlorine peroxide, and chlorhexidine gluconate (CHG)
are superior to povidone-iodine preparations as skin disinfec-
tants for blood culture (data summarized in refs [1] and [2]).
Iodine tincture and CHG require about 30 seconds to exert an
antiseptic effect compared with 1.5–2 minutes. for povidone-
iodine preparations [2]. CHG is not recommended for use in
infants less than 2 months of age.
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Table I-1. Blood Culture Laboratory Diagnosis Organized by Etiologic Agent
Etiologic Agents Diagnostic Procedures Optimum Specimens Transport Issues
Staphylococcus spp Adults: 20–30 mL of blood per culture set in
adults injected into at least 2 blood
culture bottlesa
Inoculated culture vials should be
transported to the Laboratory as
soon as possible (ASAP) at RT,
organisms will usually survive in









Acinetobacter spp Infants and children: Blood volume depends on the child’s
weight (see Table in footnote 3)b
HACEKc bacteria 2 or more blood culture sets
Brucella spp
Anaerobic bacteria
Bartonella spp 2 or more lysis- centrifugation
(Isolator) blood culture vialsd
10 mL of blood should be inoculated
directly into each lysis-
centrifugation culture vial
Lysis-centrifugation culture vials
should be transported at RT to the
laboratory ASAP and processed
within 8 h of blood inoculation
NAAT 5 mL of plasma EDTA tube, RT, 2 h
Legionella spp 2 or more lysis- centrifugation
(Isolator) blood culture vialse
10 mL of blood should be inoculated
directly into each lysis-
centrifugation culture vial
Lysis-centrifugation culture vials
should be transported at RT to the
laboratory ASAP and processed
within 8 h of blood inoculation
Legionella urine antigen test
(for serotype 1)
10 mL of mid-stream, clean-catch
urinef
Closed container, RT, 2 h
Coxiella burnetii Coxiella IFA serology 5 mL of serum Clot tube, RT, 2 h
NAAT 5 mL of plasma EDTA tube, RT, 2 h
Tropherymawhipplei NAAT 5 mL of plasma EDTA tube, RT, 2 h
Yeast Adults: 2–4 blood culture sets
(see above)
20–30 mL of blood per culture in
adults injected into at least 2 blood
culture bottlesg
Inoculated culture vials should be
transported ASAP at RT to the
laboratory for early incubation
Infants and children: 2 or more
blood culture sets (see
above)
As much blood as can be
conveniently obtained from
children; volume depends on
weight of child (see following
table)b
Organisms will usually survive in
inoculated culture vials even if not
incubated immediately.Malassezia
spp require lipid supplementation;
lysis-centrifugation is
recommended for their recovery.
Filamentous and
dimorphic fungih
2 or more lysis- centrifugation
(Isolator) blood culture vials
10 mL of blood should be inoculated
directly into each lysis-
centrifugation culture vial
Lysis-centrifugation culture vials
should be transported to the
laboratory ASAP and processed
within 8 h of blood inoculation
Mycobacteria 3 cultures using AFB-specific
blood culture bottles
5 mL of blood inoculated directly into
AFB-specific blood culture bottle
Inoculated culture vials should be
transported to the laboratory ASAP
for early incubation
Abbreviations: AFB, acid fast bacillus; IFA, indirect fluorescent antibody; NAAT, nucleic acid amplification test; RT, room temperature.
a Typically, blood specimens are split between aerobic and anaerobic blood culture bottles. There may be circumstances in which it is prudent to omit the anaerobic
vial and split blood specimens between 2 aerobic vials. One example is when fungemia due to yeast is strongly suspected. Most manufacturers’ bottles accept a
maximum of 10 mL per bottle.
b Recommended volumes of blood for culture in pediatric patients (Table I-1a) [1].
c HACEK bacteria include Haemophilus (Aggregatibacter) aphrophilus, Haemophilus parainfluenzae, Aggregatibacter (formerly Actinobacillus)
actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae.
d The success rate for recovery of Bartonella spp from blood even when optimummethods are used is extremely low.
e Legionella bacteremia occurs infrequently and rarely is the organism recovered from blood even when optimum culture techniques are employed.
f The optimum urine specimen is the first voided specimen of the day.
g Because yeast are highly aerobic, when fungemia due to yeast is suspected, it might be prudent within a series of blood cultures, to inoculate at least 1 blood
specimen into 2 aerobic vials rather than the customary aerobic and anaerobic vial pair. Alternatively, a broth medium designed for enhanced yield of yeast (eg,
MycoF/Lytic [BD Diagnostics, Sparks, MD]) or lysis-centrifugation may be used.
h Some dimorphic fungi and yeasts (eg,Malassezia spp) may be visualized on peripheral blood smears in some patients using one of a variety of fungal stains. Such
requests should be made in consultation with the Microbiology Laboratory director.
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Blood cultures contaminated with skin flora during collec-
tion are common, but contamination rates should not exceed
3%. Laboratories should have policies and procedures for ab-
breviating the work-up and reporting of common blood culture
contaminants (eg, coagulase-negative staphylococci, viridans
group streptococci, diphtheroids, Bacillus species other than B.
anthracis). These procedures may include abbreviated identifi-
cation of the organism, absence of susceptibility testing, and a
comment that instructs the clinician to contact the laboratory if
the culture result is thought to be clinically significant and re-
quires additional work-up and susceptibility results.
Physicians should expect to be called and notified by the lab-
oratory every time a blood culture becomes positive because
these specimens often represent life-threatening infections. If
the physician wishes not to be notified during specific times, ar-
rangements must be made by the physician for a delegated
healthcare professional to receive the call and relay the report.
Key points for the laboratory diagnosis of bacteremia/funge-
mia:
• Volume of blood collected, not timing, is most critical.
• Disinfect the venipuncture site with chlorhexidine or 2%
iodine tincture in adults and children >2 months old (chlorhex-
idine NOT recommended for children <2 months old).
• Draw blood for culture before initiating antimicrobial
therapy.
• Catheter-drawn blood cultures have a higher risk of con-
tamination (false positives).
• Do not submit catheter tips for culture without an ac-
companying blood culture obtained by venipuncture.
• Never refrigerate blood prior to incubation.
• Use a 2–3 bottle blood culture set for adults, at least one
aerobic and one anaerobic; use 1–2 aerobic bottles for children.
• Streptococcus pneumoniae and some other gram-positive
organisms may grow best in the anaerobic bottle.
B. Infections Associated With Vascular Catheters
The diagnosis of catheter-associated BSIs often is one of exclu-
sion, and a microbiologic gold standard for diagnosis does not
exist. Although a number of different microbiologic methods
have been described, the available data do not allow firm con-
clusions to be made about the relative merits of these various
diagnostic techniques [8, 9]. Fundamental to the diagnosis of
catheter-associated BSI is documentation of bacteremia. The
clinical significance of a positive culture from an indwelling
catheter segment or tip in the absence of positive blood cultures
is unknown. The next essential diagnostic component is dem-
onstrating that the infection is caused by the catheter. This
usually requires exclusion of other potential primary foci for
the BSI.
Numerous diagnostic techniques for catheter cultures have
been described and may provide adjunctive evidence of cathe-
ter-associated BSI; however, all have potential pitfalls that make
interpretation of results problematic. Routine culture of intrave-
nous (IV) catheter tips at the time of catheter removal has no
clinical value and should not be done [10]. Although not per-
formed in most laboratories, the methods described include the
following:
• Time to positivity (not performed routinely in most labo-
ratories): Standard blood cultures (BCs) obtained at the same
time, one from the catheter or port and one from peripheral ve-
nipuncture, processed in a continuous-monitoring blood
culture system. If both BCs grow the same organism and the
BC drawn from the device becomes positive more than 2 hours
before the BC drawn by venipuncture, there is a high probabili-
ty of catheter-associated BSI [11].
• Quantitative BCs (not performed routinely in most labora-
tories): one from catheter or port and one from peripheral veni-
puncture obtained at the same time using lysis-centrifugation
(Isolator) or pour plate method. If both BCs grow the same or-
ganism and the BC drawn from the device has 5-fold more
















≤1 50–99 2 . . . 2 4
1.1–2 100–200 2 2 4 4
2.1–12.7 >200 4 2 6 3
12.8–36.3 >800 10 10 20 2.5
>36.3 >2200 20–30 20–30 40–60 1.8–2.7
When 10 mL of blood or less is collected, it should be inoculated into a single aerobic blood culture bottle.
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organisms than the BC drawn by venipuncture, there is a high
probability of catheter-associated BSI [12].
• Catheter tip or segment cultures: The semiquantitative
method of Maki et al [10] is used most commonly; interpreta-
tion requires an accompanying peripheral blood culture.
However, meticulous technique is needed to reduce contamina-
tion and to obtain the correct length (5 cm) of the distal cathe-
ter tip. This method only detects organisms colonizing the
outside of the catheter, which is rolled onto an agar plate after
which the number of colonies is counted; organisms that may
be intraluminal are missed. Modifications of the Maki method
have been described as have methods that utilize vortexing of
the catheter tip or an endoluminal brush (not performed rou-
tinely in most laboratories). Biofilm formation on catheter tips
prevents antimicrobial therapy from clearing agents within the
biofilm, thus requiring removal of the catheter to eliminate the
organisms.
C. Infected (Mycotic) Aneurysms and Vascular Grafts
Infected (mycotic) aneurysms and infections of vascular grafts
may result in positive blood cultures. Definitive diagnosis re-
quires microscopic visualization and/or culture recovery of eti-
ologic agents from representative biopsy or graft material
(Table I-2).
D. Pericarditis and Myocarditis
Numerous viruses, bacteria, rickettsiae, fungi, and parasites
have been implicated as etiologic agents of pericarditis and
myocarditis. In many patients with pericarditis and in the
overwhelming majority of patients with myocarditis, an etio-
logic diagnosis is never made and patients are treated empiri-
cally. In selected instances when it is important clinically to
define the specific cause of infection, a microbiologic diagno-
sis should be pursued aggressively. Unfortunately, however,
the available diagnostic resources are quite limited, and there
are no firm diagnostic guidelines that can be given. Some of
the more common and clinically important pathogens are
listed in Table I-3 below. When a microbiologic diagnosis of
less common etiologic agents is required, especially when
specialized techniques or methods are necessary, consultation
with the laboratory director should be undertaken. There is
considerable overlap between pericarditis and myocarditis
with respect to both etiologic agents and disease manifesta-
tions.
II. CENTRAL NERVOUS SYSTEM (CNS)
INFECTIONS
Clinical microbiology tests of value in establishing an etiologic
diagnosis of infections within the central nervous system are
outlined below. In this section, infections are categorized as
follows: meningitis, encephalitis, focal infections of brain pa-
renchyma, central nervous system shunt infections, subdural
empyema, epidural abscess, and suppurative intracranial
thrombophlebitis.
Organisms usually enter the central nervous system by cross-
ing a mucosal barrier into the bloodstream followed by pene-
tration of the blood-brain barrier. Other routes of infection
include direct extension from a contiguous structure, move-
ment along nerves, or introduction by foreign devices.
Usually 3 or 4 tubes of cerebrospinal fluid (CSF) are collected
by lumbar puncture for diagnostic studies. The first tube has
the highest potential for contamination with skin flora and
should not be sent to the microbiology laboratory for direct
smears, culture, or molecular studies. A minimum of 0.5–1 mL
of CSF should be sent to the microbiology laboratory in a
sterile container for bacterial testing. Larger volumes (5–10
mL) increase the sensitivity of culture and are required for
optimal recovery of mycobacteria and fungi. When the speci-
men volume is less than required for multiple test requests, pri-
oritization of testing must be provided to the laboratory.
Whenever possible, specimens for culture should be obtained
prior to initiation of antimicrobial therapy.
CSF Gram stains should be prepared after cytocentrifugation
and positive results reported immediately to the caregiver.
Identification and susceptibility testing of bacteria recovered
from cultures is routinely performed unless contamination
during collection or processing is suspected.
Table I-2. Laboratory Methods for Diagnosis of Infected Aneu-






























Abbreviations: KOH, potassium hydroxide; RT, room temperature.
a Tissue specimens or a portion of the graft material are always superior to
swab specimens of infected sites, even when collected using sterile
technique during surgery.
b If aerobic bacteria are suspected. If anaerobes are suspected, then the
culture should consist of an aerobic and anaerobic bacterial culture.
c Calcofluor stain is a fluorescent stain and requires special microscopy
equipment and may not be available at all facilities.
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Most clinical microbiology laboratories do not perform all of
the testing listed in the tables. This is especially true of serologic
and many molecular diagnostic tests. NAATs for most agents
are not commercially available, so only laboratory-developed
tests can be used, with variable sensitivities and specificities. Se-
rologic diagnosis is based on CSF to serum antibody index, 4-
fold rise in acute to convalescent immunoglobulin G (IgG)
titer, or a single positive immunoglobulin M (IgM). Detection
of antibody in CSF may indicate CNS infection, blood contami-
nation, or transfer of antibodies across the blood-brain barrier.
Submission of acute (3–10 days after onset of symptoms) and
convalescent (2–3 weeks after acute) serum samples is recom-
mended. Serum should be separated from red cells as soon as
possible.
Key points for the laboratory diagnosis of central nervous
system infections:
• Whenever possible, collect specimens prior to initiating
antimicrobial therapy.
• Two to four blood cultures should also be obtained if bac-
terial meningitis is suspected.
• Inform the Microbiology Laboratory if unusual organ-
isms are possible (such as Nocardia, fungi, mycobacteria, etc.),
for which special procedures are necessary.
• Do not refrigerate cerebrospinal fluid.
• Attempt to collect as much sample as possible for multi-
ple studies (minimum recommended is 1 mL); prioritize
multiple test requests on small volume samples.






Transport Issues; Optimal Transport
Time
Bacteria Gram stain Pericardial fluid or pericardium
biopsy
Sterile container or blood culture vial
(pericardial fluid only) RT, immediatelyAerobic bacterial cultureb
Blood cultures (see I-a above)
Fungi Calcofluor-KOH stain
Fungal culture
Pericardial fluid or pericardium
biopsy
Sterile container, RT, 2 h
Blood cultures (see I-A above)
Mycobacteria Acid fast smear Pericardial fluid or pericardium
biopsyc
Sterile container, RT, 2 h
AFB culture




Virus-specific serology Acute and convalescent sera Clot tube, RT, 2 h
Echovirus Virus-specific NAAT (may be first
choice if test is available)
Pericardial fluid or pericardium
biopsy
Closed container, RT, 2 h
Polio virus
Adenovirus Virus culture (culture not
productive for all virus types)
Pericardial fluid or pericardium
biopsy
Virus transport device, on ice,
immediatelyHIV
Mumps virus Histopathologic examination Pericardial fluid or pericardium
biopsy






Trypanosoma cruzi Parasite-specific serology Acute and convalescent sera Clot tube, RT, 2 h
Trichinella spiralis Blood smearse 5 mL of peripheral blood EDTA tube, RT
Toxoplasma gondii Histopathologic examination Endomyocardial biopsy or
surgical specimen
Consultation with the laboratory is
recommended.
Toxoplasma NAAT For histopathology, place in formalin and
transport to histopathology laboratory
for processing.
Abbreviations: AFB, acid-fast bacillus; HIV, human immunodeficiency virus; KOH, potassium hydroxide; NAAT, nucleic acid amplification test; RT, room
temperature.
a Other infectious causes of pericarditis and myocarditis include rickettsiae (R. rickettsii, C. burnetii), chlamydiae, B. burgdorferi, T. pallidum, Nocardia spp,
T. whipplei, L. pneumophila, Actinomyces spp, E. histolytica, Ehrlichia spp, T. canis, Schistosoma, andMycoplasma spp.
b If aerobic bacteria are suspected. If anaerobes are suspected, then the culture should consist of both a routine aerobic and anaerobic culture.
c Pericardial tissue is superior to pericardial fluid for the culture recovery ofMycobacterium spp.
d If parasites other than T. cruzi, T. gondii, or T. spiralis are suspected, consult CDC Parasitic Consultation Service (http://dpd.cdc.gov/dpdx/HTML/Contactus.htm).
e Blood smears may be useful in detection of infection caused by Trypanosoma spp.
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A. Meningitis
The most common etiologic agents of acute meningitis are en-
teroviruses (primarily echoviruses and coxsackieviruses) and
bacteria (Streptococcus pneumoniae and Neisseria meningitidis;
Table II-1). Patient age and other factors (ie, immune status,
post neurosurgery, trauma) are associated with specific bacteri-
al pathogens.
Molecular testing has replaced viral culture for the diagnosis
of enteroviral meningitis, but is not routinely available for the
detection of bacteria in CSF. The sensitivity of the Gram stain
for the diagnosis of bacterial meningitis is 60%–80% in patients
who have not received antimicrobial therapy and 40%–60% in
patients who have received treatment [13]. Bacterial antigen
testing on CSF is not recommended but may have some value
in patients who received therapy prior to specimen collection
with negative Gram stain and negative culture results [14]. In
patients suspected of having bacterial meningitis, at least 2–4
blood cultures should be performed, but therapy should not be
delayed.
Organisms expected to cause chronic meningitis (symptoms
≥4 weeks) include Mycobacterium tuberculosis, fungi, and spi-
rochetes (Table II-1). Because the sensitivity of nucleic acid am-
plification tests (NAAT) for M. tuberculosis in nonrespiratory
specimens may be poor, culture should also be requested [15].
The reported sensitivity of culture for diagnosing tuberculous
meningitis is 25%–70% [16]. The highest yields for acid fast ba-
cillus (AFB) smear and AFB culture occur when large volumes
(≥5 mL) of CSF are used to perform the testing. The cryptococ-
cal antigen test has replaced the India ink stain for rapid diag-
nosis of meningitis caused by C. neoformans or C. gattii and
should be readily available in most laboratories. This test is
most sensitive when performed on CSF rather than serum. The
sensitivity and specificity of cryptococcal antigen tests are
>90%, but false negative and false positive results may occur,
for example, in patients with HIV/AIDS. Complement fixation
test performed on CSF is recommended for the diagnosis of
coccidioidal meningitis since direct fungal smear and culture
are often negative. Detection of Coccidioides antibody in CSF
by immunodiffusion has lower specificity than complement
fixation.
B. Encephalitis
Encephalitis is an infection of the brain parenchyma causing
abnormal cerebral function (altered mental status, behavior or
speech disturbances, sensory or motor deficits). Despite ad-
vancements in molecular technology for the diagnosis of CNS
infections, the etiologic agent of encephalitis often cannot be
identified. The California Encephalitis Project identified a defi-
nite or probable etiologic agent for only 16% of 1570 immuno-
competent patients enrolled from 1998 to 2005 (69% viral, 20%
bacterial, 7% prion, 3% parasitic, 1% fungal); a possible cause
was identified for an additional 13% of patients [17]. Immune
status, travel, and other exposure history (insects, animals,
water, sexual) should guide testing. IDSA practice guidelines
provide a detailed listing of risk factors associated with specific
etiologic agents [18].
Although the diagnosis of a specific viral cause is usually
based on testing performed on CSF, testing of specimens col-
lected from other sites may be helpful. The virus most com-
monly identified as causing encephalitis is herpes simplex virus
(HSV) with 90% HSV-1. The sensitivity and specificity of
NAAT for HSV encephalitis are >95%; HSV is cultured from
CSF in <5% of cases [19, 20]. The sensitivity of NAAT per-
formed on CSF for enterovirus encephalitis is >95% and the
sensitivity of culture is 65%–75% (recovery from throat or stool
is circumstantial etiologic evidence) [19]. Because the perfor-
mance characteristics of molecular testing for other causes of
viral encephalitis are not well established, serology and repeat
molecular testing may be required (Table II-2).
C. Focal Infections of Brain Parenchyma
Focal parenchymal brain infections start as cerebritis, then pro-
gress to necrosis surrounded by a fibrous capsule. There are
2 broad categories of pathogenesis: (1) contiguous spread (otitis
media, sinusitis, mastoiditis, and dental infection), trauma,
neurosurgical complication or (2) hematogenous spread from a
distant site of infection (skin, pulmonary, pelvic, intraabdomi-
nal, esophageal, endocarditis). A brain abscess in an immuno-
competent host is usually caused by bacteria (Table II-3). A
wider array of organisms is encountered in immunocompro-
mised individuals.
D. Central Nervous System Shunt Infections
Shunts are placed to divert cerebrospinal fluid for the treatment
of hydrocephalus. The proximal portion is placed in a cerebral
ventricle, intracranial cyst, or the subarachnoid space (lumbar
region). The distal portion may be internalized (peritoneal, vas-
cular, or pleural space) or externalized. In total, 5%–15% of
shunts become infected (Table II-4). Potential routes of shunt in-
fection include contamination at time of placement, contamina-
tion from the distal portion (retrograde), breakdown of the skin
over the shunt, and hematogenous seeding. Blood cultures
should also be collected if the shunt terminates in a vascular
space (ventriculoatrial shunt). Most CNS shunt infections are
caused by bacteria. Fungi are more likely to cause shunt infec-
tions in immunocompromised patients and those receiving total
parenteral nutrition, steroids, or broad-spectrum antibiotics.
E. Subdural Empyema, Epidural Abscess, and Suppurative
Intracranial Thrombophlebitis
Cranial subdural empyema and cranial epidural abscess are
neurosurgical emergencies that are usually caused by bacteria
(streptococci, staphylococci, aerobic gram-negative bacilli,
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Mycobacterium tuberculosis AFB smear Cerebrospinal fluid (≥5 mL) Sterile container, RT;2 h
AFB culture




VDRL, FTA-ABS Cerebrospinal fluid Sterile container, RT, 2 h
Traditional: RPR screening test with
positive RPR confirmed by T. pallidum
particle agglutination (TP-PA) test or
other treponemal confirmatory test
1 mL serum Clot tube, RT, 2 h
Reverse sequence: EIA or
chemiluminescent immunoassay
treponemal screening test with
positive confirmed by RPR (negative
RPR reflexed to TP-PA)
Borrelia burgdorferi (Lyme
disease)
B. burgdorferi antibodies, IgM and IgG
with Western blot assay confirmation
(not validated for CSF)
1 mL serum Clot tube, RT, 2 h
1 mL CSF (include a CSF index:
simultaneous CSF:serum ratio
of B. burgdorferi antibodies with
normalized protein amounts).
B. burgdorferi antibodies, IgM and IgG
with Western blot assay confirmation
(not validated for CSF)
Cerebrospinal fluid Closed container, RT, 2 h
B. burgdorferi NAAT (low sensitivity) Cerebrospinal fluid Closed container, RT, 2 h
Leptospira species Leptospira culture (special media
required; rarely available in routine
laboratories)
1st week of illness: Cerebrospinal
fluid, 10 mL blood
Sterile container, heparin or
citrate tube (blood),
RT, immediately










Cryptococcus antigen test Cerebrospinal fluid Closed container, RT, 2 h
Gram stain Cerebrospinal fluid Sterile container, RT, 2 h
Aerobic bacterial culture (faster growth
on blood agar medium)
Fungal culture
Coccidioides speciesc Coccidioides antibody, complement
fixation and immunodiffusionc
Cerebrospinal fluid and/or 1 mL
serum
Closed container or clot
tube (blood), RT, 2 h
Calcofluor stain Cerebrospinal fluid Sterile container, RT, 2 h
Fungal culture
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anaerobes, often polymicrobial; Table II-5). Mycobacteria and
fungi are rare causes. Predisposing conditions include sinusitis,
otitis media, mastoiditis, neurosurgery, head trauma, subdural
hematoma, and meningitis (infants).
The pathogenesis of spinal epidural abscess includes hema-
togenous spread (skin, urinary tract, mouth, mastoid, lung in-
fection), direct extension (vertebral osteomyelitis, discitis),
trauma, or post-procedural complication (surgery, biopsy,
lumbar puncture, anesthesia). Spinal epidural abscess is usually
caused by staphylococci, streptococci, aerobic gram-negative
bacilli, and anaerobes. Nocardia spp, mycobacteria, and fungi
may also cause spinal epidural abscess. Spinal subdural
empyema is similar to spinal epidural abscess in clinical presen-
tation and causative organisms.
Magnetic resonance imaging (MRI) is the optimal diagnostic
procedure for suppurative intracranial thrombophlebitis. The eti-
ologic agent may be recovered from cerebrospinal fluid and blood
cultures. Causative organisms are similar to cranial epidural
abscess and cranial subdural empyema. Empiric antimicrobial
therapy is usually based on the predisposing clinical condition.
III. OCULAR INFECTIONS
The spectrum of ocular infections can range from superficial,
which may be treated symptomatically or with empiric topical
antimicrobial therapy, to those sight-threatening infections that
require aggressive surgical intervention and either topical and/or
parenteral antimicrobial therapy. Infections may occur in the an-
atomical structures surrounding the eye (conjunctivitis, blephari-
tis, canniculitis, dacryocystitis, orbital and periorbital cellulitis),
on the surface of the eye (keratitis), or within the globe of the eye
(endophthalmitis and uveitis/retinitis). Recommendations for
the laboratory diagnosis of ocular infections are often based on
studies where only small numbers of clinical specimens were ex-
amined so the evidence base for many recommendations is
limited. Studies comparing multiple diagnostic approaches to de-
termine the optimal means for detection of the infectious etiolo-
gy of keratitis and endophthalmitis are further hampered by
small specimen size. Finally, frequent pretreatment with topical
antibacterial agents further complicates laboratory diagnosis of











Acanthamoeba spp See Table II-2 – Encephalitis
Naegleria fowleri
Viral
Enteroviruses (nonpolio) Enterovirus NAAT Cerebrospinal fluid Closed container, RT, 2 h
Parechoviruses Parechovirus NAAT Cerebrospinal fluid Closed container, RT, 2 h
Herpes simplex virus (HSV) HSV 1 and 2 NAAT Cerebrospinal fluid Closed container, RT, 2 h




LCM antibodies, IgM and IgG, IFA Cerebrospinal fluid and/or 1 mL
serum
Closed container or clot
tube (blood), RT, 2 h
Mumps virus Mumps virus antibodies, IgM and IgG Cerebrospinal fluid and/or 1 mL
serum
Closed container or clot
tube (blood), RT, 2 h
Mumps culture and Mumps NAAT Cerebrospinal fluid, urine, buccal
swab







Abbreviations: AFB, acid-fast bacillus; CSF, cerebrospinal fluid; EIA, enzyme immunoassay; FTA, fluorescent treponemal antibody; HIV, human immunodeficiency
virus; HSV, herpes simplex virus; IFA, indirect fluorescent antibody; IgG, immunoglobulin G; IgM, immunoglobulin M; LCM, lymphocytic choriomeningitis virus;
NAAT, nucleic acid amplification test; RPR, rapid plasma reagin; RT, room temperature; TP-PA, T. pallidum particle agglutination; VDRL, Venereal Disease Research
Laboratory; VZV, varicella zoster virus.
a Gram stains may be performed on uncentrifuged specimens when the CSF is visibly turbid.
b A negative result does not rule outM. tuberculosis.
c Complement fixation on CSF is optimal test; serum complement fixation antibody may reflect a remote rather than an active infection.
d The diagnosis of acute meningitis due to HIV, a condition that often arises during the early stages of the HIV retroviral syndrome, is best established based on
compatible CSF findings (ie. a mild CSF lymphocytosis with a mildly elevated CSF protein level and normal glucose) combined with definitive evidence of recent
HIV infection (see Section XIV – VIRAL SYNDROMES; HIV diagnosis).
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Table II-2. Laboratory Diagnosis of Encephalitis




Herpes simplex virus (HSV) HSV 1 and 2 NAAT Cerebrospinal fluid Closed container, RT, 2 h
Enteroviruses (nonpolio) Enterovirus NAAT Cerebrospinal fluid Closed container, RT, 2 h
Parechoviruses Parechovirus NAAT Cerebrospinal fluid Closed container, RT, 2 h
West Nile virus (WNV) WNV IgM antibodya Cerebrospinal fluid and/or 1 mL
serum
Closed container or clot tube (blood),
RT, 2 h
WNV NAATb Cerebrospinal fluid and/or 1 mL
serum
Closed container, RT, 2 h
Other arbovirusesc Virus specific antibodies,
IgM and IgG
Cerebrospinal fluid and/or 1 mL
serum
Closed container or clot tube (blood),
RT, 2 h
Varicella-zoster virus (VZV)d VZV NAAT Cerebrospinal fluid or 1 mL plasma Closed container or EDTA tube (blood),
RT, 2 h
VZV antibodies, IgM and IgG Cerebrospinal fluid and/or 1 mL
serum
Closed container or clot tube (blood),
RT, 2 h
Epstein-Barr virus (EBV) EBV NAATe Cerebrospinal fluid or 1 mLplasma Closed container or EDTA tube (blood),
RT, 2 h
EBV antibodies, VCA IgG
and IgM, EBNA
Cerebrospinal fluid and/or 1 mL
serum
Closed container or clot tube (blood),
RT, 2 h
Cytomegalovirus (CMV)f CMV NAATg Cerebrospinal fluid or 1 mL plasma Closed container or EDTA tube (blood),
RT, 2 h
CMV antibodies, IgM and IgG Cerebrospinal fluid and/or 1 mL
serum
Closed container or clot tube (blood),
RT, 2 h
Human herpes virus 6
(HHV-6)
HHV-6 NAAT Cerebrospinal fluid Closed container, RT, 2 h
JC virus JC virus NAAT Cerebrospinal fluid Closed container, RT, 2 h
Mumps virus Mumps virus antibodies,
IgM and IgG
Cerebrospinal fluid and/or 1 mL
serum
Closed container or clot tube (blood),
RT, 2 h
Mumps culture Cerebrospinal fluid, urine Sterile container, on ice, immediately
Mumps NAAT




Measles antibodies, IgM and
IgG
Cerebrospinal fluid and/or 1 mL
serum
Closed container or clot tube (blood),
RT, 2 h
Measles culture and Measles
NAAT
Cerebrospinal fluid, urine Sterile container, RT, 2 h
Throat swab Viral transport device, on ice,
immediately
Influenza virus Influenza DFA and culture or
NAAT
Nasopharyngeal wash or other
respiratory specimen
Viral transport device, on ice,
immediately
Adenovirus Adenovirus DFA and culture or
NAAT
Nasopharyngeal wash or other
respiratory specimen
Viral transport device, on ice,
immediately
Adenovirus NAAT Cerebrospinal fluid or 1 mL plasma Closed container or EDTA (blood),
RT, 2 h
Rabies virush Rabies antigen, DFA Nuchal skin biopsy Closed container, RT, immediately
Rabies NAAT Saliva Sterile container, RT, immediately





LCM antibodies, IgM and
IgG, IFA
Cerebrospinal fluid and/or 1 mL
serum
Closed container or clot tube,
RT (blood), 2 h
Bacterial
Mycobacterium tuberculosis See Table II-1 - Meningitis
Bartonella spp Bartonella spp NAAT Cerebrospinal fluid or plasma Closed container or EDTA (blood), RT,
2 h
Bartonella spp antibodies, IgM
and IgG
Cerebrospinal fluid and/or 1 mL
serum
Closed container or clot tube (blood),
RT, 2 h
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Table II-2 continued.
Etiologic Agents Diagnostic Procedures Optimum Specimens
Transport Issues;
Optimal Transport Time
Mycoplasma pneumoniae M. pneumoniae NAAT Cerebrospinal fluid or respiratory Closed container, RT, 2 h
M. pneumoniae antibodies,
IgM and IgG
Cerebrospinal fluid and/or 1 mL
serum




Tropherymawhipplei NAAT Cerebrospinal fluid Closed container, RT, 2 h
Listeria monocytogenes Gram stain Cerebrospinal fluid, blood Sterile container, aerobic blood
culture bottle, RT, 2 hAerobic bacterial culture
Listeria antibody, CF Cerebrospinal fluid and/or 1 mL
serum
Closed container or clot tube (blood),
RT, 2 h
Coxiella burnetii (Q fever) C. burnetii antibodies, IgM and
IgG
1 mL serum Clot tube, RT, 2 h
C. burnetii NAAT Whole blood EDTA tube, RT, 2 h




Rickettsia spp antibodies, IgG and
IgM, IFA
Cerebrospinal fluid and/or 1 mL
serum
Closed container or clot tube (blood),
RT, 2 h
R. rickettsii DFA or IHC and NAAT Skin biopsy from rash Closed container, RT, 2 h




E. chaffeensis and A.
phagocytophilum antibodies,
IgM and IgG
Cerebrospinal fluid and/or 1 mL
serum
Closed container or clot tube (blood),
RT, 2 h
E. chaffeensis and A.
phagocytophilum NAAT








Cryptococcus antigen test Cerebrospinal fluid,1 mL serum Closed container,clot tube (blood), RT, 2 h
Gram stain Cerebrospinal fluid Sterile container, RT, 2 h
Aerobic bacterial culture
Fungal culture
Coccidioides species Coccidioides antibody,
immunodiffusion and
complement fixation
Cerebrospinal fluid and/or 1 mL
serum
Closed container or clot tube (blood),
RT, 2 h
Calcofluor stain Cerebrospinal fluid, other sites Sterile container, RT, 2 h
Fungal culture
Histologic examination Tissue or formalin-fixed tissue Sterile container, RT, 2 h or formalin,
indefinite
Parasitic
Acanthamoeba spp Microscopic wet mount Cerebrospinal fluid Closed container, RT, 2 h
Naegleria fowleri Giemsa stain
Histology (trichrome stain) Cerebrospinal fluid, brain tissue Closed container, RT, 2 h
Culture Cerebrospinal fluid, brain tissue Sterile container, RT, 2 h
Acanthamoeba antibody IFAi 1 mL serum Clot tube, RT, 2 h
Acanthamoeba IIF stainingi Brain tissue Closed container, RT, 2 h
Histology (trichrome stain) Brain tissue Closed container, RT, 2 h
Balamuthia mandrillaris Balamuthia antibody, IFAi 1 mL serum Clot tube, RT, 2 h
Balamuthia IIF stainingi Brain tissue Closed container, RT, 2 h
Baylisascaris procyonisj B. procyonis antibodies Cerebrospinal fluid and/or 1 mL
serum
Closed container or clot tube (blood), RT,
2 h
Trypanosoma brucei spp Giemsa stain Cerebrospinal fluid, brain tissue Closed container, RT, 2 h
Blood EDTA tube, RT, 2 h
Toxoplasma gondii Toxoplasma NAAT Cerebrospinal fluid, 1 mL serum,
plasma
Closed container, clot tube (blood),
EDTA tube (blood), RT, 2 h
Toxoplasma antibodies, IgM
and IgGk
Cerebrospinal fluid and/or 1 mL
serum
Closed container or clot tube (blood),
RT, 2 h
Giemsa stain, histology Cerebrospinal fluid, brain tissue Closed container, RT, 2 h
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Key points for the laboratory diagnosis of ocular infections:
• Specimens should be labeled with the specific anatomic
source, ie conjunctiva or cornea, but not just “eye.”
• The Gram stain is useful in the diagnosis of conjunctivitis
so two swabs per site may be appropriate; a paired specimen
from the uninfected eye can be used as a “control” to assist in
culture or Gram stain interpretation.
• Swab specimens are routinely used but provide a minimum
amount of material. Consult the laboratory regarding suspicious
agents. Corneal scrapings are preferred for keratitis diagnosis.
• Normal skin flora are usually not involved in conjunctivitis.
Specimen Collection, Processing, and Transport
Because ocular infections may involve one or both eyes and eti-
ologies may differ, clinicians must clearly mark specimens as to
which eye has been sampled, especially in those patients who
have bilateral disease.
Collection of specimens from anatomical structures sur-
rounding the eye is typically performed using swabs (Table III-
1). The most commonly collected specimens are from the
conjunctiva. Cultures for aerobic bacteria and detection of
Chlamydia and viruses either by culture or nucleic acid amplifi-
cation testing (NAAT) are most commonly performed. Because
direct microscopic examination may be useful in preliminary
diagnosis of conjunctivitis, obtaining dual swabs, one for
culture and one for smear preparation, is recommended.
Smears may be made for Gram stain, calcofluor stain for fungi
and Acanthamoeba, or direct fluorescent antibody (DFA) for
Chlamydia trachomatis. Appropriate transport media should
be provided by the laboratory and available at the collection site
for specimens submitted for Chlamydia and/or viral culture or
Table II-2 continued.




Creutzfeldt-Jakob diseasel 14-3-3 protein Cerebrospinal fluid Closed container, RT, 2 h
Neuron-specific enolase (NSE) Cerebrospinal fluid Closed container, RT, 2 h
Routine histology, immune stain
for prion protein
Formalin fixed brain tissue Contact surgical pathologist prior to
collection of tissuem
Western blot for prion protein Frozen brain tissue Contact surgical pathologist prior to
collection of tissuem
PrP gene sequencing Blood, other tissues EDTA tube, closed container, RT, 2 h
Abbreviations: CF, complement fixation; CMV, cytomegalovirus; DFA, direct fluorescent antibody; EBV, Epstein-Barr virus; HHV-6, human herpes virus 6; HSV,
herpes simplex virus; IFA, indirect fluorescent antibody; IHC, immunohistochemical stain method; IIF, indirect immunofluorescent antibody; IgG, immunoglobulin
G; IgM, immunoglobulin M; LCM, lymphocytic choriomeningitis virus; NAAT, nucleic acid amplification test; RMSF, Rocky Mountain spotted fever; RT, room
temperature; VCA, viral capsid antigen; VZV, varicella-zoster virus; WNV, West Nile virus.
aWNV IgM antibody may persist for >6 months. False positives may occur with recent immunization ( Japanese encephalitis, yellow fever) or other flavivirus
infection (dengue, St. Louis encephalitis) [21].
b Sensitivity of WNV NAAT in immunocompetent host is <60% [21]. Testing for IgM in CSF is preferred, but may be falsely negative during first week of symptoms.
Persistent viremia in immunocompromised hosts lacking serologic response may improve WNV-NAAT sensitivity.
c Eastern equine, Western equine, St. Louis and California encephalitis viruses
d Detection of VZV DNA in CSF (approximately 60% of cases), CSF IgM, or intrathecal antibody synthesis distinguishes meningoencephalitis from post infectious,
immune-mediated process [19].
e Quantitative EBV NAAT may help distinguish true positive from latent virus [19].
f Congenital disease in newborns and reactivation in immunocompromised hosts. False positive CSF CMV NAAT results have been reported in immunocompetent
patients with bacterial meningitis [19].
g In HIV patients, detection of CMV DNA in CSF has 82%–100% sensitivity and 86%–100% specificity for diagnosing CNS CMV infection [19].
h Contact state public health department to arrange testing; Questions regarding sampling techniques and shipping may be directed to the Rabies section at the
CDC (404)-639-1050.
i Available at the California State Department of Health Services and the Centers for Disease Control and Prevention [22].
j Consider if eosinophilia or exposure to raccoon feces [23]. Testing available at Dept of Veterinary Pathobiology, Purdue University (West Lafayette, IN; phone 765-
494-7558).
k Refer positive IgM to Toxoplasma Serology Laboratory in Palo Alto, CA for confirmatory testing (http://www.pamf.org/serology/). The absence of serum IgM or IgG
does not exclude Toxoplasma infection (22% of AIDS patients with Toxoplasma encephalitis lack IgG; IgM is rarely detected) [24].
l Testing available at the National Prion Disease Pathology Surveillance Center (NPDPSC) http://www.cjdsurveillance.com [25]. The 14-3-3 protein has limited
specificity for prion disease.
m Compliance with appropriate infection control protocols is essential.
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Aerobic and anaerobic bacterial
culture (Propionibacterium
culture should be held up to
14 d)






Aerobic bacterial culture (hold 7 d;
add buffered charcoal yeast
extract [BCYE] agar)
Histology (Gomori Methenamine
Silver [GMS], Gram stain)
Tissue Closed container, RT, 2 h
Mycobacterium
tuberculosis
AFB smear Aspirate of abscess
contents (no swabs),
tissue
Sterile container, RT, 2 h
AFB culture
Histology (AFB stain) Tissue Closed container, RT, 2 h
M. tuberculosis NAATa Aspirate, tissue Closed container, RT, 2 h
Fungal
Candida spp Calcofluor stain
Cryptococcus spp Fungal culture Aspirate of abscess
contents, tissue
Sterile container, RT, 2 h















Toxoplasma gondii Toxoplasma NAAT Aspirate of abscess
contents, tissue
Closed container, RT, 2 h
Toxoplasma antibodies, IgM and
IgGb
1 mL serum Clot tube, RT, 2 h
Giemsa stain Aspirate of abscess
contents, tissue




T. solium antibodies, IgG, ELISA,
confirmatory Western blotc
1 mL serum Clot tube, RT, 2 h
Histologyd Brain tissue Closed container, RT, 2 h
Formalin, indefinite
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NAAT [26]. Specimens for viral cultures should be submitted
on ice, especially if specimen transport is prolonged.
Specimens obtained from either the surface or the globe of
the eye are almost always collected by ophthalmologists. Speci-
men types include swabs of ulcers, corneal scrapings, biopsies,
or anterior chamber or vitreous aspirates. The volume of speci-
mens is always limited. This specimen limitation makes it
necessary for the laboratory to prioritize procedures depending
on what organisms are sought, and this should always be done
after discussion with the ophthalmologist who collects the
specimen and the infectious disease consultant when appropri-
ate. This is particularly important because all major pathogen
groups—viruses, parasites, bacteria, mycobacteria, and fungi—










Acanthamoeba spp Microscopic wet mount Aspirate of abscess
contents, tissue
Closed container, RT, 2 h
Giemsa stain
Histology (trichrome stain) Aspirate of abscess
contents, tissue
Closed container, RT, 2 h
Culture Aspirate of abscess
contents, tissue
Sterile container, RT, 2 h
Acanthamoeba antibody, IFAe 1 mL serum Clot tube, RT, 2 h
Acanthamoeba IIF staininge Brain tissue Closed container, RT, 2 h
Balamuthia mandrillaris Histology (trichrome stain) Brain tissue Closed container, RT, 2 h
Formalin, indefinite
Balamuthia antibody, IFAe 1 mL serum Clot tube, RT, 2 h
Balamuthia IIF staininge Brain tissue Closed container, RT, 2 h
Abbreviations: AFB, acid fast bacillus; IFA, indirect fluorescent antibody; IIF, indirect immunofluorescent antibody; IgG, immunoglobulin G; IgM, immunoglobulin M;
NAAT,nucleic acid amplification test; RT, room temperature.
a A negative result does not rule outM. tuberculosis.
b Refer positive IgM to Toxoplasma Serology Laboratory in Palo Alto, CA, for confirmatory testing (http://www.pamf.org/serology/). The absence of IgM or IgG does
not exclude Toxoplasma infection [24].
c Only 50% sensitivity if patient has solitary parenchymal lesion [24]; potential for false positive ELISA results due to cross reactivity with Echinococcus.
d Diagnosis usually on basis of clinical presentation, neuroimaging, and serology. Only occasionally are invasive procedures (brain biopsy) required.
e Available at the California State Department of Health Services and the Centers for Disease Control and Prevention [22].




















Aerobic and anaerobic bacterial
culture (hold 14 d for P.
acnes)
Mycobacterium spp (rare) AFB smear Cerebrospinal fluid (≥5 mL) Sterile container, RT, 2 h
AFB culture
Fungal
Candida spp, other fungi Calcofluor stain Cerebrospinal fluid Sterile container, RT, 2 h
Fungal culture
Abbreviation: RT, room temperature.
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presentation are used to narrow the organism(s) sought and
the laboratory tests requested. Because of the limited specimen
size seen with scrapings and biopsies, the laboratory and oph-
thalmologist may agree to inoculate these specimens onto
media and prepare smears at the bedside. In this case, the labo-
ratory should supply the necessary media and slides to the oph-
thalmologist. If these supplies are stored in the clinic or
operating suite for ready access by the surgeon, it is the labora-
tory’s responsibility to assure that these materials are not out-
dated. Aspirates from the anterior chamber or vitreous are the
optimal specimens for detection of anaerobic bacteria and viral
agents; they can be submitted in syringes with needles
removed. Syringes should be placed in a leakproof outer con-
tainer for transport. Injection of the fluid into a small sterile
vial (provided by the laboratory) is preferable. The same princi-
ples for specimen collection and transport described for con-
junctival specimens apply to these specimens as well.
A. Orbital and Periorbital Cellulitis
Orbital cellulitis is almost always a complication of sinusitis,
and the organisms associated with it include Streptococcus
pneumoniae, nontypeable Haemophilus influenzae, Streptococ-
cus pyogenes, Moraxella spp, anaerobic bacteria, Aspergillus
spp, and the zygomycetes. Periorbital cellulitis usually arises as
a result either of localized trauma or bacteremia most often
caused by Staphylococcus aureus, S. pyogenes, or S. pneumonia
[27]. Diagnosis of these infections is either based on positive
blood cultures or in the case of orbital cellulitis, culture of
drainage material aspirated from the subperiosteal region of the
sinuses.
B. Infection of the Eyelids and Lacrimal System
Blepharitis, canaliculitis, and dacryocystitis are all superficial
infections that are generally self-limited. The organisms associ-
ated with these infections are predominantly gram-positive
bacteria although various gram-negative bacteria, anaerobes,
and fungi all have been recovered [28]. A limitation of many
studies of these infections is that microbiologic data on control
populations are frequently lacking. The organisms commonly
recovered are part of the indigenous skin microflora such as co-
agulase negative staphylococci and diphtheroids, so attributing
a pathogenic role to these organisms in these conditions is dif-
ficult. Cultures from these sites are rarely submitted for diag-
nostic work-up. If cultures for canaliculitis are considered,
concretions recovered during canalicular compression or canal-
iculotomy are recommended. Strategies for the diagnosis of
these superficial infections should be similar to those for
conjunctivitis.


























Aerobic and anaerobic bacterial
culture
Nocardia spp Gram stain, modified acid fast
stain
Aspirate of purulent material Sterile container, RT,
immediately
Aerobic bacterial culture (hold 7 d;
add BCYE agar)
Mycobacterium spp AFB smear Aspirate of purulent material Sterile container, RT, 2 h
AFB culture
M. tuberculosis NAATa (rarely
available)
Fungal
Candida spp, other fungi Calcofluor stain Aspirate of purulent material Sterile container, RT, 2 h
Fungal culture
Abbreviations: AFB, acid fast bacillus; NAAT, nucleic acid amplification test; RT, room temperature.
a Negative NAAT for tuberculosis does not rule outM. tuberculosis.
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C. Conjunctivitis
Most cases of conjunctivitis are caused by bacteria or viruses
that are typically associated with upper respiratory tract infec-
tions [29, 30]. Because of the distinctive clinical presentation of
both bacterial and viral conjunctivitis coupled with the self-
limited nature of these infections, determining its etiology is in-
frequently attempted [31]. When tests are requested, diagnosis
of bacterial conjunctivitis is often compromised by the prior
use of empiric antibacterial therapy [29, 30]. Sexually active pa-
tients who present with bacterial conjunctivitis should have an
aggressive diagnostic work-up with Gram stain and cultures
because of their risk for Neisseria gonorrhoeae conjunctivitis.
This is a sight-threatening infection that can result in perfora-
tion of the globe. In the developing world, trachoma, a form of
conjunctivitis due to specific strains of Chlamydia trachomatis,
is a leading cause of blindness, especially in children [32]. Off-
label use of commercial NAAT assays is used for detection of
this agent in research settings [33]. Certain organisms that are
part of the indigenous skin and mucous membrane microflora
such as coagulase negative staphylococci, Corynebacterium spp,
and viridans streptococci are generally considered nonpatho-
genic when recovered from the conjunctival mucosa and are
considered to be “normal flora.” In specimens taken from the
surface or interior of the eye, these organisms along with Pro-
pionibacterium acnes are considered pathogens, especially in
patient post-cataract or LASIK surgery [26]. Adenovirus, the
etiologic agent of “pink eye,” is highly transmissible in a variety
of settings. This is almost always a clinical diagnosis although











Haemophilus influenzae Gram stain Conjunctival swab Swab transport device, RT,








Actinomyces spp Anaerobic bacterial culture Conjunctival scraping or
biopsy
Sterile anaerobic container,
RT, immediatelyOther anaerobic bacteria
(rare cause of
canaliculitis)
Chlamydia trachomatis Direct fluorescent antibody
stain
Conjunctival swab Virus swab transport




Herpes simplex virus (HSV) HSV NAAT Conjunctival swab Virus swab transport
device, RT, 2 hHSV culture
Varicella zoster virus (VZV) VZV NAAT Conjunctival swab Virus swab transport
device, RT, 2 hVZV culture
Adenovirus Adenovirus NAAT Conjunctival swab Virus swab transport
device, RT, 2 hAdenovirus culture
Herpes B virus c
Abbreviations: NAAT, nucleic acid amplification test; RT, room temperature
a NAATs for detection of C. trachomatis have not yet been approved in the United States for use with conjunctival swab specimens. Individual laboratories,
however, may have validated NAATs for examination of specimens obtained from patients with conjunctivitis and studies suggest that NAATs are more sensitive
than cultures.
b Use of NAAT for detection of C. trachomatisis is considered an “off label” use of this test. Laboratories that offer such testing must conduct in house validation of
these assays before offering NAAT as a diagnostic test.
c Culturing of specimens thought to harbor Herpes B virus (primate origin) requires use of biosafety level 4 precautions in the laboratory and testing is almost
always referred to a specialized reference laboratory. Consult the laboratory when Herpes B virus is suspected.
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for epidemiologic purposes culture or NAAT can be done [26].
Most cases of neonatal conjunctivitis are due to either Neisseria
gonorrhoeae, Chlamydia trachomatis, or herpes simplex virus.
Commercial NAATs for both N. gonorrhoeae and C. trachoma-
tis are not FDA approved for this specimen type, so culture or
in the case of C. trachomatis, direct fluorescent antibody
testing, if available, can be used [26].
D. Keratitis
Corneal infections usually occur in 3 distinct patient populations:
those with ocular trauma by foreign objects, those with postsur-
gical complications of corneal surgery, and in patients who prac-
tice poor hygiene associated with their extended wear contact
lenses [26, 34]. Corneal infections can also result from reactiva-
tion of herpes viruses including herpes simplex virus and varicel-
la zoster virus [35]. Post-vaccination keratitis is a well-recognized
complication of vaccinia vaccination and should be considered
in the appropriate clinical setting [36]. It is important to note
that the use of dyes and topical anesthetics may inhibit NAAT re-
actions used to diagnose keratitis. The eye surface should be thor-
oughly rinsed with nonbacteriostatic saline before specimens for
NAATs are obtained [37, 38] (Table III-2).
The most common corneal infections occur in patients who
improperly use their contact lens system. Because these patients
are usually treated with antimicrobial agents prior to obtaining
specimens for bacterial cultures, some ophthalmologists favor cul-
turing contact lens solution and cases. However, culture of such
solutions and cases is not recommended because of the frequency
with which they are falsely positive [39, 40]. Pseudomonas aerugi-
nosa is the most common cause of sporadic contact lens associat-
ed keratitis but outbreaks of keratitis due to contamination of
contact lens care solutions have been recently reported with both
Fusarium and Acanthamoeba [39–42]. Post-surgical keratitis in-
fections are frequently due to either coagulase-negative staphylo-
cocci and P. acnes, so in this setting these organisms should not
be considered contaminants but as potential pathogens [26].
Keratitis following trauma due to foreign objects is frequent-
ly caused by organisms found in the environment. Included
in this group are environmental gram-negative rods such as
P. aeruginosa, Nocardia spp, moulds including dematiceous
fungi, and environmental mycobacteria [26].
E. Endophthalmitis
Endophthalmitis can arise either by exogenous introduction of
pathogens into the eye following trauma or surgery, or as a
result of endogenous introduction of pathogens across the
blood-eye barrier. Depending on the mode of pathogenesis, the
spectrum of causative agents will vary (Table III-3). Specimens
for diagnosis of endophthalmitis can be obtained by aspiration
of aqueous or vitreous fluid or via biopsy [43]. Specimen
amounts are small, so discretion must be exercised in
determining for which agents the specimen should be exam-
ined. Post-operative endophthalmitis is most often caused by
gram-positive organisms with coagulase-negative staphylococci
predominating; chronic post-operative endophthalmitis can be
due to P. acnes, so this organism should not be dismissed as a
contaminant [44, 45]. Environmental organisms such as dema-
tiaceous fungi, Fusarium spp, Bacillus cereus, Nocardia spp, My-
cobacterium chelonae, and glucose fermenting gram-negative
rods are more commonly encountered in patients with exoge-
nous endophthalmitis [45, 46]. Endogenous endophthalmitis,
because of its association with bacteremia and fungemia, is
usually caused by those organisms most responsible for blood-
stream infections (eg Candida albicans and related species, As-
pergillus spp, S. aureus, S. pneumoniae, the Enterobacteriaceae,
especially Klebsiella pneumoniae, and Pseudomonas aeruginosa)
[45, 47, 48]. Viruses and parasites are rarely found to cause en-
dophthalmitis, however, as in cases of trauma or severe immuno-
suppression, infection due to agents such as the herpes viruses,
Toxoplasma gondii, Toxocara spp, Echinococcus spp, and Oncho-
cerca volvulus do occur [39, 49] and typically involve the uvea
and retina. For further information on the diagnosis of ocular in-
fections caused by Onchocerca volvulus, see Section XV-C.
F. Uveitis/Retinitis
The inflammation characteristic of uveitis/retinitis is typically
due to either autoimmune conditions or is idiopathic [50].
Only infrequently is it due to infection that is almost always
caused by endogenous microbes accessing the eye via a breach
in the blood-eye barrier. Because uveitis and retinitis, like en-
dogenous endophthalmitis, are localized manifestations of sys-
temic infections, diagnosis of the etiology of systemic infections
should be coupled with a careful ocular examination performed
preferably by an ophthalmologist with specific infectious
disease expertise. Important causes of uveitis/retinitis include
Toxoplasma gondii, cytomegalovirus, HSV, VZV, Mycobacteri-
um tuberculosis, and Treponema pallidum [49, 51–53].
T. gondii is the most common infectious cause of retinitis.
Diagnosis is typically made on clinical grounds supported by
serology. In the industrialized world, the presence of T. gondii
IgG lacks specificity for the diagnosis of ocular toxoplasmosis;
therefore, serology is only valuable in the setting of acute infec-
tion or when the patient has an ocular examination pathogno-
monic for toxoplasmosis, demonstrating retinochoroiditis in a
majority of cases. The comparison of intraocular antibody
levels in aqueous humor to that in serum has been found to be
a useful means for diagnosing ocular toxoplasmosis but
because the specimen needed for testing can only be obtained
by a highly invasive procedure, it is unlikely that this technique
will be used outside the research setting [54]. NAAT of blood,
vitreous or aqueous fluids, is not as sensitive as intraocular anti-
body determinations, but the specimens for testing may be
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Gram stainb Corneal scrapings Inoculated plates and prepared
slide transported directly to the
laboratoryb, RT, immediatelyPseudomonas aeruginosa Aerobic bacterial culture (with
bedside inoculation of plates)b
Propionobacterium acnes
Streptococcus pneumoniae
Anaerobic culture (for P. acnes) Corneal scrapings Place second sample into













Nocardia sppc Add BCYE agar for Nocardia
Mycobacterium sppd Acid fast smear Corneal scrapings Sterile container, RT, 2 h
AFB culture
Fungal
Aspergillus spp Calcofluor-KOH staine Corneal scrapings Inoculated plates and prepared
slide transported directly to the
laboratorye, RT, immediately
Fusarium spp Fungal culture (with bedside
inoculation of plates)eDematiaceous fungi
Viral
Herpes simplex virus (HSV) HSV NAAT (for initial diagnosis) Corneal swab Virus swab transport device, RT,
2 hHSV culture
Varicella zoster virus (VZV) VZV NAAT Corneal swab Virus swab transport device, RT,
2 hVZV culture
Adenovirus Adenovirus NAAT Corneal swab Viral swab transport device, RT,
2 hAdenovirus culture
Parasites
Acanthamoeba spp Giemsa stain Corneal scrapings Sterile container,RT, immediately
Calcaflour-KOH stain
Acanthamoeba culture (with bedside
inoculation of culture plate)f
Corneal swab Inoculated plate transported
directly to the laboratoryf, RT,
immediately
Abbreviations: AFB, acid fast bacillus; BCYE, buffered charcoal yeast extract; KOH, potassium hydroxide; NAAT, nucleic acid amplification test; RT, room
temperature.
a The relative likelihood of a specific etiology depends on the underlying reason for the development of keratitis.
b Culture plates, including a sheep blood agar plate and a chocolate agar plate, should be inoculated directly with material collected on the Kimura spatula directly at
the patient’s bedside at the time corneal scrapings are obtained,usually applied to the agar surface as a number of small “C” shaped inocula. If sufficient sample is
available, a smear on a glass slide may also be prepared at the patient’s bedside after the plates are inoculated. The inoculated plates and slide (if prepared) are then
transported directly to the microbiology laboratory.
c The laboratory should be notified when Nocardia spp is suspected so that culture plates may be incubated for longer periods than normal, thus enhancing the
chance of recovering this slow growing organism. Additional media, such as buffered charcoal yeast extract, can enhance recovery of Nocardia.
d Acid fast smears and mycobacterial cultures should be performed in all post-operative infections of the cornea. Mycobacterium chelonei is a common finding in
such cases.
e At least 1 culture plate or slant containing a nonselective fungal growth medium should be inoculated directly at the patient’s bedside at the time corneal
scrapings are obtained. If sufficient sample is available, a smear on a glass slide may also be prepared at the patient’s bedside. This should be attempted only after
plates/slants have been inoculated. The inoculated plates/slants and slide (if prepared) are then transported directly to the microbiology laboratory. The smear is
stained with Calcofluor-KOH in the laboratory and examined for fungal elements.
f A corneal swab specimen is used to inoculate an agar plate containing nonnutritive medium at the patient’s bedside and then transported immediately to the
laboratory. In the laboratory, the plate is overlaid with a lawn of viable E. coli or some other member of the Enterobacteriaceae (ie, cocultivation) prior to incubation.
Alternatively, plates seeded with the bacteria are inoculated with a bit of corneal scraping material or a drop of a suspension of the scraped sample in sterile saline.
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Gram stainb Vitreous aspirate or biopsy Inoculated plates and prepared
slide transported directly to the
laboratoryb, RT, immediatelyStaphylococcus aureus Aerobic bacterial culture (with
bedside inoculation of plates)b
Streptococcus agalactiae
Viridans streptococci





Anaerobic culture for P. acnes Place second sample into
anaerobic broth (at bedside)
provided by laboratory











Nocardia sppc Add BCYE agar for Nocardia
Mycobacteria
Mycobacterium sppd Acid fast smeare Vitreus aspirate or biopsy Inoculated slants and smear are
transported directly to the
laboratorye, RT, immediately




Fusarium spp Calcofluor-KOH staing Vitreous aspirate or biopsy Inoculated plate and smear are
transported directly to the
laboratoryg, RT, immediately
Dematiaceaous fungi Fungal culture (with bedside




Abbreviations: AFB, acid fast bacillus; KOH, potassium hydroxide; RT, room temperature.
a Among the long list of bacterial causes of endophthalmitis, Streptococcus agalactiae; Listeria monocytogenes and Neisseria meningitidis occur almost exclusively
as a result of endogenous seeding of the eye. The other bacteria listed may cause endophthalmitis either secondary to trauma or surgery or following
hematogenous seeding.
b Culture plates, including a sheep blood agar plate and a chocolate agar plate, should be inoculated directly at the patient’s bedside at the time corneal scrapings
are obtained (see footnote for Table 2). If sufficient sample is available, a smear on a glass slide may also be prepared at the patient’s bedside after plates are
inoculated. The inoculated plates and slide (if prepared) are then transported directly to the microbiology laboratory.
c The laboratory should be notified when Nocardia spp is suspected so that special media can be used and routine culture plates will be incubated for up to 7 days.
d The most common Mycobacterium spp recovered from intraocular infections is M. chelonae and this occurs almost exclusively as a complication of surgical
procedures.
e Acid fast smears and mycobacterial cultures should be performed in all post-surgical infections of the eye. A 7H-11 agar or a Lowenstein-Jensen agar slant should
be inoculated at the patient’s bedside. If sufficient clinical sample remains, a smear should be prepared. Both the slant and the smear (if prepared) should be
transported directly to the laboratory for further processing. If after inoculating a slant and preparing a smear at the bedside, there is still unused specimen
remaining, it should be transported in a sterile container immediately to the laboratory at room temperature for inoculation into broth media and subsequent
instrument-based processing.
f Among the fungi listed, Candida albicans, C. glabrata, and other Candida spp cause endogenous endophthalmitis as a result of hematogenous seeding of the eye.
The other fungi listed typically cause infection following traumatic inoculation of the eye.
g At least one culture plate or slant containing a nonselective fungal growth medium should be inoculated directly at the patient’s bedside at the time corneal
scrapings are obtained. If sufficient sample is available, a smear on a glass slide may also be prepared at the patient’s bedside after plates/slants have been
inoculated. The inoculated plates/slants and slide (if prepared) are then transported directly to the microbiology laboratory. The smear is stained with Calcofluor-
KOH in the laboratory and examined for fungal elements.
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more easily obtained. Sensitivities of NAATs ranging from 50%
to 80% have been reported in patients with T. gondii retinitis
depending on the sequence used and the specimen tested. It
should be noted that the total numbers of specimens tested in
these studies are small, so the diagnostic value of NAAT in T.
gondii retinitis is not yet clear [55, 56].
Since the advent of highly active antiretroviral treatment
(HAART), cytomegalovirus (CMV) retinitis has become much
less frequent. Nevertheless, cases do occur in HIV patients who
have either failed HIV therapy or as an AIDS-presenting diag-
nosis [53]. In addition, CMV retinitis has been a well-recognized
complication of bone marrow and solid organ transplantation,
less frequent recently due to improvements in preemptive detec-
tion and therapy. CMV retinitis is frequently diagnosed clinically
because of characteristic lesions seen on ophthalmologic exami-
nation. Quantitative CMV NAAT performed on peripheral
blood is also a useful tool in the diagnosis and management of
this infection. Patients with detectable CMV viral loads have a
higher likelihood of retinal disease progression, and those with
high CMV viral loads have increased mortality. Patients with un-
detectable CMV viral loads have a low likelihood of having virus
that is resistant to antiviral agents [57]. Because of inter-laborato-
ry variation in viral quantification, what represents a positive
CMV viral load and a high CMV viral load will vary among lab-
oratories [58]. Physicians should consult the laboratory perform-
ing the CMV viral load for assistance with test interpretation. As
with CMV viral loads, persistent CMV antigenemia also predicts
a higher likelihood of retinal disease progression and death [59].
Patients with syphilitic uveitis frequently have central nervous
system findings either associated with acute syphilitic menin-
gitis or neurosyphilis. VDRL testing of cerebrospinal fluid is
recommended in clinical settings where syphilitic uveitis is sus-
pected [51] (see section II-A).
IV. SOFT TISSUE INFECTIONS OF THE HEAD
ANDNECK
Infection of various spaces and tissues that occur in the head
and neck can be divided into those arising from odontogenic,
oropharyngeal, or exogenous sources [60]. Odontogenic infec-
tions are usually caused by endogenous periodontal or gingival
flora. These infections include peritonsillar and pharyngeal ab-
scesses, deep space abscesses, such as those of the retrophar-
yngeal, parapharyngeal, submandibular, and sublingual spaces,
and cervical lymphadenitis [61, 62]. Complications of odonto-
genic infection can occur by hematogenous spread or by
direct extension resulting in septic jugular vein thrombophlebi-
tis (Lemierre syndrome), bacterial endocarditis, intracranial
abscess, or acute mediastinitis [63, 64]. Accurate etiologic diag-
nosis depends on collection of an aspirate or biopsy of inflam-
matory material from affected tissues and tissue spaces while
avoiding contamination with mucosal flora. The specimen
should be placed into an anaerobic transport container to
support the recovery of anaerobic bacteria (both aerobic and
facultative bacteria survive in anaerobic transport). Requests for
Gram-stained smears are standard for all anaerobic cultures
because they allow the laboratorian to evaluate the adequacy of
the specimen by identifying inflammatory cells, provide an
early, presumptive etiologic diagnosis, and possibly identify
mixed aerobic and anaerobic infections [65]. Additionally, spi-
rochetes (often involved in odontogenic infection) cannot be
recovered in routine anaerobic cultures but will be seen on the
smear.
Infections caused by oropharyngeal flora include epiglottitis,
mastoiditis, inflammation of salivary tissue, and suppurative
parotitis [60, 66]. Because the epiglottis may swell dramatically
during epiglottitis, there is a chance of sudden occlusion of the
trachea if the epiglottis is disturbed, such as by an attempt to
collect a swab specimen. Blood cultures are the preferred
sample for the diagnosis of epiglottitis; if swabbing is attempt-
ed, it should be in a setting with available appropriate emergen-
cy response. Oropharyngeal flora also can extend into tissues of
the middle ear, mastoid and nasal sinuses causing acute infec-
tion [60, 67]. In addition, mycobacteria, staphylococci, and
gram-negative bacilli occasionally are implicated. Aspirated
material, saline lavage of a closed space, and tissue or tissue
scrapings are preferred specimens and must be transported in a
sterile container. Tissues should be transported under sterile
conditions so that the specimen remains moist. Because anaer-
obic bacteria are infrequent pathogens in these infections, an-
aerobic transport is not needed routinely. Note that fungi are
common causes of chronic sinusitis, and they may not be re-
covered on swabs, even those obtained endoscopically. Endo-
scopic sinus aspirates are the specimens of choice. For
microbiology analysis, it is always best to submit the actual
specimen, not a swab of the specimen.
Infections caused by exogenous pathogens (not part of the
oral flora) include malignant otitis externa, mastoiditis, animal
bites and trauma, irradiation burns, and complications of surgi-
cal procedures [67, 68]. Although oral flora may play an occa-
sional etiologic role, gram-negative bacilli and staphylococci are
most frequently associated with these conditions.
Key points for the laboratory diagnosis of head and neck soft
tissue infections:
• A swab is not the specimen of choice for these specimens.
Submit tissue, fluid, or aspirate when possible.
• Resist swabbing in cases of epiglottitis.
• Use anaerobic transport containers if anaerobes are sus-
pected.
• Keep tissue specimens moist during transport.
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Table IV-1. Laboratory Diagnosis of Infections of the Oral Cavity and Adjacent Spaces and Tissues Caused by Odontogenic and Oropha-
ryngeal Flora




Mixed infection due to
Fusobacterium spp and
commensal Borrelia spp
of the oral cavity
Gram stain; culture not
recommended
Biopsy or irrigation and aspiration




If culture attempted, anaerobic
transport vial, RT, 2 h
Epiglottitis and Supraglottitis
Normal Host
Haemophilus influenzae Gram stain Clinical diagnosis may not require
specimen
Swab transport device, RT, 2 h
Streptococcus pneumoniae Aerobic bacterial culture Swab of epiglottisa only if
necessary




Same bacteria as in the
normal host above but
also other agents such
as Pasteurella multocida
Gram stain Clinical diagnosis may not require
specimen
Swab transport device, RT, 2 h
Aerobic bacterial culture Swab of epiglottisa only if
necessary
Blood cultures Blood, 2–4 sets Aerobic blood culture bottle,
RT, immediately
Aspergillus spp Calcofluor-KOH stain Biopsy or protected specimen
brush.
Sterile container, RT, 2 h
Other fungi Fungal culture Swab much less likely to recover
fungi.
Fungal blood cultures Blood, 2–4 sets Aerobic blood culture bottle






Streptococcus pyogenes Gram stain Biopsy, aspiration or irrigation of
abscess; swab not
recommended
Sterile anaerobic container, RT,











Gram stain Biopsy, aspiration or irrigation of
lesion; swab not recommended










Blood culturesb Blood, 2–4 sets Aerobic and anaerobic blood
culture bottle, RT,
immediately
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The following tables include the most common soft tissue
and tissue space infections of the head and neck that originate
from odontogenic, oropharyngeal and exogenous sources. The
optimum approach to establishing an etiologic diagnosis of
each condition is provided.
A. Infections of the Oral Cavity, and Adjacent Spaces and
Tissues Caused by Odontogenic and Oropharyngeal Flora
(Table IV-1)
B. Mastoiditis and Malignant Otitis Externa Caused
by Oropharyngeal and Exogenous Pathogens (Table IV-2)
V. UPPER RESPIRATORY TRACT BACTERIAL
AND FUNGAL INFECTIONS
Infections in the upper respiratory tract usually involve the
ears, the mucus membranes lining the nose and throat above
the epiglottis, and the sinuses. Most infections involving the
Table IV-1 continued.
Etiologic Agents Diagnostic Procedures Optimum Specimens
Transport Issues; Optimal
Transport Time
Submandibular, Retropharyngeal and Other Deep Space Infections Including Ludwig’s Angina
Streptococcus pyogenes Gram stain Biopsy, aspiration or irrigation of
lesion; swab not recommended
Sterile anaerobic container, RT,














Gram stain Biopsy, aspiration or irrigation of
abscess; swab not
recommended








of the oral cavity






Acid fast smear Biopsy, aspiration or irrigation of
abscess;swab not
recommended
Sterile container, RT, 2 h
M. tuberculosis AFB culture
Other mycobacteria






Bartonella henselae Bartonella NAATc 5 mL plasma EDTA tube, RT, 2 h






Starry and H&E stains)




Abbreviations: AFB, acid fast bacillus; KOH, potassium hydroxide; NAAT, nucleic acid amplification test ; RT, room temperature.
a Alert! Consider risk. During specimen collection, airway compromise may occur, necessitating the availability of intubation and resuscitation equipment and
personnel.
b Blood cultures should be performed at the discretion of the healthcare provider.
c Note that nucleic acid tests are not usually available locally and must be sent to a reference laboratory with the resulting longer turnaround time.
d The laboratory should be alerted if Bartonella cultures will be requested so that appropriate media are available at the time the specimen arrives in the laboratory;
even then, the yield of Bartonella culture is very low. When available, Bartonella nucleic acid testing is more sensitive. A portion of the specimen should be sent to
the histopathology laboratory for H&E and Warthin-Starry stains.
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nose and throat are caused by viruses (see XIV Viral Syn-
dromes section for testing information). Inappropriate utiliza-
tion of antibiotics for viral infections is a major driver of
increasing antibiotic resistance. Proper diagnosis of infectious
syndromes in this environment must involve laboratory tests to
determine the etiology and thus inform the proper therapy.
Key points for the laboratory diagnosis of upper respiratory
tract infections:
• Swabs are not recommended for otitis media or sinusitis.
Submit an aspirate for culture.
• Most cases of otitis media can be diagnosed clinically and
treated without culture support.
• Throat specimens require a firm, thorough sampling of
the throat and tonsils, avoiding cheeks, gums, and teeth.
• Haemophilus influenzae, Staphylococcus aureus, Neisseria
meningitidis, and Streptococcus pneumoniae are not etiologic
agents of pharyngitis and should not be sought in throat cul-
tures; nor can nasopharyngeal cultures accurately predict the
etiologic agent of sinusitis.
A. Otitis Media
Otitis media is the single most frequent condition causing pedi-
atric patients to be taken to a healthcare provider [69]. Acute
otitis media with effusion (AOME) is the clinical variant of
otitis media most likely to have a bacterial etiology and as a
result, most likely to benefit from antimicrobial therapy
(Table V-1). Streptococcus pneumoniae, nontypeable Haemo-
philus influenzae, and Moraxella catarrhalis are the most
common bacterial causes of AOME, with S. aureus,
Streptococcus pyogenes, and Pseudomonas aeruginosa occur-
ring less commonly [70]. Alloiococcus otitidis is also thought
to cause AOME, but additional studies are needed to deter-
mine the true significance of this organism [70]. A variety of
respiratory viruses are known to cause AOME; however,
there exists no pathogen specific therapy and as a result,
there is little reason to attempt to establish an etiologic diag-
nosis in patients with a viral etiology. Efforts to determine
the cause of AOME are best reserved for patients likely to
have a bacterial etiology (recent onset, bulging tympanic
membrane, pain, or exudate) who have not responded to
prior courses of antimicrobial therapy, patients with immu-
nological deficiencies, and acutely ill patients [69, 71]. The
only representative specimen is middle ear fluid obtained
either by tympanocentesis or, in patients with otorrhoea or
myringotomy tubes, by collecting drainage on minitipped
swabs directly after cleaning the ear canal. Cultures of the
pharynx, nasopharynx, anterior nares, or of nasal drainage
material are of no value in attempting to establish an etiolog-
ic diagnosis of bacterial AOME.
Viruses are often the etiologic agent, but microbiologic
studies do not help with treatment decisions.
B. Sinusitis
The etiological agents of sinusitis vary based upon the duration
of symptoms and whether it is community-acquired or of noso-
comial origin (Table V-2). Streptococcus pneumoniae, nontype-
able Haemophilus influenzae, and Moraxella catarrhalis are the
most common bacterial causes of acute maxillary sinusitis. The
role of respiratory viruses in sinusitis needs further studies.









Streptococcus pneumoniae Gram stain Middle ear fluid obtained by
tympanocentesis or biopsy of
mastoid tissue; swab not
recommended
Sterile anaerobic container, RT,









Acid fast smear Biopsy of mastoid tissue Sterile container, RT, 2 h
AFB culture
Malignant Otitis Externa
Pseudomonas aeruginosa Gram stain Scraping or fluid from external
canal or tissue biopsy from
temporal bone or mastoid
Sterile container, RT, 2 h
Aerobic bacterial culture
Abbreviations: AFB, acid fast bacillus; RT, room temperature.
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Staphylococcus aureus, gram-negative bacilli, Streptococcus spp,
and anaerobic bacteria are associated more frequently with sub-
acute, chronic, or nosocomial sinusitis. The role of fungi as eti-
ological agents is more controversial, possibly due to numerous
publications that used poor sample collection methods and
thus did not recover the fungal agents. In immunocompetent
hosts, fungi are associated most often with chronic sinusitis
[72, 73]. Sinusitis due to fungal infections in severely immuno-
compromised persons or uncontrolled diabetic patients is often
severe and carries a high mortality rate.
Attempts to establish an etiologic diagnosis of sinusitis are
typically reserved for patients with complicated infections or
chronic disease. Swabs are not recommended for collecting sinus
specimens because an aspirate is much more productive of the
true etiologic agent(s). Endoscopically obtained swabs can
recover bacterial pathogens but rarely detect the causative fungi
[74–76]. In maxillary sinusitis, antral puncture with sinus aspira-
tion and, in adults, swabs of material draining from the middle
meatus obtained under endoscopic guidance represent the only
adequate specimens. Cultures of middle meatus drainage speci-
mens are not recommended for pediatric patients due to poten-
tial colonization with respiratory tract pathogens. Examination
of nasal drainage material is of no value in attempting to deter-
mine the cause of maxillary sinusitis. Surgical procedures are
necessary to obtain specimens representative of infection of the
frontal, sphenoid, or ethmoid sinuses. To establish a fungal etiol-
ogy, an endoscopic sinus aspirate is recommended [76].
C. Pharyngitis
Pharyngitis accounts for an estimated 40 million visits by
adults to medical facilities annually in the United States. The
condition occurs even more often in children. Differences
between the epidemiology of various infectious agents related
to the age of the patient, the season of the year, accompanying
signs and symptoms, and the presence or absence of systemic
disease are not sufficiently precise to permit establishing a
definitive etiologic diagnosis on clinical and epidemiologic
grounds alone [77]. Consequently, the results of laboratory tests
play a central role in guiding therapeutic decisions (Table V-3).
Antimicrobial therapy is only warranted in patients with phar-
yngitis with a proven bacterial etiology [78].
Streptococcus pyogenes (Group A β-hemolytic Streptococcus) is
the most common bacterial cause of pharyngitis and carries with
it potentially serious sequelae, primarily in children, if left undi-
agnosed or inadequately treated. Several laboratory tests, includ-
ing culture, rapid antigen tests, and molecular methods, have
been used to establish an etiologic diagnosis of pharyngitis due to
this organism [77]. During the past decade, rapid antigen tests
for S. pyogenes, in particular, have been used extensively in the
evaluation of patients with pharyngitis. Such tests are technically
nondemanding, generally reliable and often performed at the
point-of-care. For any of these methods, accuracy and clinical rel-
evance depends on appropriate sampling technique.
There has been a general consensus among the professional
societies that negative rapid antigen tests for S. pyogenes in chil-
dren should be confirmed by culture or molecular assay. Al-
though this is generally not necessary for negative test results in
adults, new guidelines suggest that either conventional culture
or confirmation of negative rapid antigen test results by culture
should be used to achieve maximal sensitivity for diagnosis of
S. pyogenes pharyngitis in adults [79]. Laboratories accredited
by the College of American Pathologists are required to back
up negative rapid antigen tests with culture.
The role of non-Group A β-hemolytic streptococci, in partic-
ular, Groups C and G, as causes of pharyngitis is controversial.
However, many healthcare providers consider these organisms
to be of significance and base therapeutic decisions on their de-
tection. Rare cases of post-streptococcal glomerulonephritis
after infection with these species have been reported. Therefore,
we have included guidance for detecting Groups C and G β-
hemolytic streptococci (large colony producers, since S. anginosus
group, characteristically yielding pinpoint colonies, does not
Table V-1. Laboratory Diagnosis of Otitis Media
Etiological Agentsa Diagnostic Procedures Optimum Specimens
Transport Issues; Optimal
Transport Time
Streptococcus pneumoniae Gram stain, Tympanocentesis fluid Sterile container, RT, immediately
Haemophilus influenzae Aerobic bacterial culture Mini-tipped swab of fluid draining
from the middle ear cavity in
patients with myringotomy
tubes or otorrhoea






Abbreviation: RT, room temperature.
a Viruses are often the etiologic agent but microbiologic studies do not help with treatment decisions.
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cause pharyngitis) in pharyngeal swab specimens but indicate
that this should be done only in settings in which these organ-
isms are considered to be of significance, such as outbreaks of
epidemiologically associated cases of pharyngitis. Recovery of
the same organism from multiple patients during an outbreak
should be investigated. Arcanobacterium haemolyticum also
causes pharyngitis but less commonly. It occurs most often in
teenagers and young adults and is often found to cause a highly
suggestive scarlatina-form rash in some patients. Neisseria gon-
orrhoeae and Corynebacterium diphtheriae, in very specific epi-
demiologic settings, may also cause pharyngitis.
Respiratory viruses are the most common cause of pharyngi-
tis in both adult and pediatric populations; however, it is un-
necessary to define a specific etiology in patients with
pharyngitis due to respiratory viruses because there exists no
pathogen-directed therapy for these agents. Herpes simplex
virus (HSV), human immunodeficiency virus (HIV), and
Epstein-Barr virus (EBV) may also cause pharyngitis. Because
of the epidemiologic and clinical implications of infection due
to HSV, HIV, and EBV, circumstances may arise in which it is
important to attempt to determine if an individual patient’s in-
fection is caused by one of these 3 agents.
Recent studies have shown a relationship between Fusobacte-
rium necrophorum and pharyngitis in some patients. In this case,
throat infection could be a prelude to Lemierre syndrome. F. nec-
rophorum is an anaerobic organism and as such, will require addi-
tional media and the use of anaerobic isolation and identification
procedures, which most laboratories are not prepared to use
with throat specimens. Notify the laboratory of the suspected
diagnosis and the etiologic agent so appropriate procedures can
be available. In the absence of anaerobic capability of the labo-
ratory, this would be sent out to a reference laboratory [80–85].
Table V-2. Laboratory Diagnosis of Sinusitis





Streptococcus pneumoniae Gram stain Aspirate obtained by antral
puncture
Sinus secretion collector (vacuum
aspirator)
Haemophilus influenzae Aerobic bacterial culture Sterile container, RT, immediately
Moraxella catarrhalis Middle meatal swab specimen
obtained with endoscopic
guidance





Streptococcus pneumoniae Gram stain Aspirate obtained by antral
punctureb
Sinus secretion collector (vacuum
aspirator)
Haemophilus influenzae Aerobic and anaerobic
bacterial culture
Sterile anaerobic container, RT,
immediatelycMoraxella catarrhalis
Staphylococcus aureus Tissue or aspirate obtained
surgically





flora from the oral cavity
Fungal




Zygomycetes Fungus culture Sterile aerobic container, RT,
immediatelyFusarium spp.
Other moulds Tissue or aspirate obtained
surgically
Sterile aerobic container, RT,
immediately
Abbreviations: KOH, potassium hydroxide; RT, room temperature.
a Staphylococcus aureus and Streptococcus pyogenes do cause acute maxillary sinusitis but only infrequently [75].
b Antral puncture is a useful method for sampling the maxillary sinuses.
c Anaerobic transport vials are good for both aerobic and anaerobic bacteria.
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VI. LOWER RESPIRATORY TRACT INFECTIONS
Respiratory tract infections are among the most common infec-
tious diseases. The list of causative agents continues to expand
as new pathogens and syndromes are recognized. This section
describes the major etiologic agents and the microbiologic ap-
proaches to the diagnosis of bronchitis and bronchiolitis;
community-acquired pneumonia; healthcare-associated and
Table V-3. Laboratory Diagnosis of Pharyngitis




Streptococcus pyogenes Rapid direct antigen test (followed by a
secondary test if negative)a
Dual pharyngeal swab Swab transport device, RT, 2 h
Direct nucleic acid amplification test (NAAT)b Pharyngeal swab Swab transport device, RT, 2 h
Nucleic acid probe testsb Pharyngeal swab
Groups C and G β-hemolytic
streptococcic
Throat culture and antigen tests on isolates for
Groups C and G streptococci
Pharyngeal swab Swab transport device, RT, 2 h
Arcanobacterium haemolyticumd Throat culture for A. haemolyticum Pharyngeal swab Swab transport device, RT, 2 h
Neisseria gonorrhoeaed Throat culture for N. gonnorrhoeae Pharyngeal swab Swab transport device, RT, 2 h
Corynebacterium diphtheriaed Methylene blue stain C. diphtheriae culture Pseudomembrane Sterile container, RT,
immediately
Fusobacterium necrophorum Anaerobic incubation. A selective medium is availablePharyngeal swab Anaerobic swab transport,
RT, 2 h
Viral
Epstein-Barr virus (EBV) Monospot teste 5 mL serum Clot tube, RT, 2 h
EBV serology
Herpes Simplex virus (HSV)
[usually Type 1]
Direct detection testf Swab of pharyngeal
lesion
Swab transport device, RT, 2 h
Culturef
HSV IgG and IgM serologyg 5 mL serum Clot tube, RT, 2 h
Cytomegalovirus (CMV) CMV IgM serology 5 mL serum Clot tube, RT, 2 h
Human immunodeficiency
virus (HIV)
(see XIV Viral Syndrome)
Abbreviations: IgG, immunoglobulin G; IgM, immunoglobulin M; NAAT, nucleic acid amplification test; RT, room temperature.
a A rapid antigen test for Streptococcus pyogenes may be performed at the point-of-care by healthcare personnel or transported to the laboratory for performance
of the test. There are numerous commercially available direct antigen tests. These vary in terms of sensitivity and ease of use; the specific test employed will
dictate the swab transport system used. In pediatric patients, if the direct antigen test is negative, and if the direct antigen test is known to have a sensitivity of
<80%, a second throat swab should be examined by a more sensitive direct NAAT or by culture as a means of arbitrating possible false negative direct antigen test
results [78]. This secondary testing is usually unnecessary in adults [79]. A convenient means of facilitating this two-step algorithm of testing for Streptococcus
pyogenes in pediatric patients is to collect a dual swab initially, recognizing that the second swab will be discarded if the direct antigen test is positive.
b Direct NAATs for Streptococcus pyogenes are more sensitive than direct antigen tests and, as a result, negative direct NAAT results do not have to be arbitrated
by a secondary test. The swab transport device should be compatible with the NAAT used. Nucleic acid probe tests are usually performed on enriched broth
cultures, thus requiring longer turnaround times.
c Detection of Groups C and G β-hemolytic streptococci is accomplished by throat culture in those patients in whom there exists a concern for an etiologic role for
these organisms. Only large colony types are identified, as tiny colonies demonstrating groups C and G antigens are in the S. anginosus (“S. milleri”) group. Check
with the laboratory to determine if these are routinely looked for.
dArcanobacterium haemolyticum, Neisseria gonorrhoeae and Corynebacterium diphtheriae only cause pharyngitis in restricted epidemiologic settings. The
laboratory will not routinely attempt to recover these organisms from throat swab specimens. If a clinical suspicion exists for one of these pathogens, the laboratory
should be notified so that appropriate measures can be applied to aid in their detection.
e If the Monospot test is positive, it may be considered diagnostic for EBV infection. Up to 10% of Monospot tests are, however, falsely negative. False negative
Monospot tests are encountered most often in younger children. In a patient with a strong clinical suspicion for EBV infection and a negative Monospot test, a
definitive diagnosis can be achieved with EBV-specific serologic testing. Such testing can be performed on the same sample that yielded a negative Monospot
test. Alternatively, the Monospot test can be repeated on a serum specimen obtained 7–10 days later at which time, if the patient had EBV infection, the Monospot
is more likely to be positive.
f Probable cause of pharyngitis only in immumocompromised patients. Numerous rapid tests based on detecting HSV-specific antigen (by DFA) directly in clinical
material have been developed; however the nonspecific stain Tzanck test is very insensitive and not recommended. A swab should be used to aggressively collect
material from the base of multiple pharyngeal lesions and then placed in a swab transport device that is compatible with the test to be performed. Culture may be
useful in immunocompromised patients.
g The serologic test should distinguish between IgG and IgM. Depending on the age of the patient and the specific serologic assay used, in the face of a compatible
illness, a single HSV-specific IgG level may be considered presumptive evidence of HSV infection. The presence of HSV-specific IgM may be considered
diagnostic.
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Table VI-1. Laboratory Diagnosis of Bronchitis and Bronchiolitis




Mycoplasma pneumoniae NAATa,b Throat swabc, nasopharyngeal
(NP) swab, sputum
NP swab, aspirate or wash
Suitable transport device, RT, 2 h
Mycoplasma IgG and IgM
serology (enzyme
immunoassay [EIA])
5 mL serum Clot tube, RT, 2 h
Chlamydophila
pneumoniae
NAATa,b Nasopharyngeal (NP) swab,
sputum
Suitable transport device, RT, 2 h
Chlamydia IgG and IgM serology
(microimmunofluorescent stain;
MIF)
5 mL serum Clot tube, RT, 2 h
Bordetella pertussis Bordetella culture and/or NAAT Nasopharyngeal (NP) swab Suitable transport device, RT, 2 h
Viruses
Influenza virus Rapid antigen detection testsd Nasal aspirates or washes, NP
swabs or aspirates, throat
washes or swabs
Suitable transport device, wet ice,
2 hAdenovirus Virus culture
Parainfluenza virus
Respiratory syncytial virus NAATe Nasal aspirates or washes, NP
swabs or aspirates, throat
washes or swabs








Gram stain Expectorated sputum Sterile container, RT, 2 h
Moraxella catarrhalis Aerobic bacterial culture
Chlamydophila
pneumoniae
See above under Acute Bronchitis See Chlamydophila and
Mycoplasma above
See above
Mycoplasma pneumoniae See above under Acute Bronchitis See Chlamydophila and
Mycoplasma above
See above
Streptococcus pneumoniae Gram stain
Aerobic bacterial culture
Urine Antigenf First voided clean catch urine
specimen
Sterile container, RT, 2 h
Viruses
Rhinovirus Rapid antigen detection testsd Nasal aspirates or washes, NP
swabs or aspirates, throat
washes or swabs
Suitable transport device, RT, 2 h
Coronavirus Virus culture Note that transport on wet ice is
preferable, and recommended if







Abbreviations: IgG, immunoglobulin G; IgM, immunoglobulin M; NAAT, nucleic acid amplification test; RT, room temperature.
a There is only one FDA cleared assay available at this time. Availability is laboratory specific. Clinician should check with the laboratory for optimal specimen source,
performance characteristics, and turnaround time.
b Avoid calcium alginate swabs for nucleic acid amplification tests.
cWhile approved for use with certain commercial products, throat specimens, especially swabs, are the least desirable and provide the poorest recovery.
d Rapid antigen tests for respiratory virus detection lack sensitivity and, depending upon the product, specificity. They should be considered as screening tests only.
At a minimum a negative result should be verified by another method. Specimen quality is critical to optimize these tests.
e Several FDA cleared NAAT platforms are currently available and vary in their approved specimen requirements and range of analytes detected. Readers should
check with their laboratory regarding availability and performance characteristics including certain limitations.
f Sensitivity in nonbacteremic patients with pneumococcal pneumonia is 52%–78%; sensitivity in bacteremic cases of pneumococcal pneumonia is 80%–86%;
specificity in adults is >90%. However, studies have reported a 21%–54% false positive rate in children with NP carriage and no evidence of pneumonia [87] and
adults with chronic obstructive pulmonary disease [88].
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Table VI-2. Laboratory Diagnosis of Community-acquired Pneumonia




Streptococcus pneumoniae Gram stain Sputum, bronchoscopic
specimens
Sterile container, RT, 2 h; >2–24 h, 4°C
Culture
Urine antigena Urine Sterile container, RT, 24 h; >24 h–14 d,
2–8°C
Staphylococcus aureus Gram stain Sputum, bronchoscopic
specimens




Legionella species Urine antigen Urine Sterile container, RT, 24 h; >24 h–14 d,
2–8°CL. pneumophila serogroup 1
Selective culture on BCYE Induced sputum, bronchoscopic
specimens
Sterile container, RT, 2 h; >2–24 h, 4°C
NAATb Induced sputum, bronchoscopic
specimens
Sterile container, RT, 2 h; >2–24 h, 4°C
Mycoplasma pneumoniae NAATb Throat swab, NP swab, sputum,
bronchoalveolar lavage (BAL)
Transport in M4 media or other
Mycoplasma-specific medium at RT or
4°C up to 48 h; ≥48 h, −70°C
Serology IgM, IgG antibody
detection
Serum Clot tube, RT, 24 h; >24 h, 4°C
Chlamydophila
pneumoniae
NAATb NP swab, throat washings,
sputum, bronchial specimens
Transport in M4 or other specialized
medium at RT or 4°C up to 48 h;≥48 h,
−70°C
Serology (MIF) IgM antibody titer;
IgG on paired serum 2–3 wk
apart
Serum Clot tube, RT, 24 h; >24 h, 4°C
Mixed anaerobic bacteria
(Aspiration pneumonia)
Gram stain Bronchoscopy with protected
specimen brush
Sterile tube with 1 mL of saline or
thioglycolate; RT, 2 h; >2–24 hAerobic and anaerobic culture
Pleural fluid (if available) Sterile container RT, without transport







AFB smear Expectorated sputum; induced
sputum; bronchoscopically
obtained specimens










Sterile container, RT, <2 h; ≤24 h, 4°C
Fungal culture
Histology Tissue Sterile container 4°C; Formalin container,
RT, 2–14 d
Antigen Tests Serum, urine, pleural fluid (if
available)
Clot tube, RT, 2 d; 2–14 d. 4°C
Sterile container (urine), RT 2 h; >2–72 h,
4°C
Serum antibody (CF) Serum Clot tube, RT, 24 h; 4°C, >24 h
Coccidioides immitis/
posadasii





Sterile container, RT, <2 h; ≤24 h, 4°C
Fungal culture
Histology Tissue Formalin container, RT, 2–14 d; Sterile
container 2–14 d, 4°C
Serum antibody IgM (ID, LA, EIA) Serum Clot tube, RT, 24 h;>24 h, 4°C
IgG antibody (CF, EIA)
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ventilator-associated pneumonia; infections of the pleural
space; bronchopulmonary infections in patients with cystic fi-
brosis; and pneumonia in the immunocompromised host. The
reader is referred to various IDSA practice guidelines that have
been written in recent years that describe the clinical features,
diagnostic approaches, and patient management aspects of
many of these syndromes.
The Key Points below summarize some important caveats
when obtaining specimens for the diagnosis of respiratory
infections.
Table VI-2 continued.
Etiologic Agents Diagnostic Procedures Optimum Specimens
Transport Issues; Optimal
Transport Time





Sterile container, RT, < 2 h; ≤24 h, 4°C
Fungal culture
Histology Tissue Sterile container 4°C, Formalin container,
RT, 2–14 d
Antigen Tests Serum, Clot tube, RT, 24 h
Urine, pleural fluid (if available) Sterile container 4°C, 2–14 d
Serum antibody (CF) Serum Clot tube, RT, 24 h; >24 h, 4°C
Viruses
Influenza viruses A, B Rapid antigen detection Nasal aspirates, nasal washes, NP swabs, throat washes, throat swabs,
bronchoscopically obtained samples






Parainfluenza viruses 1–4 DFA
Viral culture methods
NAATc







Rhinovirus Viral culture methods
NAATc
Enteroviruses Viral culture methods
NAATc
Parasites
Paragonimus westermani Direct microscopic examination of
pleural fluid and sputum for
characteristic ova
Pleural fluid Sterile container, fresh samples 4°C, 60
min; preserved samples, RT, >60 min–
30 d
Sputum
Abbreviations: BAL, bronchoalveolar lavage; BCYE, buffered charcoal yeast extract; CF, complement fixation; DFA, direct fluorescent antibody test; EIA, enzyme
immunoassay; ID, immunodiffusion; KOH, potassium hydroxide; LA, latex agglutination; NAAT, nucleic acid amplification test; NP, nasopharyngeal; RT, room
temperature.
a Sensitivity in nonbacteremic patients with pneumococcal pneumonia is 52%–78%; sensitivity in bacteremic cases of pneumococcal pneumonia is 80%–86%;
specificity in adults is > 90%. However, studies have reported a 21%–54% false positive rate in children with NP carriage and no evidence of pneumonia [87].
b Currently there is one FDA approved platform (see text). Availability is laboratory specific. Provider needs to check with the laboratory for optimal specimen
source, performance characteristics and turn around time.
c Several FDA cleared NAAT platforms are currently available and vary in their approved specimen requirements and range of analytes detected. Readers should
check with their laboratory regarding availability and performance characteristics including certain limitations.
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Blood culture Blood cultures Sterile cup or tube RT, 2 h; 4°C, >2–24 h
Escherichia coli Gram stain Sputum





Serratia marcescens Protected specimen brush samplesa












Gram stain Protected specimen brush samplesa Sterile tube with 1 mL of thioglycolate
(for brush samples); Sterile container
for tissue; RT, 2 h; 4°C, >2–24 h
Culturea Lung tissue
Legionella spp Culture on BCYEmedia Induced sputum Sterile cup or tube RT, 2 h; 4°C, >2–24 h
NAATc Endotracheal aspirates
BAL
Protected specimen brush samples
Lung tissue
Urine antigen (L. pneumophila
serogroup 1 only)
Urine Sterile container RT, <24 h; 4°C
>24 h–14 d
Fungi
Aspergillus spp Fungal stain—KOHwith
calcofluor; other fungal
stains
Endotracheal aspirates Sterile cup or tube RT, 2 h; 4°C, >2–24 h
Fungal culture BAL
Protected specimen brush samples




Serum, Clot tube 4°C, ≤5 d; >5 d, −70°C
BALe Sterile cup or tube RT, 2 h; 4°C, >2–24 h
Viruses
Influenza viruses A, B Rapid antigen detection Nasal washes, aspirates Transport in viral transport media, RT or
4°C, 5 d; −70°C, >5 dParainfluenza viruses Viral culture methods NP swabs




DFA Protected specimen brush samples
Abbreviations: BAL, bronchoalveolar lavage; BCYE, buffered charcoal yeast extract; DFA, direct fluorescent antibody; KOH, potassium hydroxide; MRSA,
methicillin-resistant Staphylococcus aureus; NAAT, nucleic acid amplification test; NP, nasopharyngeal; RT, room temperature.
a Anaerobic culture should only be done if the specimen has been obtained with a protected brush or catheter and transported in an anaerobic transport container or
by placing the brush in 1 mL of pre-reduced broth prior to transport.
b Sensitivity in nonbacteremic patients with pneumococcal pneumonia is 52%–78%; sensitivity in bacteremic cases of pneumococcal pneumonia is 80%–86%;
specificity in adults is >90%. However, studies have reported a 21%–54% false positive rate in children with NP carriage and no evidence of pneumonia [87].
c No FDA cleared test is currently available. Availability is laboratory specific. Provider needs to check with the laboratory for optimal specimen source, performance
characteristics and turnaround time.
d Performance characteristics of these tests are reviewed in reference [93].
e Testing from this source is not offered in all microbiology laboratories.
f Several FDA cleared NAAT platforms are currently available and vary in their approved specimen requirements and range of analytes detected. Readers should
check with their laboratories regarding availability and performance characteristics including certain limitations.
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Table VI-4. Laboratory Diagnosis of Infections of the Pleural Space





Staphylococcus aureus Gram stain Pleural fluid Sterile container, RT, 2 h; 4°C,
>2–24 hCulture
Streptococcus pneumoniae As above plus S. pneumoniae
urinary antigen
Urine Sterile container, RT, 24 h;
>24 h–14 d, 2–8°C
Streptococcus pyogenes Gram stain Pleural fluid Sterile container, RT, 2 h; 4°C,







Modified acid fast stain




Pleural fluid Sterile container, RT, 2 h; 4°C,
>2–24 h
Culture on BCYE
Legionella urinary antigen (L.
pneumophila serogroup 1 only)
Urine Sterile container, RT, <24 h; 4°
C, >24 h–14 d
Anaerobes
Bacteroides fragilis group Gram stain Pleural fluid Anaerobic transport vial, RT,
72 h; without transport RT
≤60 min







Acid fast stain Pleural fluid Sterile container, RT, 2 h; 4°C,
>2–24 hMycobacterial Culture
NAATa
Histology Pleural or lung biopsy Sterile container, RT, 2 h; 4°C,
3 d
Pleural fluid Formalin container, RT, 2–14 d
Fungi
Fungi Fungal stain—calcofluor - KOH;
other fungal stains
Pleural fluid Sterile container, RT, 2 h; 4°C,
>2–24 h
Fungal culture Pleural biopsy required for
some diseases
Candida spp As above plus may be evident on
Gram stain
Pleural fluid Sterile container, RT, 2 h; 4°C,
>2–24 h




BAL Sterile container, 4°C, ≤5 d;
−70°C >5 d
Serum Clot tube RT, 2 d; 4°C,
Histoplasma capsulatum Fungal stain—calcofluor - KOH;
other fungal stains
Pleural fluid Sterile container, RT, 2 h; 4°C,
>2–24 h
Fungal culture Pleural biopsy Sterile container, RT, 2 h; 4°C,
>2–24 h; Formalin container
for histology, RT 2–14 d
Histology
Antigen testc Serum, urine, pleural fluid, Clot tube, RT, 2 d; 4°C, 2–14 d
Sterile container (urine and
fluid), RT 2 h; >2–72 h, 4°C
Serum antibody (CF) Serum Clot tube RT, 2 d; 4°C, 2–14 d
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Key points for the laboratory diagnosis of lower respiratory
tract infections:
• First morning sputum is always best for culture.
• Calcium alginate swabs are not acceptable for nucleic
acid amplification testing.
• Most negative rapid antigen test results should be con-
firmed by another method.
• Blood cultures that accompany sputum specimens may
occasionally be helpful, particularly in high risk community ac-
quired pneumonia patients.
• The laboratory should be contacted for specific instruc-
tions prior to collection of specimens for fastidious pathogens
such as Bordetella pertussis.
• The range of pathogens causing exacerbations of lung
disease in cystic fibrosis patients has expanded and specimens
for mycobacterial and fungal cultures should be collected in
some patients.
• In the immunocompromised host, a broad diagnostic ap-
proach based on invasively obtained specimens is suggested.
A. Bronchitis and Bronchiolitis
Table VI-1 lists the etiologic agents and diagnostic approaches
for acute bronchitis, acute exacerbation of chronic bronchitis
and bronchiolitis, 3 clinical syndromes that involve inflamma-
tion of the tracheobronchial tree [86]. Acute bronchitis is
largely due to viral pathogens and is less frequently caused by
Mycoplasma pneumoniae and Chlamydophila pneumoniae.
Bordetella pertussis should be considered in an adolescent or
young adult with prominent cough. Direct fluorescent antibody
testing has been replaced by nucleic acid amplification tests
(NAATs) in combination with culture as the recommended
tests of choice for B. pertussis detection. Currently, there is one
FDA cleared platform for B. pertussis detection. Streptococcus
pneumoniae and Haemophilus influenzae do not play an estab-
lished role in acute bronchitis, but they, along with Moraxella
catarrhalis, do figure prominently in cases of acute exacerbation
of chronic bronchitis. Bronchiolitis is almost exclusively caused
by viruses and M. pneumoniae. Several FDA-approved NAAT
platforms are available for the detection of select respiratory
viruses.
B. Community-Acquired Pneumonia
The diagnosis of community-acquired pneumonia is based on
the presence of specific symptoms and suggestive radiographic
features, such as pulmonary infiltrates and/or pleural effusion.
Carefully obtained microbiological data can support the diag-
nosis but often fails to provide an etiologic agent. Table VI-2
lists the more common causes of community-acquired pneu-
monia. Other less common etiologies may need to be consid-
ered depending upon recent travel history or exposure to
vectors or animals that transmit zoonotic pathogens such as Sin
Nombre virus (hantavirus pulmonary syndrome) or Yersinia
pestis (pneumonic plague, endemic in the western US).
The rationale for attempting to establish an etiology is that
identification of a pathogen will focus the antibiotic management
Table VI-4 continued.





General fungal assays (ie stains,
culture, serology) plus histology
Pleural fluid Sterile container, RT, 2 h; 4°C,
> 2–24 hPleural biopsy
Serum antibody IgM (ID, LA, EIA) Serum Clot tube, RT, 2 d; 4°C, 2–14 d
IgG antibody (CF, EIA)
Blastomyces dermatitidis Fungal stains and cultures (but not
serology) plus histology
Pleural fluid Sterile container, RT, 2 h; 4°C,
> 2–24 hPleural biopsy
Antigen testc Urine, pleural fluid, serum Sterile container, 4°C, ≤5 d;
clot tube (blood)
Parasites
Paragonimus westermani Direct microscopic examination of
pleural fluid and sputum for
characteristic ova
Pleural fluid Sterile container, fresh




Abbreviations: BAL, bronchoalveolar lavage; BCYE, buffered charcoal yeast extract; EIA, enzyme immunoassay ID, immunodiffusion; KOH, potassium hydroxide;
LA, latex agglutination; NAAT, nucleic acid amplification test; RT, room temperature.
a No FDA cleared test is currently available. Availability is laboratory specific. Provider needs to check with the laboratory for optimal specimen source, performance
characteristics and turnaround time.
b Performance characteristics of these tests are reviewed in reference 12 [93].
c May cross react with other endemic mycoses.
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for a particular patient. In addition, identification of certain
pathogens such as Legionella species, influenza viruses, and the
agents of bioterrorism have important public health significance.
Currently, IDSA/ATS practice guidelines consider diagnostic
testing as optional for the patient who is not hospitalized [89].
Those patients who require admission should have pretreat-
ment blood cultures, culture and Gram stain of good-quality
samples of expectorated sputum and, if disease is severe, urinary
antigen tests for S. pneumoniae and Legionella pneumophila
where available. Laboratories must have a mechanism in place
for screening sputum samples for acceptability (to exclude
those that are heavily contaminated with oropharyngeal flora
and not representative of deeply expectorated samples) prior to
setting up routine bacterial culture. Poor-quality specimens
provide misleading results and should be rejected because in-
terpretation would be compromised. Endotracheal aspirates or
bronchoscopically obtained samples (including “mini BAL”
using the Combicath [KOL Bio Medical Instruments, Chantilly,
Table VI-5. Laboratory Diagnosis of Pulmonary Infections in Cystic Fibrosis




Staphylococcus aureus Culture Expectorated sputum;
throat swabsa; other
respiratory samples
Sterile container, RT, 2 h;

































Sterile container, RT, 2 h;










Sterile container, RT, 2 h;
>2–24 h, 4°CScedosporium spp
Trichosporon Fungal culture
Viruses






Transport in viral transport
media, RT or 4°C, 5 d;
−70°C, >5 d
Influenza DFA





Abbreviations: DFA, direct fluorescent antibody; KOH, potassium hydroxide; NAAT, nucleic acid amplification test; RT, room temperature.
a Young children <8 years. of age only; often called “gag sputum.”
b Several FDA cleared NAAT platforms are currently available and vary in their approved specimen requirements and range of analytes detected. Readers should
check with their laboratories regarding availability and performance characteristics including certain limitations.
e56 • CID 2013:57 (15 August) • Baron et al
Table VI-6. Laboratory Diagnosis of Pneumonia in the Immunocompromised Host




See list of bacterial agents
responsible for CAP and
HAP above










Nocardia and other aerobic
Actinomycetes
Gram stain Expectorated sputum Sterile cup or tube RT, 2 h; 4°C,
>2–24 hModified acid fast stain Bronchoscopically obtained
specimens






Respiratory viruses See Tables VI-2 and 3 above See Tables VI-2 and 3 above See Tables VI-2 and 3 above
Cytomegalovirus Shell vial culture combined with
antigen detection; use with
cytologic analysis and or tissue
histology for interpretation
Expectorated sputum Transport in viral transport media,
4°C, 5 d; −70°C >5 dBronchoscopically obtained
specimens
Lung tissue




Plasma EDTA tube RT, 6–8 h; 4°C>8–24 h





Transport in viral transport media,
4°C, 5 d; −70°C >5 d
Formalin container, RT, 2–14 dUsewith cytologic analysis and or




M. tuberculosis Acid fast stain Expectorated sputum Sterile cup or tube RT, 2 h; 4°C,
>2–24 hAFB Culture Bronchoscopically obtained
specimens







Acid fast stain Expectorated sputum Sterile cup or tube RT, 2 h; 4°C,
>2–24 h
M. kansasii AFB culture Bronchoscopically obtained
specimens
Formalin container, RT, 2–14 d





Pneumocystis jiroveci DFA on BAL or sputum, (not tissue) Expectorated sputum Sterile cup or tube RT, 2 h; 4°C,
>2 h–7 dNAATa Induced sputum
Cytologic stains (liquid samples) Bronchoscopically obtained
specimens Sterile container
RT, 2 h; 4°C, >2–24 h
Formalin container, RT, 2–14 d
Tissue stains Tissue
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Table VI-6 continued.
Etiologic Agents Diagnostic Procedures Optimum Specimens
Transport Issues; Optimal
Transport Time
Cryptococcus neoformans Calcofluor or other fungal stain Expectorated sputum Sterile cup or tube RT, 2 h; 4°C,
>2–24 hFungal culture Induced sputum
Bronchoscopically obtained
specimens
Cryptococcal antigen test Serum, 1 mL Clot tube RT, 1 h; 4°C, >1 h–7 d
Tissue stains Tissue Formalin container, RT, 2–14 d
Sterile container, RT, 2 h; 4°C, >2–
24 h
Aspergillus spp Calcofluor -KOH or other fungal
stain
Expectorated sputum Sterile cup or tube RT, 2 h; 4°C,
>2–24 h




Galactomannan (1–3)-β-D-glucan Serum Clot tube 4°C, ≤5 d; >5 d, −70°C
BALb Sterile container for BAL RT, 2 h;
4°C, >2–24 h
Fusarium spp Calcofluor -KOH; or other fungal
stain
Expectorated sputum Sterile cup or tube RT, 2 h; 4°C,
>2–24 h
Fungal culture Induced sputum
Histology/GMS stain Bronchoscopically obtained
specimens
Sterile cup or tube RT, 2 h; 4°C,
>2–24 h
Lung tissue Formalin container, RT, 2–14 d
Fungal blood culture (see blood
culture section)







Calcofluor -KOH or other fungal
stain
Expectorated sputum Sterile cup or tube RT, 2 h; 4°C,
>2–24 h




Histoplasma capsulatum Calcofluor- KOH or other fungal
stain
Expectorated sputum Sterile container RT, 2 h; 4°C, >2–
24 h




Fungal blood culture (see blood
culture section)




Antigen test Serum, urine, BAL,pleural fluid (if
applicable)
Clot tube for serum RT, 2 d; 4°C,
2–14 d
Sterile container for other samples
4°C, ≤5 d
Serology (CF) Serum RT, 2 d; 4°C, 2–14 d
Coccidioides immitis/
posadasii
Calcofluor -KOH or other fungal
stain
Expectorated sputum Sterile container RT, 2 h; 4°C, >2–
24 h




Serum antibody IgM (ID, LA, EIA) Serum Clot tube RT, 2 d; 4°C, 2–14 d
IgG antibody (CF, EIA)
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VA] or similar technology) may be required in the hospitalized
patient who is intubated or unable to produce an adequate
sputum sample. A thoracentesis should be performed in the
patient with a pleural effusion. Recently, the FDA approved the
BioFire (Salt Lake City, UT) Film Array nucleic acid amplifica-
tion test (NAAT) for detection of Mycoplasma pneumoniae
and Chlamydophila pneumoniae [90]. Some laboratories have
developed their own NAAT assays. Currently, serological
testing is still considered the gold standard for these agents, al-
though this is likely to change.
Mycobacterial infections should be in the differential diag-
nosis of community-acquired pneumonia (CAP) that fails to
respond to therapy for the typical CAP pathogens.Mycobacterium
tuberculosis, while declining in the United States in recent years,
is still an important pathogen among immigrant populations.
Mycobacterium avium complex is also important, not just
among patients with HIV, but in patients with chronic lung
disease, cystic fibrosis, and in middle-aged or elderly thin
women [91].
C. Healthcare-Associated Pneumonia, Hospital-Acquired
Pneumonia, and Ventilator-Associated Pneumonia
Healthcare-associated (HCAP), hospital-acquired pneumo-
nia (HAP), and ventilator-associated (VAP) pneumonias are
Table VI-6 continued.
Etiologic Agents Diagnostic Procedures Optimum Specimens
Transport Issues; Optimal
Transport Time
Other endemic fungi Calcofluor -KOH or other fungal
stain
Expectorated sputum Sterile container RT, 2 h; 4°C, >2–
24 h




Antigen test (Blastomyces) Serum, urine, BAL,pleural fluid (if
applicable)
Clot tube for serum RT, 2 d; 4°C,
2–14 d
Sterile container for other samples
4°C, ≤5 d
Parasites
Toxoplasma gondii Microscopy—Giemsa stain smears
(tissue)




Lung tissue Formalin container, RT, 2–14 d
IgM antibody detection Serum Clot tube RT, 2 d; 4°C, 2–14 d
Enterocytozoon bieneusi
(Microsporidiosis)
Histologic stains Lung tissue Formalin container, RT, 2–14 d




Cryptosporidiosis Modified acid fast stain
DFA
NAATa
Histologic stains Lung tissue Formalin container, RT, 2–14 d
Strongyloides stercoralis Microscopic wet mount
examination of liquid samples for
larval forms
Induced sputum Sterile container RT, 2 h; 4°C,>2–
24 h




Histologic stains Lung tissue Formalin container, RT, 2–14 d
Abbreviations: AFB, acid fast bacillus; BAL, bronchoalveolar lavage; BCYE, buffered charcoal yeast extract; CAP, community acquired pneumonia; CF, complement
fixation; DFA, direct fluorescent antibody test; EIA, enzyme immunoassay; HAP, healthcare associated pneumonia; ID, immunodiffusion; KOH, potassium
hydroxide; LA, latex agglutination; NAAT, nucleic acid amplification test; RT, room temperature.
a No FDA cleared test is currently available and availability is laboratory specific. Provider needs to check with the laboratory for optimal specimen source,
performance characteristics and turnaround time.
b Not FDA cleared for this source.
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frequently caused by multidrug-resistant gram-negative bacte-
ria or other bacterial pathogens. Aside from respiratory viruses
that may be nosocomially transmitted, viruses and fungi are
rare causes of HCAP, HA, and VAP in the immunocompetent
patient. Table VI-3 lists the organisms most commonly associ-
ated with pneumonia in the immunocompromised patient.
Two diagnostic strategies have been recommended by the
American Thoracic Society and the Infectious Diseases Society
of America [92]. The clinical strategy is based on the presence
of a new lung infiltrate plus the presence of 2 of 3 clinical fea-
tures (fever, leukocytosis or leucopenia, and purulent secre-
tions) [92]. Determining the cause of the pneumonia relies on
initial Gram stain and semiquantitative cultures of endotrache-
al aspirates or sputum. A smear lacking inflammatory cells and
a culture absent of potential pathogens have a very high nega-
tive predictive value. Cultures of endotracheal aspirates, while
likely to contain the true pathogen, also consistently grow more
mixtures of species of bacteria than specimens obtained by
bronchoscopic techniques. This may lead to additional unnec-
essary antibiotic therapy. The bacteriologic strategy uses quan-
titative cultures of lower respiratory tract secretions obtained
either bronchoscopically or via endotracheal aspiration without
a bronchoscope [92]. Quantities of bacterial growth above a
threshold are diagnostic of pneumonia and quantities below
that threshold are more consistent with colonization. The gen-
erally accepted thresholds are as follows: Endotracheal aspi-
rates, 106 CFU/mL; BAL, 104 CFU/mL; protected specimen
brush samples (PSB), 103 CFU/mL. These values have signifi-
cance only when the samples have been obtained >72 hours
before the initiation or a change of antibiotic therapy. Quantita-
tive studies require extensive laboratory work and special pro-
cedures that smaller laboratories may not accommodate.
Bronchial washes are not appropriate for routine bacterial
culture.
Table VII-1. Laboratory Diagnosis of Esophagitis
Etiologic Agents Diagnostic Procedures Optimum Specimens Transport Issues; Optimal Transport Time
Candida spp Calcofluor-KOH stain Esophageal brushing or biopsy Sterile container, RT, 2 h
Fungus culture
Histopathological examination Esophageal biospy Formalin container, RT, 2–14 d
Herpex simplex virus HSV Culture Esophageal brushing or biopsy Viral transport device, on ice, immediately
Direct fluorescent stain
Nucleic acid amplification test (NAAT) Esophageal brushing or biopsy Closed container, RT, 2 h
Histopathological examination Esophageal biopsy Formalin container, RT, 2–14 d
Cytomegalovirus CMV Culture Esophageal brushing or biopsy Viral transport device, on ice, immediately
Direct fluorescent stain
NAAT Esophageal brushing or biopsy Closed container, RT, 2 h
Immunohistochemical stain Esophageal biopsy Formalin container, RT, 2–14 d
Abbreviations: NAAT, nucleic acid amplification test; KOH, potassium hydroxide; RT, room temperature.










H. pylori stool antigen test Stool specimen Closed container, RT, 2 h
Urea breath test Radiolabeled breath Special collection device
Gram stain Two biopsies from antrum and two
biopsies from posterior corpus
Sterile container, RT, immediately
H. pylori culturea
Histopathological examinationa Same as above Formalin container, RT, 2–14 d
Agar-based or rapid tissue urease testsb Same as above Closed container, RT, 2 h
Abbreviation: RT, room temperature.
a Gram stain and culture of properly collected and transported stool specimens has a sensitivity of 95% as does histopathological examination. Culture may not be
routinely available.
b Agar-based or rapid urease tests have a slightly lower sensitivity of 90%–95% but offer the advantage of providing rapid results. They may be performed point-of-
care or in the laboratory. When these tests are performed on gastric fluid, orogastric brush or “string” specimens, they have lower sensitivity than when performed
on biopsy specimens.
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Clostridium difficile Nucleic acid amplification test (NAAT) Stool Closed container, RT, 2 h
Glutamate dehydrogenase (GDH) antigen
with or without toxin detection
followed by cytotoxin or NAAT
confirmation
Stool Closed container, RT, 2 h
Salmonella spp Routine stool enteric pathogen culturea Stool Closed container, RT, 2 hb
Shigella spp Cary-Blair transport medium, RT, 24 h
Campylobacter spp
Enterohemorrhagic E.




Culture for E. coliO157:H7c Stool Closed container, RT, 2 hb
Shiga-toxin immunoassay Stool Closed container, RT, 2 hb
NAAT for Shiga toxin genes Stool Closed container, RT, 2 hb











Bacillus cereus Specialized procedure for toxin
detectione




Clostridium botulinum Mouse lethality assayf (Usually





Store and transport specimens at 4°C.
Do not freeze
Parasites
E. histolytica Ova and parasite examination including
permanent stained smear
Stool Stool not in fixative <1 h RT, 5 or 10%
buffered formalin and modified PVA,













E. histolytica E. histolytica species specific
immunoassay
Stool
Giardia lambliaj Enzyme immunoassay Stool




Modified acid fast staink performed on
concentrated specimen
Stool
Microsporidia Modified trichrome staink performed on
concentrated specimen
Stool
Histologic examination with EM
confirmation
Small bowel biopsy Formalin container, RT, 2–14 d
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D. Infections of the Pleural Space
The infectious causes of pleural effusions have shifted from the
traditional pneumonia pathogens of S. pneumoniae and S. pyo-
genes to polymicrobial infections in which anaerobic bacteria
play a major role. Table VI-4 summarizes the major pathogens.
Any significant accumulation of fluid in the pleural space
should be sampled by thoracentesis. Specimens should be hand
carried immediately to the laboratory or placed into appropri-
ate anaerobic transport media for transport. In some
institutions, bedside inoculation into blood culture bottles has
become an established practice. This is acceptable providing
that the manufacturer’s guidelines are followed with respect to
the volume inoculated and whether supplementation is re-
quired to enhance recovery of fastidious pathogens such as S.
pneumoniae. If blood culture bottles are used, an additional
sample should be sent to the microbiology laboratory for Gram
stain and culture of nonbacterial pathogens when indicated.



















Rotavirus Enzyme immunoassayn Stool Closed container, RT, 2 h
Enteric Adenovirus
Enteric Adenoviruso Viral Culture Stool Viral transport medium, on ice, 2 h
Enterovirus/
Parechovirusm
Cytomegalovirus Histopathological examination Biopsy Formalin container, RT, 2–14 d
CMV Culture Biopsy Sterile container, RT, immediately
Calicivirus (Norovirusl,
Sapovirus)
Outbreak investigation performed by
public health officials
Stool Closed container, RT, 2 h
Abbreviations: CMV,cytomegalovirus; NAAT, nucleic acid amplification test; RT, room temperature.
a A routine stool culture in most laboratories is designed to detect Salmonella spp, Shigella spp, Campylobacter spp and E. coli O157 or Shiga-toxin producing E.
coli.
b If the specimen cannot be transported to the laboratory within 2 hours, then it should be placed in vial containing Cary-Blair transport medium and transported to
the laboratory within 24 hours.
c It is recommended that laboratories routinely process stool specimens for the presence of Shiga-toxin-producing strains of E. coli including O157:H7. However, in
some settings, this testing may be done only on specific request.
d Specialized cultures are required to detect these organisms in stool specimens. In many cases, such cultures are performed only in public health laboratories and
only in the setting of an outbreak. The laboratory should be notified whenever there is a suspicion of infection due to one of these pathogens.
e Bacillus cereus, Clostridium perfringens and Staphylococcus aureus cause diarrheal syndromes that are toxin mediated. An etiologic diagnosis is made by
demonstration of toxin in stool. Toxin assays are either performed in public health laboratories or referred to laboratories specializing in such assays.
f Testing for Clostridium botulinum toxin is either performed in public health laboratories or referred to laboratories specializing in such testing. The toxin is lethal
and special precautions are required for handling. Note that it is considered a bioterrorism agent and rapid sentinel laboratory reporting schemes must be followed.
Immediate notification of a suspected case to the state health department is mandated. For this purpose, 24 hours hotlines are available.
g Implicated food materials may also be examined for C. botulinum toxin but most hospital laboratories are not equipped for food analysis.
h The role of Blastocystis hominis as a pathogen remains controversial. In the absence of other pathogens it may be important where symptoms persist. Reporting
semi-quantitative results (rare, few, many) can help determine significance and is a College of American Pathologists accreditation requirement for participating
laboratories.
i Detection of Strongyloides in immunocompromised patients may require the use of Baermann technique or agar plate culture.
j Cryptosporidium and Giardia lamblia testing is often offered and performed together as the primary parasitology examination. Further studies should follow if a
travel history or clinical symptoms suggest parasitic disease.
k These stains may not be routinely available.
l Sporadic disease has been associated with norovirus. Testing is available at public health and some reference laboratories.
m Asymptomatic shedding is common.
n Norovirus antigen assays have limited sensitivity and specificity and are not recommended for clinical use.
o Enteric adenoviruses may not be recovered in routine viral culture
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lactate dehydrogenase (LDH). These values assist with the de-
termination of a transudative or exudative process and in the
subsequent management of the syndrome. For example, the fol-
lowing parameters suggest the need for drainage: pH <7.28;
glucose <40 mg/dL; LDH >1000 IU/L or the presence of poly-
morphonuclear leucocytes (PMNs) [94]. Most infections result
in an exudate or PMNs (empyema) within the pleural cavity.
When tuberculosis or a fungal pathogen is thought to be the
likely cause, a pleural biopsy sent for culture and histopathology
increases the diagnostic sensitivity. Always notify the laboratory
of a suspicion of tuberculosis so that appropriate safety precau-
tions can be employed. An elevated adenosine deaminase level
in the pleural fluid (>70 IU/L) in a patient with appropriate
risk factors for tuberculosis has been shown to have a high sen-
sitivity in high prevalence regions. A level <40 IU/L excludes
the diagnosis. This marker of lymphocyte differentiation
should be used in conjunction with hematologic and chemical
parameters and other diagnostic tests such as NAAT, culture,
and histology of a pleural biopsy. The performance of this assay
in developed countries has been shown to be quite variable and
is related to multiple factors including the type of method used,
the likelihood of tuberculosis, and “false positive” results in pa-
tients with other causes of lymphocytic pleural effusion such as
rheumatoid disease, mesothelioma, and histoplasmosis [95].
E. Pulmonary Infections in Cystic Fibrosis
Patients with cystic fibrosis (CF) suffer from chronic lung infec-
tions due to disruption of exocrine function that does not allow
them to clear microorganisms that enter the distal airways of
the lung. A limited number of organisms have been implicated
in chronic infections (Table VI-5). Early in childhood, infec-
tions are caused by organisms frequently seen in the non-CF
pediatric population such as S. pneumoniae, H. influenzae, and
S. aureus. At some point later in childhood or adolescence, P.
aeruginosa becomes the most important pathogen involved in
chronic lung infection and the concomitant lung destruction
that follows. The P. aeruginosa strains adapt to the hypoxic
stress of the retained mucoid secretions by converting to a
biofilm mode of growth (mucoid colonies). Nosocomial patho-
gens such as S. maltophilia and Achromobacter xylosoxidans
may be acquired during a hospital or clinic visit. Burkholderia
cepacia complex is a very important pathogen in these patients.
B. cepacia genomovar III (B. cenocepacia) is highly pathogenic
and is responsible for rapid decline and death in a subset of pa-
tients who acquire the virulent clones. Special microbiological
techniques are required to recover and differentiate B. cepacia
complex from the mucoid P. aeruginosa strains. Less common
gram-negative organisms that appear to be increasing in their
frequency of recovery, but whose role in the pathogenesis of CF
lung disease is still unclear, include B. gladioli, Ralstonia spp,
Cupriavidus spp, and Pandorea [96].
As CF patients have survived into adulthood, opportunistic
pathogens such as nontuberculous mycobacteria have been iso-
lated with increasing frequency. There is evidence to suggest
that both M. abscessus and M. avium complex contribute to
lung destruction and should be treated when cultures are re-
peatedly positive. Mycobacterial culture should be added to the
routine cultures obtained from patients older than 15 years of
Table VII-4. Laboratory Diagnosis of Proctitis






employing media for the
recovery of N.
gonorrhoeae
Rectal swab Swab in Amies or Stuart’s
transport medium, RT, 8 h
Neisseria
gonorrhoeae












Viral culture Rectal swab Viral transport medium, RT,
2 h, wet ice if >2 h
Treponema
pallidium
RPR or VDRL with
confirmatory T. pallidum
specific test or syphilis
IgG
Serum Clot tube, RT, 2 h
Abbreviations: NAAT, nucleic acid amplification test; RT, room temperature.
a This is not an FDA-approved specimen source. Availability of testing on this sample type is laboratory specific based on individual laboratory validation. Provider
needs to check with the laboratory for optimal specimen and turn around time.
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age who present with exacerbations, as the incidence of Myco-
bacterium species is likely underestimated due to failure to rou-
tinely assess patients for these organisms [96].
Aspergillus fumigatus is the most common fungus recovered
from CF patients where it causes primarily allergic bronchopul-
monary disease. Scedosporium apiospermum may cause a
similar syndrome. Exophiala dermatitidis has been reported by
some centers to cause chronic colonization of the CF airway
[96]. Trichosporon mycotoxinivorans is a newly recognized
pathogen that has a propensity to cause disease in patients with
cystic fibrosis [97]. Table VI-5 summarizes the organisms most
likely to cause exacerbation of pulmonary symptoms in CF pa-
tients [91, 96, 98, 99]. While a number of environmental non-
fermenting gram-negative bacilli are frequently recovered from
the sputum of these patients, their role in CF lung disease is
either unknown at this time or unlikely to be of significance.
These organisms have not been included in the table. Laborato-
ries should spend resources on those pathogens proven or
likely to play a significant role in pulmonary decline in these
patients.
F. Pneumonia in the Immunocompromised Host
Advances in cancer treatments, transplantation immunology,
and therapies for autoimmune diseases and HIV have expand-
ed the population of severely immunocompromised patients.
Pulmonary infections are the most common syndromes con-
tributing to severe morbidity and mortality among these
groups of patients.
Virtually any potential pathogen may result in significant
illness, and the challenge for both clinicians and microbiolo-
gists is to rapidly differentiate infectious from noninfectious
causes of pulmonary infiltrates. The likelihood of a specific in-
fection may be affected by recently administered prophylaxis.
Table VI-6 focuses on the major infectious etiologies likely to
be of interest in most immunocompromised hosts [98]. Pa-
tients are still vulnerable to the usual bacterial and viral causes
of CAP and HAP. In addition, fungi, herpesviruses, and proto-
zoa play a more significant role and should be considered.
When rapid and noninvasive tests such as urine or serum
antigen tests and rapid viral diagnostics are not revealing, more
definitive procedures to sample the lung are required. Several
diagnostic procedures can be performed but usually the patient
initially undergoes bronchoscopy with bronchoalveolar lavage
with or without transbronchial biopsy. It is suggested that mi-
crobiology laboratories in collaboration with infectious diseases
physicians and pulmonologists, develop an algorithm for pro-
cessing samples that includes testing for all major categories of
pathogens as summarized in the table. Cytologic analysis and/
or histopathology are often needed to interpret the significance
of positive NAAT or culture for herpesviruses, for example, and
to definitively diagnose filamentous fungi. It should be noted,
however, that histopathology alone is not sensitive enough to
diagnose fungal infections and should be accompanied by
immunostain, culture, and, when available, NAAT [100]. In
addition, serum and BAL galactomannan and serum 1–3 β-D-
glucan tests may be helpful. However, cytology and or histopa-
thology are quite useful for distinguishing conditions such as
pulmonary hemorrhage and rejection from infectious causes of
infiltrates. Transthoracic needle aspiration, CT-guided biopsies
of pleural-based lesions, and open lung likewise may be consid-
ered if less invasive diagnostics are unrevealing.
VII. INFECTIONS OF THE GASTROINTESTINAL
TRACT
Gastrointestinal (GI) infections include a wide variety of
disease presentations as well as infectious agents. For many of
these infections, particularly noninflammatory diarrhea and
acute gastroenteritis of short duration, no laboratory testing is
recommended [101]. This section addresses the laboratory ap-
proach to establishing an etiologic diagnosis of esophagitis, gas-
tritis, gastroenteritis and proctitis.
Key points for the laboratory diagnosis of gastrointestinal in-
fections:
• The specimen of choice to diagnose diarrheal illness is
the diarrheal stool, not a formed stool or a swab.
• Toxin or nucleic acid amplification testing for C. difficile
should only be done on diarrheal stool, not formed stools,
unless the physician notes that the patient has ileus.
A. Esophagitis
Esophagitis is most often caused by noninfectious conditions,
such as gastroesophageal reflux disease. Infectious causes are
often seen in patients with impaired immunity (Table VII-1). Cal-
cofluor, potassium hydroxide (KOH), or Gram stain of esophage-
al brushings with histopathological examination and viral culture
of esophageal biopsies will establish the diagnosis in most cases.
B. Gastritis
Both invasive and noninvasive tests (Table VII-2) are available
to aid in the diagnosis of H. pylori infection, the major infec-
tious etiology of gastritis [102]. Invasive tests such as Gram
stain and culture of endoscopy tissue, histopathologic staining,
and direct tests for urease require the collection of biopsy
samples obtained during endoscopy from patients that have
not received antimicrobial agents or proton pump inhibitors in
the 2 weeks prior to collection and as such pose greater risks to
the patient. The advantage to the noninvasive assays such as
the urea breath test and stool antigen determinations is that pa-
tients can avoid endoscopy and gastric biopsy. They are also
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Table VIII-2. Specimen Management for Intra-abdominal Infections





Aerobic and anaerobica culture 10–50 mL concentrated peritoneal
fluid and
RT; if >1 h, 4°C
Secondary Peritonitis;
Tertiary Peritonitis
Gram stain prior to culture Sample in blood culture bottlea
Peritoneal Dialysis-
associated Peritonitis
Blood culture 2–3 sets blood culture bottles RT, do not refrigerate
AFB stain and culture
Mycobacterium Peritoneal fluid, aspirate or tissue RT <1 h or 4°C
NAATb
Fungal culture and KOH or
calcofluor white microscopy
Peritoneal fluid, aspirate or tissue RT <1 h or 4°C
Microscopy for ova and parasitesc Stool, peritoneal fluid, bile,
duodenal aspirate
Transport stool in parasite
transport vial; others <1 h at RT
Space-Occupying Lesions
of the Liver
Aerobic and anaerobic culture Lesion aspirate Anaerobic transport; RT, if >1 h,
4°CGram stain specimen prior to
culture
Blood culture 2–3 sets in blood culture bottles RT, do not refrigerate
Cultures for N. gonorrhoeae and
C. trachomatis
Lesion aspirates For N. gonorrhoeae: Amies
charcoal transport, RT.
C. trachomatis specimenmay
include swab of liver capsule or
surrounding peritoneum
For C. trachomatis: Chlamydia
transport medium at 4°C
NAAT for N. gonorrhoeae and C.
trachomatis
Urethra, pelvic specimen
(approved swabs), or urine
(sterile cup)
RT for <1 h or 4°C
Fungal culture and KOH or
calcofluor white microscopy
10–50 mL fluid RT, if >1 h, 4°C
Serology Serum Clot tube, RT, 2 h
Antigen detection for Entamoeba
histolytica
Liver aspirate RT for <30 min, then 4°C. Freeze
(−20°C) if shipping to reference
laboratory
Infections of the Biliary
Tree
Aerobic and anaerobic culture Aspirate from lesion Anaerobic transport device; RT, if
>1 h, 4°CGram stain before culture
Blood culture 2–3 sets RT; do not refrigerate
AFB stain and culture Fluid or tissue ≤1 h at RT or 4°C
Ova and parasite exam Stool, peritoneal fluid, bile or
duodenal aspirate
Closed container, RT, <2 h
O&P transport vial, RT, 2–24 h




Serum RT for <30 min, then 4°C.
Freeze (-20°C) if shipping to
reference laboratory
Splenic Abscess Aerobic and anaerobic culture Aspirate from lesion Anaerobic transport at RT. If >1 h,
4°C
Gram stain
Blood culture 2–3 sets RT; do not refrigerate
AFB stain and culture Fluid or tissue RT. If >1 h, 4°C
Mycobacterium NAAT can be
doneb
Fungal culture and KOH or
calcofluor white microscopy
10–50 mL of aspirate or tissue RT. If >1 h, 4°C
Serology for Entamoeba and
Echinococcus
Serum RT for <30 min, then 4°C.
Freeze (−20°C) if shipping to
reference laboratory.
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useful to test for organism eradication after therapy. The urea
breath test is performed in the clinic. The patient ingests a
cocktail containing 13C-labeled urea and 15–30 minutes later,
a breath sample is obtained and analyzed for the presence of
13C-labeled CO2 as an indication of the presence of H. pylori in
the stomach. This assay has a sensitivity of approximately 95%,
comparable to the invasive assays. Stool antigen tests have a re-
ported sensitivity of 88%–98% with sensitivity being higher in
adults than in children. The noninvasive assays are also useful
to test for organism eradication after therapy; the urea breath
test having a somewhat higher sensitivity than stool antigen de-
tection. Serodiagnosis has a lower sensitivity (<90%) and spe-
cificity (90%) and is not useful for test of cure after therapy.
C. Gastroenteritis, Infectious and Toxin-Induced Diarrhea
GI infections encompass a wide variety of symptoms and rec-
ognized infectious agents (Table VII-3). The appropriate diag-
nostic approach to diarrheal illness is determined by the
patient’s age, severity of disease, duration and type of illness,
time of year, and geographic location. Fecal testing is indicated
for severe, bloody, febrile, dysenteric, nosocomial, or persistent
diarrheal illnesses. Communication with the laboratory is re-
quired to determine what organisms, methods, and screening
parameters are included as part of the routine enteric pathogen
culture. Most laboratories will have the ability to culture for Sal-
monella, Shigella, Campylobacter, and test for Clostridium diffi-
cile and Shiga toxin-producing Escherichia coli. Consult with
the laboratory if other pathogens are suspected; special media
may be required. The specimen of choice is the diarrheal stool
(ie, takes the shape of the container). NAAT tests are being de-
veloped and will eventually be the first test of choice; currently
only one commercial panel has received FDA clearance, al-
though individual Shiga-toxin NAATs are available.
Stool Culture
Stool culture is indicated for detection of invasive bacterial
enteric pathogens. Most laboratories employ culture techniques
to routinely detect Salmonella, Shigella, and Campylobacter
and, more recently, Shiga toxin-producing E. coli in all stools
submitted for culture. Salmonella spp can take 24–72 hours to
recover and identify to genus alone with the specific serotyping
usually performed at the State Public Health Laboratory level.
It is recommended that tests for the detection of Shiga toxin, or
tests to specifically detect Shiga toxin-producing E. coli O157:
H7 or other Shiga toxin-producing serotypes be included as
part of the routine test. However, in some settings, these tests
may require a specific request. Tests that detect only E. coli
O157:H7 will not detect the increasing number of non-O157
isolates being reported and may not detect all E. coli O157:H7
[103]. Screening algorithms that limit testing to bloody stools
may also miss both O157 and non-O157 isolates. Detection of
Vibrio and Yersinia in the United States is usually a special
request and requires additional media or incubation conditions.
Communication with the laboratory is necessary. Laboratory
reports should indicate which of the enteric pathogens would
be detected. Laboratories are encouraged to provide enteric
pathogen isolates to their Public Health Laboratory and/or the
Center for Disease Control and Prevention for pulsed-field gel
analysis for national surveillance purposes.
Multiple stool specimens are rarely indicated for detection of
stool pathogens. In studies of adult patients who submitted
more than 1 specimen, the enteric pathogen was detected in the
first sample 87%–94% of the time, with the second specimen
bringing the positive rate up to 98% [104]. In pediatric patients,
the first specimen detects 98% of the enteric pathogens [105].
Thus, 1 sample for children and a second for selected adult pa-
tients may be considered. Rectal swabs are less sensitive than
stool specimens and are not recommended in adults but in
symptomatic pediatric patients rectal swabs and stool culture
are equivalent in the ability to detect fecal pathogens [106, 107].
Clostridium botulinum
Botulism is an intoxication in which a protein exotoxin, bot-
ulinum toxin, produced by Clostridium botulinum causes a life-
Table VIII-2 continued.





Aerobic and anaerobic culture Aspirate from lesion Anaerobic transport at RT. If >1 h,
4°C.Gram stain prior to culture
Blood culture 2–3 sets RT; do not refrigerate
Fungal culture and KOH -calcofluor
microscopy
10–50 mL aspirate or tissue RT; if >1 h, 4°C
Abbreviations: AFB, acid-fast bacillus; CMV, cytomegalovirus; KOH, potassium hydroxide; NAAT, nucleic acid amplification test; RT, room temperature.
a If Gram stain reveals multiple morphologies of organisms, do not inoculate blood culture bottles with the fluid as competitive bacterial growth could mask the
recovery of clinically significant pathogens. Anaerobic cultures of peritoneal fluid are only necessary in cases of secondary peritonitis.
b Depends on availability and should never substitute for culture because of variable sensitivity. Check with the microbiology laboratory for transport conditions. No
commercial NAAT for mycobacteria available for nonrespiratory samples.
c Procedure to be used in cases of secondary peritonitis in appropriate clinical situations.
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threatening flaccid paralysis. Diagnosis, while not usually con-
firmed by the hospital microbiology laboratory, is made by
clinical criteria, allowing prompt initiation of essential antitox-
in therapy. The microbiologic diagnosis is dependent on detec-
tion of botulinum toxin in serum (in patients with wound,
infant, and food-borne disease), stool (in patients with infant
and food-borne disease), and gastric contents/vomitus (in pa-
tients with food-borne disease). Toxin detection is performed
in many State Public Health Laboratories and at the Center for
Disease Control and Prevention. Culture can be performed on
both feces and wounds, but the yield is low and most laborato-
ries lack the necessary expertise to isolate and identify this
organism [108].
Clostridium difficile
Numerous methods have been employed for the laboratory
diagnosis of infection caused by Clostridium difficile. Toxigenic
culture is probably the most sensitive and specific of the assays
for the detection of C. difficile. It is slow and labor intensive
and not routinely performed in the community hospital
setting. Compared to toxigenic culture, the cytotoxin assay has
a sensitivity of 85%–90%. The cytotoxin assay requires 24–48
hours and is also labor intensive. Thus, toxin detection by
either enzyme immunoassay (EIA) or immunochromato-
graphic methods has been performed. These assays have re-
ported sensitivity of 70%–85% but are significantly faster with
results available in <2 hours. Utilization of an assay that detects
both toxin A and toxin B improves the sensitivity. With the
availability of NAAT assays, EIAs for toxin alone are no longer
recommended as stand-alone assays.
Nucleic acid amplification assays for the detection of C.
difficile are available and should be considered the test of
choice for the diagnosis of enterocolitis due to C. difficile.
They have reported sensitivity of 93%–100%. To reduce turn-
around time and costs, some laboratories may employ an al-
gorithm that uses a rapid screening test for glutamate
dehydrogenase (GDH) antigen with or without toxin A and
B detection followed by cytotoxin or NAAT confirmation
where indicated. NAAT testing should be employed if GDH
antigen and toxin screening results do not agree. This algo-
rithm allows for both the rapid reporting of most negative
specimens and the sensitivity of cytotoxin testing or NAAT
but could result in delays in diagnosis that range from hours
to days, depending on the laboratory testing platform em-
ployed [109, 110].
Diarrheal stool specimens (not formed stools or rectal
swabs) are required for the diagnosis of C.difficile disease (not
colonization). The specimen should be loose enough to take
the shape of the container. Formed stools should be appropri-
ately rejected by the laboratory but with the proviso that
formed stools from patients with ileus, or potential toxic mega-
colon, as noted by the physician, should be tested. Repeat
testing of patients previously positive as a “test of cure” is not
appropriate. Repeat testing of patients negative by NAATs
should not be performed for at least 6 days [111].
Since 2000, an increase in C. difficile-associated disease with
increased morbidity and mortality has been reported in the
United States, Canada, and the United Kingdom. The epidemic
strain is toxinotype III, North American PFGE type 1 (NAP1)
and PCR-ribotype 027 (NAP1/027). It carries the binary toxin
genes cdtA and cdtB and an 18 bp deletion in tcdC. It produces
both toxin A and toxin B [112]. A commercially available FDA-
cleared NAAT for binary toxin and the tcdC deletion genes
identifies this strain for epidemiological purposes. The severity
of disease is believed to be due to toxin hyperproduction [113].
The association of binary toxin with disease severity is contro-
versial.
Parasites
The number of specimens to be submitted for parasitologic
examination may be a controversial subject [114, 115]. Histori-
cally, when using conventional microscopic procedures, it was
recommended that 3 specimens collected over a 7–10 days
period be submitted for ova and parasite (O&P) examination.
Options for cost-effective testing today include examination of
a second specimen only when the first is negative and the
patient remains symptomatic, with a third specimen being sub-
mitted only if the patient continues to be O&P negative and
symptomatic. Targeted use of immunoassay testing for the
most common parasites based on geography, patient demo-
graphics, and physician request, can also be used as a screen
with only negative patients with continued symptoms or pa-
tients with specific risk factors requiring full O&P examination.
Immunoassays for Giardia are sensitive enough that only a
single specimen may be needed.
The specimen preservative to be employed, often supplied by
the laboratory, depends on the need to perform immunoassay
procedures or special stains on the specimens and the manufac-
turer’s recommendations for specimen fixative. Polyvinyl
alcohol (PVA) is the gold standard; however, due to the pres-
ence of mercuric chloride, modifications that do not employ
mercury have been developed. None of these modified preser-
vatives allow stains to provide the same level of microscopic
detail, although with experience, they are acceptable alterna-
tives.
In routine procedures, pathogenic E. histolytica cannot be
differentiated from nonpathogenic E. dispar using morphologic
criteria, so the laboratory report may indicate E. histolytica/
dispar [116]. Only an immunoassay or NAAT can differentiate
these organisms.
D. Proctitis
Proctitis is most commonly due to sexually transmitted agents,
a result of anal-genital contact, although abscesses or perirectal
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wound infections may present with similar symptoms. One
sample is usually sufficient for diagnosis (Table VII-4).
VIII. INTRAABDOMINAL INFECTIONS
This section is designed to optimize the activities of the micro-
biology laboratory to achieve the best approach for the identifi-
cation of microorganisms associated with peritonitis and
intraperitoneal abscesses, hepatic and splenic abscesses, pancre-
atitis, and biliary tract infection. As molecular means begin to
be used to define the microbiome of the gastrointestinal and
genitourinary tract, contemporary culture protocols will surely
evolve to accommodate new, emerging information. The future
use of gene amplification and sequencing for identification of
microorganisms in these infections will likely show that for
every organism currently identified by culture there will be
several times that number cannot be cultivated using current
technologies. To remain focused on contemporary methods
currently available in the diagnostic microbiology laboratory,
the tables outline the most likely agents of each entity
(Table VIII-1) and how best to evaluate the situation with exist-
ing techniques (Table VIII-2).
Factors to consider when collecting specimens for laboratory
diagnosis of intraabdominal infections:
Key points for the laboratory diagnosis of intraabdominal in-
fections:
• The laboratory needs the specimen—not a swab of the
specimen. Sufficient quantity of specimen must be collected to
allow the Microbiology laboratory to perform all the necessary
tests.
• The specimen of choice for an abscess is a sample of the
contents plus a sample of the wall of the abscess.
• Pus alone may not reveal the etiologic agent since the
PMNs may have destroyed morphological evidence of microbi-
al invasion.
• While most molecular tests have excellent sensitivity, a
Mycobacterium tuberculosis NAAT test should be an adjunct to
a culture and never ordered alone. No current commercial
methods are FDA-cleared for these specimens, so laboratories
must have validated the test they use.
• IfM. tuberculosis is present, it is usually a sign of dissemi-
nated disease that must be thoroughly investigated.
A. Spontaneous Bacterial Peritonitis and Ascites
In cases of spontaneous bacterial peritonitis (SBP), the source
of the invading organism(s) is unknown, and the syndrome can
also be seen in patients with preexisting risk factors such as cir-
rhosis with ascites [117, 118]. SBP tends to be monomicrobic
and caused by aerobic organisms from the intestinal tract;
therefore, anaerobic cultures are less valuable. Sufficient fluid
(eg, 10–50 mL if available) should be obtained to allow for con-
centration by centrifugation and a cytospin Gram stain evalua-
tion. At a minimum, at least 10 mL of peritoneal fluid (not
swabs of the fluid) should be collected aseptically and trans-
ported to the laboratory prior to the administration of antimi-
crobial agents. Additional laboratory testing should include
fluid analysis for protein, cell count and differential, lactate
concentration and pH along with 2–3 sets of blood cultures for
the identification of concomitant bacteremia (Table VIII-1).
Alternatively, because SBP and infections of ascites fluid tend
to be monomicrobic, an aerobic blood culture bottle can be in-
oculated with fluid (volume dependent on blood culture
system) if the presence of a single organism is reasonably
certain. A Gram stain may be used prior to broth inoculation to
evaluate the morphology of the organism(s) present. Since the
differentiation between SBP and secondary peritonitis may be
uncertain, it may be beneficial to submit peritoneal fluid in a
sterile container for conventional culture and stain as well as in-
oculate blood culture bottles at the bedside with the fluid. Se-
quencing and 16S PCR can be used to identify isolates present
in these specimens if these techniques are available to the labo-
ratory. In the next few years, next generation sequencing will be
able to analyze such specimens to determine the total microbial
load by species. If more than 1 morphologic type is noted in
the Gram stain, a broth should not be inoculated. The caveat
for use of blood culture bottles with fluid other than blood is
that not all systems have been evaluated for this purpose.
Further, broth cultures do not accurately reflect the bacterial
burden or the variety of organisms at the time the specimen is
obtained and the presence of a true pathogen may be obscured
by the overgrowth of a more rapidly growing organism.
Negative culture results in the presence of other indicators of
infection should prompt an evaluation for fastidious or slowly
growing organisms such as Mycobacterium spp, fungi, Chla-
mydia trachomatis, or Neisseria gonorrhoeae.
B. Secondary Peritonitis
The diagnosis of secondary peritonitis is dependent upon iden-
tifying a source for invading microorganisms—usually genito-
urinary or gastrointestinal flora [118, 119]. There are numerous
causes of secondary peritonitis including iatrogenic or acciden-
tal trauma, perforated appendix or diverticuli, typhlitis, or
intra-abdominal abscess. Unlike SBP, however, secondary peri-
tonitis tends to be polymicrobic and may include anaerobic
flora. Organisms such as S. aureus, N. gonorrhoeae, and Myco-
bacterium spp are unusual in this setting. Common etiologies
include aerobic and anaerobic gram-negative rods (Bacteroides
spp, E. coli, Klebsiella spp), and gram-positive flora (Clostridi-
um spp, Enterococcus spp, Bifidobacterium spp, Peptostreptococcus
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spp). If typhlitis is suspected, C. difficile toxin testing, stool cul-
tures for enteric pathogens, and blood cultures should be re-
quested. Additionally, C. septicum should be considered in
neutropenic enterocolitis.
Peritoneal fluid should be sent to the laboratory in an anaer-
obic transport system for Gram stain and aerobic and anaerobic
bacterial cultures. Inoculation of blood culture bottles alone
with peritoneal fluid is not appropriate in this setting, as com-
petitive bacterial growth in broth cultures could mask the re-
covery of clinically important pathogens (Table VIII-1).
Because cytomegalovirus (CMV) is a possible cause of second-
ary peritonitis, the microbiology laboratory should be contacted
to arrange for special processing if CMV is of concern. The mi-
crobiology laboratory should also be contacted if N. gonorrhoeae
is of concern since special processing or NAAT (this specimen
type has no FDA-cleared commercial platform for testing) will
be necessary.
Because of the polymicrobic nature of secondary peritonitis,
clinicians should not expect or request identification and sus-
ceptibility testing of all organisms isolated. Rather, the labora-
tory should provide a general description of the culture results
(eg, mixed aerobic and anaerobic intestinal flora) and selective
identification of certain organisms such as MRSA, β-hemolytic
Streptococcus spp, multi-drug-resistant gram-negative bacilli,
VRE, etc.) to guide empiric antimicrobial therapy [117, 118, 120].
Patients who do not respond to conventional therapy should
have additional specimens collected to examine for resistant or-
ganisms or for the presence of intra-abdominal abscesses.
Table IX-1. Laboratory Diagnosis of Osteomyelitis
Etiologic Agents Diagnostic Procedures Optimum Specimens
Transport Issues; Optimal
Transport Time
Hematogenous Seeding of Bone
Staphylococus aureus Gram stain Bone biopsy Sterile container, RT, immediately







Acid fast smear Bone biopsy Sterile container, RT, 2 h
AFB culture
M. tuberculosis NAATe
Blastomyces dermatitidis Calcofluor-KOH stain Bone biopsy Sterile container, RT, 2 h
Coccidioides immitis Fungus culture
Extension from a Contiguous Skin or Soft Tissue Site of Infection
Staphylococcus aureus Gram stain Bone biopsy Sterile container, RT, immediately
Other bacteriaf Aerobic bacterial culture
Mixed aerobic and
anaerobic bacterial flora
of the oral cavity
including Actinomyces
sppg





Mixed bacterial flora in
diabetic patients with
skin and soft tissue
extremity infectionsh
Gram stain Bone biopsy Sterile anaerobic transport
container, RT, immediatelyAerobic and anaerobic
bacterial culture




Gram stain Bone biopsy or sinus tract
specimen (curetting or
tissue biopsy)
Sterile container, RT, immediately
Aerobic bacterial culture
Silver stain Bone biopsy or sinus tract
specimen
Sterile container, RT, 2 h
Calcofluor-KOH stain
Buffered charcoal yeast
extract (BCYE) agar for
Nocardia
Fungus culture
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C. Tertiary Peritonitis
This entity refers to persistent or recurrent peritonitis following
unsuccessful treatment of secondary peritonitis. Tertiary peri-
tonitis might also indicate the presence of an intra-abdominal
abscess or organisms that are refractory to broad spectrum anti-
microbial therapy such as vancomycin-resistant Enterococcus
spp, Candida species, Pseudomonas aeruginosa, or biofilm-
producing bacteria like coagulase-negative Staphylococcus spp.
Fluid cultures from cases of tertiary peritonitis are commonly
negative for bacteria [117]. In any case, cultures appropriate for
spontaneous or secondary peritonitis may be helpful
(Table VIII-2). The possibility of infection caused by unusual
Table IX-1 continued.




Staphylococcus aureus Gram stain Bone biopsy Sterile anaerobic transport
container, RT, immediatelyEnterobacteriaceae Aerobic and anaerobic
bacterial culturePseudomonas aeruginosa j
Bacterial flora of the skin




Acid fast smear Bone biopsy Sterile container, RT, 2 h
AFB culture
Environmental moulds Calcofluor-KOH stain Bone biopsy or sinus tract
specimen (curetting or
tissue biopsy)
Sterile container, RT, 2 h
Fungus culture
Abbreviations: AFB, acid-fast bacillus; KOH, potassium hydroxide; NAAT, nucleic acid amplification test; RT, room temperature.
a Salmonella osteomyelitis occurs most often in patients with sickle cell trait or disease [137].
b Streptococcus pneumoniae as a cause of osteomyelitis occurs most often in pediatric patients, not infrequently in the setting of spontaneous pneumococcal
bacteremia [138].
c Brucella spp will be recovered in standard aerobic bacterial cultures, however, it is a slow growing bacterium and as a result, the laboratory should be notified when
Brucella is considered to be a potential cause of osteomyelitis so that cultures can be held for examination over at least a one-week period and examined only in a
biological safety cabinet. Concomitant blood cultures and serology testing are recommended (not necessary to hold blood cultures beyond standard incubation).
d Hematogenous osteomyelitis caused by Pseudomonas aeruginosa and other Pseudomonas spp occurs most often in injection drug users [139].
e The most common site of osteomyelitis due to M. tuberculosis is the vertebral bodies. This organism can also seed the clavicles and in this setting represents
one of the most common causes of clavicular osteomyelitis. Commercial NAATs are not FDA-cleared for nonrespiratory sites, so a laboratory-validated test method
must be used if NAATs are requested.
f Infections of skin and soft tissues, especially with extension of infection into deeper tissue spaces, pose a risk for the development of osteomyelitis of adjacent
bone. While S. aureus is the most commonly incriminated organism, essentially any bacterium capable of causing deep soft tissue infection can also cause
osteomyelitis.
g Chronic endodontic infections such as apical abscesses may extend into surrounding bone resulting in osteomyelitis of the maxilla or mandible. These infections
are caused by the aerobic and anaerobic bacterial flora of the oral cavity and may be either monomicrobic or polymicrobic. Actinomyces spp is a recognized
pathogen in this setting. When Actinomyces is suspected, specimens should be transported to the laboratory and then processed within 15 minutes or there is
little chance of recovering Actinomyces in culture.
h Diabetic extremity infections with underlying osteomyelitis can be caused by a diverse group of bacteria including S. aureus, Group B β-hemolytic streptococci,
Enterococcus spp, the Enterobacteriaceae, Pseudomonas spp, Stenotrophomonas maltophilia and a variety of anaerobes. This represents one of the few settings
in which osteomyelitis can be polymicrobial. Superficial debridement followed by deep sampling at the advancing margin of the lesion is essential to avoid being
misled by surface colonizing contaminants.
i Mycetoma is a chronic soft tissue infection of the extremities which can also extend into contiguous bone and connective tissue. It occurs most often in tropical
and subtropical climates and may be characterized by the development of draining sinuses. The etiologic agents (see table) are derived from the soil. Sinus tract
drainage material, when present, may be representative of the etiology of underlying osteomyelitis. In addition to the stains and cultures noted in the table, sinus
drainage should also be examined grossly and microscopically for the presence of “sulfur granules” characteristic of this disease. Further, the laboratory should be
notified of the possibility of Nocardia as a pathogen so that appropriate media, eg Neisseria selective media and Legionella selective agar, can be inoculated which
facilitate recovery of this organism.
j Pseudomonas aeruginosa is the most common bacterial cause of calcaneal osteomyelitis in individuals who develop this infection after stepping on nails while
wearing sneakers.
k Direct trauma to bone such as may occur in open fractures with contamination of the site by soil, animal feces, water, etc, may lead to the development of
osteomyelitis due to essentially any microorganism present in the contamination source. This includes the Enterobacteriaceae, Pseudomonas aeruginosa, unusual
gram-negative bacilli, Bacillus spp, anaerobes such as Clostridium spp, Nocardia and other aerobic actinomycetes. This represents another form of osteomyelitis
that can be polymicrobial.
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or slowly growing organisms such as filamentous fungi and
Mycobacterium spp should be entertained if bacterial cultures
are negative for growth. If culture results in growth ofMycobac-
terium spp, it may represent disseminated disease. However,
AFB and parasitic studies would only rarely be considered.
D. Peritoneal Dialysis-Associated Peritonitis (PDAP)
The evaluation of dialysis fluid from patients with suspected
PDAP is essentially identical to that used for SBP. Infections
tend to be monomicrobic and rarely anaerobic. In the case of
PDAP, however, the list of likely suspect organisms is quite
different from SBP. Gram-positive bacteria (predominantly
Staphylococcus spp and to a lesser extent, Streptococcus and
Corynebacterium spp) account for >60% of cultured microor-
ganisms. Gram-negative bacteria (mostly E. coli, Klebsiella,
and Enterobacter spp) represent <30% of positive cultures
while anaerobes comprise <3% of isolates [118, 121, 122].
Fungi, especially Candida species contribute to the same
number of identified infections as anaerobes [121]. Cultures
can remain negative in >20% of all cases of PDAP [121].
Again, 10–50 mL of dialysate should be collected for concen-
tration and culture, cytospin Gram stain evaluation, analysis
for protein, cell count and differential (Table VIII-2). Blood
cultures are rarely positive in cases of PDAP [118]. Direct in-
oculation of dialysate or a concentrated dialysate into an
aerobic blood culture bottle for automated detection has
proven to be as effective as direct plating of centrifuged fluid
[122, 123]. Consult directly with the microbiology laboratory
when primary cultures of fluid are negative and additional
cultures for slowly growing or highly fastidious organisms
such as Mycobacterium, Nocardia and filamentous fungi
should be pursued. If Nocardia is of concern, primary
culture plates require prolonged incubation or culture on
fungal media or buffered charcoal yeast extract agar.
E. Space-Occupying Lesions of the Liver
The primary diagnostic dilemma for cases of space-occupying
lesions of the liver is distinguishing those caused by parasites
(Entamoeba histolytica and Echinococcus) from pyogenic ab-
scesses caused by bacteria or fungi. The location, size, and
number of liver abscesses is often not helpful for differentiation
purposes as the majority are in the right lobe and can be seen
in single or multiple loci [124–126]. In regions where E. histoly-
tica disease is endemic, the use of serology or serum antigen de-
tection tests can be helpful to exclude amebic abscess [127]
whereas examination of stool for cysts and trophozoites is gen-
erally not (Table VIII-2). Liver abscess aspirates can be tested
for the presence of E.histolytica antigen as well as submitted for
direct microscopic evaluation for parasites. When amebic
disease is unlikely, the abscess should be aspirated and the
contents submitted in anaerobic transport for aerobic and an-
aerobic bacterial cultures. Commonly recovered isolates include
Klebsiella spp, E. coli, and other Enterobacteriaceae, Pseudomo-
nas spp, Streptococcus spp including Streptococcus anginosus
group spp, Enterococcus spp, viridans group Streptococcus, S.
aureus, Bacteroides spp, Fusobacterium spp (especially with
Lemierre’s syndrome), Clostridium spp, and rarely Candida
spp [124–126]. Aerobic and anaerobic bacterial culture should
be requested (Table VIII-2). Blood cultures can also be
helpful in establishing an etiology if collected prior to the insti-
tution of antimicrobial therapy [125, 126]. Occasionally, pa-
tients with primary genital infections due to N. gonorrhoeae or
C. trachomatis can have extension of the disease to involve
the liver capsule or adjacent peritoneum (Fitz-Hugh-Curtis
syndrome).
F. Infections of the Biliary Tree
Not unexpectedly, bacteria commonly associated in biliary tract
infections (primarily cholecystitis and cholangitis) are the
same organisms recovered from cases of pyogenic liver abscess
(see above and Table VIII-1). Parasitic causes include Ascaris
and Clonorchis spp or any parasite that can inhabit the biliary
tree leading to obstruction [124]. At a minimum, cultures for
aerobic bacteria (anaerobes if the aspirate is collected appropri-
ately) and Gram stain should be requested. When signs of
sepsis and peritonitis are present, blood and peritoneal cultures
should be obtained as well.
For patients with HIV infection, the list of potential agents
and subsequent microbiology evaluations needs to be expanded
to include Cryptosporidium, microsporidia, Cystoisospora (Iso-
spora) belli, CMV, and Mycobacterium avium complex [124].
As the identification of these organisms requires special pro-
cessing, it is important to communicate with the laboratory to
determine test availability either on-site or at a reference
laboratory.
G. Splenic Abscess
Most cases of splenic abscess are the result of metastatic or
contiguous infectious processes, trauma, splenic infarction, or
immunosuppression [128]. Infection is most likely aerobic
and monomicrobic with Staphylococcus spp, Streptococcus
spp, Enterococcus spp, Salmonella spp and E. coli commonly
isolated. Anaerobic bacteria have been recovered in 5%–17%
of culture-positive cases [128]. Aspirates should be processed
in a similar manner as pyogenic liver abscesses including
aerobic and anaerobic culture, Gram stain, and concomitant-
ly collected blood culture sets (Table VIII-2). Unusual causes
of splenic abscess include Bartonella spp, Streptobacillus
moniliformis, Nocardia spp, and Burkholderia pseudomallei
(uncommon outside of Southeast Asia or without suggestive
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travel history) [129]. The laboratory should be notified if this
agent is possible due to the need for increased biosafety pre-
cautions since B. pseudomallei is a potential bioterrorism
agent. As in biliary disease, the spectrum of organisms to be
considered needs to be expanded to include Mycobacterium
spp, fungi (including Pneumocystis jirovecii), and parasites
for immunocompromised patients [129].
H. Secondary Pancreatic Infection
Most cases of acute or chronic pancreatitis are produced by
obstruction, autoimmunity or alcohol ingestion [130, 131].
Necrotic pancreatic tissue generated by one of these processes
can serve as a nidus for infection [130, 131]. Infectious
agents associated with acute pancreatitis are numerous and
diverse, however, superinfection of the pancreas is most often
caused by gastrointestinal flora such as E. coli, Klebsiella spp
and other members of the Enterobacteriaceae, Enterococcus
spp, Staphylococcus spp, Streptococcus spp, and Candida spp.
Necrotic tissue or pancreatic aspirates should be sent for
aerobic bacterial culture and Gram stain and accompanied
by 2–3 sets of blood cultures (Table VIII-2). Antimicrobial
susceptibility results from isolated organisms can be used to
direct therapy to reduce the likelihood of pancreatic sepsis,
further extension of infection to contiguous organs, and
mortality. Sterile cultures of necrotic pancreatic tissue are not
unusual but may trigger consideration of an expanded search
for fastidious or slowly growing organisms, parasites, or
viruses.
IX. BONE AND JOINT INFECTIONS
Osteomyelitis may arise as a consequence of hematogenous
seeding of bone from a distant site, extension into bone from a
contiguous soft tissue infection, extension into bone from a
biofilm on a contiguous prosthesis, or direct traumatic inocula-
tion [132]. Similarly, joint infections may develop by any of
these routes, but occur most often by hematogenous seeding.
From the perspective of pathophysiology, specific nature of in-
fection and to at least some extent, clinical course, it is useful to
classify bone infections based on pathogenesis. With joint in-
fections, a classification scheme based on specific site of in-
volvement and tempo of disease is most instructive; ie, acute
versus chronic arthritis and septic bursitis.
The potential list of causative agents of bone and joint
infections is diverse and is largely predicated on the patho-
genesis of infection, the nature of the infection and the host
[130, 134]. With few exceptions, bone and joint infections
are usually monomicrobic. Rarely, such infections are poly-
microbic.
Key points for the laboratory diagnosis of bone and joint infec-
tions
• Swabs are not recommended for specimen collection; as-
pirates or 3–6 tissue biopsies are needed to provide sufficient
sample for studies
• Concomitant blood cultures are indicated for detection
of some systemic agents of osteomyelitis and joint infections,
but not for prosthetic joint infection.
• Joint fluids should have an aliquot injected into
an aerobic blood culture bottle, preferably at the bedside, in
addition to placing fluid in a sterile container for direct
processing.
• For prosthetic joint infection diagnosis, 3–6 separate
tissue samples should be submitted. As an alternative, sonica-
tion or bead mill homogenizing of samples from the removed
prosthesis are excellent methods to detect pathogens in bio-
films.
• When anaerobic bacteria are suspected, anaerobic trans-
port containers should be used.
• Some agents of joint infections are not culturable and
require molecular methods and/or serology for detection.
A. Osteomyelitis
Establishing an etiologic diagnosis of osteomyelitis nearly
always requires obtaining bone biopsy material for microbio-
logic evaluation [135]. As much specimen as possible is desir-
able; specimens may include pieces of intact bone, shavings,
scrapings and excised necrotic material. In true osteomyelitis,
the bone tissue is often so necrotic that it can be easily obtained
with a curette. Swab cultures of sinus tracts are not diagnostic
and are not recommended. Similarly, determining the etiology
of joint infections usually requires sampling the joint space di-
rectly with aspiration of synovial fluid and/or biopsy of the
synovium. Concomitant or secondary bacteremia or fungemia
occurs sporadically in patients with both osteomyelitis and in-
fections of joints, although patients with contiguous spread os-
teomyelitis rarely develop bacteremia and blood cultures are
rarely appropriate for that population. Thus, blood cultures col-
lected during febrile episodes are recommended for the evalua-
tion of patients suspected of having secondary bacteremia or
fungemia. Assessment of acute phase reactants or nonspecific
markers of inflammation such as procalcitonin, C-reactive
protein, and erythrocyte sedimentation rates are not diagnostic
in patients with these infections, but they may yield helpful in-
formation during therapy. Some less common agents may
require molecular detection methods, which will often need to
be sent to a reference laboratory with ensuing longer turn-
around time for results (Table IX-1) [136].
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B. Joint Infections
In addition to spontaneous and hematogenously seeded joint
infections (Table IX-2), a special category exists for prosthetic
joint infections, especially infections of knee and hip prosthe-
ses, which are most often caused by coagulase-negative staphy-
lococci [140, 141]. Laboratory diagnosis of prosthetic joint
infections based on peri-surgical cultures is difficult since con-
tamination with skin organisms is not uncommon in surgical
samples. It is important to change to a fresh sterile scalpel after
making the initial incision. One recommendation to differenti-
ate true coagulase-negative staphylococcal infection from con-
tamination occurring during surgical removal of tissue
surrounding a prosthetic joint is to obtain 3–6 separate small
tissue biopsies or curettings during the surgical procedure. If
the same species is recovered from 3 or more of the samples,
this is strong evidence of its pathogenicity [142].
Pre-surgical sampling of joint fluids from any suspected in-
fection should be performed in the same manner as for acute
arthritis (Table IX-2). A European publication documented
rapid (1–2 hour) pre- and perisurgical identification of S.
aureus, MRSA, and putative methicillin-resistant coagulase
negative staphylococci from joint fluids using a rapid NAAT
assay [143]. Intra-operative Gram stains have poor yield (33%–
50%) but if positive, may be helpful. Shoulder joints, whether
natural or prosthetic, are preferentially infected with Propioni-
bacterium acnes, a normally commensal skin organism [144].
Anaerobic cultures of shoulder tissue biopsies should be incu-
bated in anaerobic broth for up to 14 days before discarding as
negative. Recent work, primarily from Mayo Clinic, recom-
mends sonication of prosthetic joint biopsy samples and
culture of the post-sonication fluid [145]. Another recent tech-
nique that was found to increase yield of bacteria and perhaps
yeast from joint tissue and bone removed during prosthetic re-
vision surgery was bead mill processing using 1 mm glass beads
[146]. Since fungi and mycobacteria are extremely rare in this
setting, they should not be sought without special communica-
tion with the laboratory [147, 148]. If fungi are suspected, the
bead mill method would likely destroy hyphal elements, so
mincing bone and tissue and direct inoculation onto fungal
agar is still recommended. Both sonication and bead mill pro-
cessing are not available in most laboratories.
X. URINARY TRACT INFECTIONS
Clinical microbiology tests of value in establishing an etiologic
diagnosis of infections of the urinary tract are covered in this
section, including specimens and laboratory procedures for the
diagnosis of cystitis, pyelonephritis, prostatitis, epididymitis
and orchitis. Some special tests not available in smaller labora-
tories may be sent to a reference laboratory, but expect longer
turnaround times for results.
Key points for the laboratory diagnosis of urinary tract
infections:
• Urine should not sit at room temperature for more than
30 minutes. Hold at refrigerator temperatures if not cultured
within 30 minutes.
• Reflexing to culture after a positive pyuria screen should
be a locally approved policy.
• Three or more species of bacteria in a urine specimen
usually indicates contamination at the time of collection and
interpretation is fraught with error.
• Do not ask the laboratory to report “everything that
grows” without first consulting with the laboratory and provid-
ing documentation for interpretive criteria for culture that is
not in the laboratory procedure manual.
IDSA guidelines for diagnosis and treatment of urinary tract
infections are published [156, 139] as are ASM recommenda-
tions [158]. These provide diagnostic recommendations that
are similar to those presented here (Table X-1). The differentia-
tion of cystitis and pyelonephritis requires clinical information
and physical findings as well as laboratory information, and
from the laboratory perspective the spectrum of pathogens is
similar for the two syndromes [159]. Culturing only urines that
have tested positive for pyuria, either with a dipstick test for
leukocyte esterase or other indicators of PMNs may increase
the likelihood of a positive culture, but occasionally samples
yielding positive screening tests yield negative culture results
and vice versa [160]. The Gram stain is not the appropriate
method to detect PMNs in urine but it can be ordered as an
option for detection of high numbers of gram-negative rods
when a patient is suspected of suffering from urosepsis.
Because urine is so easily contaminated with commensal flora,
specimens for culture of bacterial urinary tract pathogens
should be collected with attention to minimizing contamina-
tion from the perineal and superficial mucosal microbiota
[161]. Although some literature suggests that traditional skin
cleansing in preparation for the collection of midstream or
“clean catch” specimens is not of benefit, many laboratories
find that such specimens obtained without skin cleansing rou-
tinely contain mixed flora and if not stored properly and trans-
ported within one hour to the laboratory, yield high numbers
of one or more potential pathogens on culture. Interpretation
of such cultures is difficult, so skin cleansing is still recom-
mended. The use of urine transport media in vacuum-fill tubes
or refrigeration immediately after collection may decrease the
proliferation of small numbers of contaminating organisms
and increase the numbers of interpretable results. Straight or
“in-and-out” catheterization of a properly prepared patient
usually provides a less contaminated specimen. If mixed enteric
bacteria in high numbers are recovered from a second, well-
e74 • CID 2013:57 (15 August) • Baron et al
Table IX-2. Laboratory Diagnosis of Joint Infections




Staphylococcus aureus Gram stain Synovial fluid and/or synovium
biopsy




Streptococcus pyogenes Inoculate up to 10 mL fluid
directly into aerobic blood
culture bottle at bedsidea








Brucella spp Brucella serology
Parvovirus-B19 [149] PV-B19 serology 5 mL serum Clot tube, RT, 2 h
PV-B19 nucleic acid
amplification test (NAAT)
Synovial fluid Closed container, RT, 2 h




Lyme serology 5 mL serum Clot tube, RT, 2 h
B. burgdorferi culturee Synovial fluid Sterile container, RT, immediately
B. burgdorferi NAAT Synovial fluid Closed container, RT, 2 h
Mycobacterium
tuberculosis
Acid fast smear Synovial fluid and/or synovium
biopsyf




Candida spp Calcofluor-KOH stain Synovial fluid and/or synovium
biopsy
Sterile container, RT, 2 h
Cryptococcus neoformans




Staphylococcus aureus Gram stain Bursa fluid Sterile container, RT, immediately
Streptococcus pyogenes Aerobic bacterial culture
Other streptococci Inoculate up to 10 mL fluid into
aerobic blood culture bottle (in





Staphylococcus aureus Aerobic bacterial culture Multiple tissue biopsy samples. Sterile container, RT, 2 h
Coagulase negative
staphylococci
Enterococcus spp Gram stain not useful Synovial fluid
Streptococcus spp (group
A, B and other β
hemolytic types)
Or submit the removed prosthesis
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collected straight-catheterized sample from the same patient, a
rectal-urinary fistula should be considered. Laboratory actions
should be based on decisions arrived at by dialogue between cli-
nician and laboratory.
Specimens from urinary catheters in place for more than a
few hours frequently contain colonizing flora due to rapid
biofilm formation on the catheter surface, which may not rep-
resent infection. Culture from indwelling catheters is therefore
strongly discouraged, but if required, the specimen should be
taken from the sampling port of a newly inserted device. Cul-
tures of Foley catheter tips are of no clinical value and will be
rejected. Collection of specimens from urinary diversions such
as ileal loops is also discouraged because of the propensity of
these locations to be chronically colonized. Chronic nephros-
tomy collections and bagged urine collections are also of
questionable value. Multiple organisms or coagulase-negative
staphylococci may be recovered in patients with urinary
stents, and may be pathogenic. It is important that Urologists
and Nephrologists who care for patients with complicated in-
fections discuss any special needs or requests with the micro-
biology director or supervisor. Specimens from these patients
may contain a mixed flora and if specific interpretive criteria
are documented for these specimen types, the laboratory must
be aware of the documentation and the special interpre-
tive standards. Laboratories routinely provide antimicrobial
susceptibility tests on potential pathogens in significant num-
bers. Specimens obtained by more invasive means, such
as cystoscope or suprapubic aspirations should be clearly
identified and the workup discussed in advance with the labo-
ratory, especially if the clinician is interested in recovery of
bacteria in concentrations less than 1000 colony forming units
(cfu) per milliliter. Identification of a single potential patho-
gen in numbers as low as 200 cfu/mL may be significant, such
as in acute urethral syndrome, but requests for culture results
reports of <10 000 cfu/mL should be coordinated with the
laboratory so that an appropriate volume of urine can be
procesed.
Recovery of yeast, usually Candida spp, even in high cfu/mL
is not infrequent from patients who do not actually have yeast
UTI, thus interpretation of cultures yielding yeast is not as stan-
dardized as that for bacterial pathogens. Yeast in urine may
rarely indicate systemic infection, for which additional tests
must be conducted for confirmation (eg, blood cultures and
β-glucan levels). Recovery ofMycobacterium tuberculosis is best
accomplished with first-voided morning specimens of >20 mL,
and requires a specific request to the laboratory so that appro-
priate processing and media are employed. Recovery of adeno-
virus in cases of cystitis requires a specific request for viral
culture. A nucleic acid amplification test (NAAT) may also be
available at reference laboratories for detection of adenovirus.
Polyoma BK virus nephropathy is best diagnosed by quantita-
tive molecular determination of circulating virus in blood
rather than detection of virus in urine. Such tests are usually
performed in reference laboratories.
Acute bacterial prostatitis is defined by clinical signs and
physical findings combined with positive urine or prostate
Table IX-2 continued.





Aerobic and anaerobic bacterial
culture (incubate anaerobic
cultures up to 14 d)
Sterile anaerobic transport
container, RT, immediately.
Polymicrobial infections Also consider submitting
prosthesis (if removed) for
sonication
Abbreviations: AFB, acid-fast bacillus; KOH, potassium hydroxide; NAAT, nucleic acid amplification test; RT, room temperature.
aWhen sufficient synovial fluid specimen has been obtained, up to 10 mL should be transferred aseptically into an aerobic blood culture bottle and processed in a
manner similar to routine blood cultures [154, 155]. This practice, however, does not obviate the value of direct specimen Gram stains and direct solid agar culture
of synovial fluid specimens. These procedures should always be done in addition to inoculation of a blood culture bottle with up to 10 mL of the fluid. Dilution of
active PMNs and other factors in the blood culture broth may allow recovery of the organism when direct culture yields no growth.
bKingella kingae is most often observed as a cause of septic joint infections in children and usually involves the knee [138, 152].
cNeisseria gonorrhoeae may yield aberrant morphologic forms on Gram stain of synovial fluid in patients with joint infections due to this organism. Synovial fluid
and synovium biopsy specimens should be processed expeditiously for culture and even then, cultures are often negative [153].
d In a patient with a compatible illness, especially with a history of recent vaccination with the live attenuated rubella virus vaccine, a negative serologic test for
rubella may be considered suggestive evidence for joint infection due to rubella virus [150].
e Culture of synovial fluid for B. burgdorferi requires use of specialized media and even with expeditious processing of specimens in an experienced laboratory,
rarely results in recovery of the organism. Most laboratories will need to send the sample to a reference laboratory, further delaying and compromising possible
cultures. Culture is rarely done except in research settings.
f Detection of M. tuberculosis or other Mycobacterium species by microscopy or in culture is very uncommon from synovial fluid specimens in patients with joint
infections due to these organisms [148]. Synovium tissue enhances the likelihood of detection.
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secretion cultures yielding usual urinary tract pathogens [162–
164]. The diagnosis of chronic prostatitis is much more prob-
lematic, and the percentage of cases in which a positive culture
is obtained is much lower [165]. The traditional Meares-Stamey
four glass specimen obtained by collecting the first 10 mL void,
a mid-stream specimen, expressed prostate secretions (EPS)
and a 10 mL post-prostate-massage urine is positive if there is a
ten fold higher bacterial count in the EPS than the mid-stream
urine. A two-specimen variant, involving only the mid-stream
and the EPS specimens, is also used. A positive test is infre-
quent, and chronic pelvic pain syndrome is not frequently
caused by a culturable infectious agent. It should be remem-
bered that prostatic massage in a patient with acute bacterial
prostatitis may precipitate bacteremia and/or shock. Table X-2
summarizes the approach to laboratory diagnosis of prostatitis.
Epididymitis in men under 35 years of age is most frequently
associated with the sexually transmitted pathogens Chlamydia
trachomatis and Neisseria gonorrhoeae. NAATs are the most sen-
sitive and rapid diagnostic procedures for these agents and each
commercially available system has its own collection kit. Culture
of N. gonorrhoeae is recommended when antibiotic resistance is
a concern, and special media are required for antimicrobial
susceptibility testing (AST), which may be referred to a public
health laboratory. In men over 35 years of age, gram-negative
and gram-positive pathogens similar to the organisms causing
UTI and prostatitis may cause invasive infections of the epididy-
mis and testis. Surgically obtained tissue may be cultured for bac-
terial pathogens, and AST will be performed. Fungal and
mycobacterial disease are both uncommon, and laboratory diag-
nosis requires communication from the clinician to the laboratory
to ensure proper medium selection and processing, particularly if
tissue is to be cultured for these organisms.
Bacterial orchitis may be caused by both gram-negative and
gram-positive pathogens, frequently by extension from a con-
tiguous infection of the epididymis. Viral orchitis is most fre-
quently ascribed to Mumps virus. The diagnosis is made by
IgM serology for Mumps antibodies, or by acute and convales-
cent IgG serology. Other viral causes of epididymo-orchitis are
Coxsackie virus, rubella virus, Epstein-Barr virus and Varicella-
Zoster virus. Systemic fungal diseases can involve the epididymis
or testis, including blastomycosis, histoplasmosis and coccidioi-
domycosis. Mycobacterium tuberculosis may also involve these
sites [166]. Table X-3 summarizes the approaches to specimen
management for cases of epididymitis and orchitis.
Table X-1. Laboratory Diagnosis of Cystitis and Pyelonephritis




Enterobacteriacae: Routine aerobic culture Mid-stream, clean catch or straight
cath urine
Closed sterile leakproof container;
refrigerate (4°C) or use urine transport













Routine aerobic culture Gram stain
(optional, low sensitivity)
Midstream, clean catch, or straight
cath urine
Closed sterile leakproof container;
refrigerate (4°C) or use urine transport











Mycobacterial culture First void urine Prefer >20 mL urine, refrigerate (4°C)
during transport
Virus
Adenovirus Virus Culture Midstream or clean catch urine Closed sterile container to laboratory
within 1 hNAATa
BK Polyoma virus Quantitative NAATa from urine,
plasma, or serum
Blood EDTA or Citrate blood collection tube, RT
Serum Clot tube, RT
Abbreviations: NAAT, nucleic acid amplification test; RT, room temperature.
a No FDA-cleared NAAT tests available
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XI. GENITAL INFECTIONS
Both point of care and laboratory tests to identify the microbio-
logical etiology of genital infections are described below. In ad-
dition, because recommendations exist for screening of genital
infections for specific risk groups, these are also presented. In
this section infections are categorized as follows: cutaneous
genital lesions, vaginitis and vaginosis, urethritis and cervicitis,
and infections of the female pelvis, including endometritis and
pelvic inflammatory disease (PID). Testing in special popula-
tions, such as pregnant patients, children and men who have
sex with men (MSM) are noted where applicable but readers
are referred to the more comprehensive guidelines referenced.
There is considerable overlap in symptoms and signs for
many genital infections and clinical diagnosis alone is neither
sensitive nor specific. Thus, diagnostic testing is recommended
for the following reasons: appropriate treatment can be focused,
specific diagnosis has the benefit of increasing therapeutic com-
pliance by the patient and the patient is more likely to comply
with partner notification [167]. Providers should also recognize
that despite diagnostic testing, 25%–40% of the causes of genital
infections or symptoms may not be specifically identified, and
that many infections are acquired from an asymptomatic partner
unaware of their infection. In fact, patients who seem to “fail”
therapy and continue to exhibit symptoms and/or have positive
tests for sexually transmitted infections (STIs), are most likely to
have been re-infected by their sexual partner [168, 169]. Thus re-
ferral for partners for specific testing and treatment is essential to
prevent re-infection and is especially true for patients who may
be pregnant. Finally, because the vast majority of genital infec-
tions are STIs and communicable, they are a public health
concern and patients and providers should note that positive
tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae
(GC), syphilis, chancroid, and human immunodeficiency virus
(HIV) require reporting in accordance with state and local statu-
tory requirements by the laboratory and/or the provider. Report-
ing of additional STIs varies by state [167].
Key points for the laboratory diagnosis of genital infections:
• For vaginosis (altered vaginal flora) a Gram stain is more
specific than culture or probe testing and culture is not recom-
mended.
• Distinguishing between HSV-1 and HSV-2 antibodies re-
quires testing with type-specific glycoprotein G (gG)-based
assays.
• Testing simultaneously for CT, GC and Trichomonas is
optimal for detection of the most common treatable STIs in
female patients.
• Screen for Group B streptococcus at 35–37 weeks of preg-
nancy using both vaginal and rectal swabs.
• Screen for HIV early in each new pregnancy and in sexu-
ally active patients age 13–64 seeking evaluation for STIs.
• Undertake partner testing and/or treatment of positive
index cases to prevent re-infection.
Table X-2. Laboratory Diagnosis of Prostatitis




E. coli, other enteric bacteria,
Pseudomonas spp
Aerobic Culture Midstream urine with or
without expressed
prostate secretions
Closed sterile container to laboratory





Pathogens similar to acute
bacterial disease
Gram stain or cell counts Midstream urine and
expressed prostate
secretions, seminal fluid
Closed sterile container to laboratory




Blastomyces dermatitidis Fungal culture Expressed prostate
secretions, prostate
biopsy
Closed sterile container to laboratory





Mycobacterium tuberculosis Mycobacterial culture First void urine, expressed
prostate secretions,
prostate biopsy
Prefer >20 mL urine, refrigerate (4°C)
during transport
Abbreviation: RT, room temperature.
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A. Genital Lesions
Genital lesions may have multiple simultaneous infectious eti-
ologies that make them a challenge to diagnose and treat prop-
erly. Centers for Disease Control and Prevention (CDC)
guidelines recommend that all patients presenting with a
genital lesion should be evaluated with a serological test for
syphilis, as well as diagnostic tests for genital herpes and for H.
ducreyi where chancroid is prevalent. Because many of the
genital lesions exhibit inflammatory epithelium that enhances
the transmission of HIV, screening with an EIA (enzyme-
immunoassay) HIV antibody test is recommended in these pa-
tients as well [167]. Table XI-1 shows the diagnostic tests for
identifying the etiology of the most common genital lesions.
For suspected cases of HSV genital lesions, viral culture,
direct fluorescent antibody (DFA) and/or nucleic acid amplifi-
cation tests (NAATs) are commonly used for diagnosis. Since
methods for specific testing for vesicles varies among laborato-
ries, consultation with the laboratory before specimen collec-
tion is appropriate. For instance, while NAATs are the most
sensitive, especially where suboptimal collection, or nonulcera-
tive or vesicular lesions may be present, there may be limita-
tions as to specimen source acceptable and patient age
depending on the NAAT used. Culture is more likely to be pos-
itive in patients that have vesicular versus ulcerative lesions,
specimens obtained from a first episodic lesion versus a
recurrent lesion, and specimens from immunosuppressed pa-
tients rather than immunocompetent. DFA allows assessment
of an adequate specimen and can be a rapid test if performed
on-site; isolates should be typed to determine if they are HSV-1
or 2 since 12-month recurrence rates are more common with
HSV-2 (90%) than HSV-1 (55%). Serology cannot distinguish
between HSV-1 and HSV-2 unless a type-specific glycoprotein
G (gG) –based assay is requested [167, 168].
Point of care tests (POCT) for HSV-2 may yield false positive
results in patient populations with a low likelihood of HSV in-
fection or in early stages of infection as well as false negative
results in primary lesions that are due to HSV-1.
In children presenting with genital lesions, providers should
not assume HSV only but should consider potential atypical
presentation of Varicella zoster virus (VZV). DFA is best for
detection of VZV as culture is less sensitive. Pregnant patients
with a history of genital herpes should be assessed for active
lesions at the time of delivery.
New consensus guidelines for the management of women
with abnormal cervical cytologic lesions and human papilloma
virus (HPV) as well as the use of genotyping tests are pending
publication. The 2006 consensus guidelines are discussed in the
American Journal of Obstetrics and Gynecology by Wright
et al. regarding routine high-risk HPV testing and available
at the website www.asccp.org/consensus/histological.shtml
Table X-3. Laboratory Diagnosis of Epididymitis and Orchitis














Tissue aspirate or biopsy Closed sterile container,
refrigerate (4°C) if delay.
Virus





EBV Culture where available Tissue aspirate or biopsy Closed sterile container,





Fungal culture Tissue aspirate of biopsy Closed sterile container,




Mycobacterial culture Tissue aspirate or biopsy Closed sterile container,
refrigerate (4°C) if delay.
Abbreviations: EBV, Epstein-Barr virus; NAAT, nucleic acid amplification test; RT, room temperature; VZV, Varicella zoster virus.
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(accessed 2-3-13) [170]. A more recent American Society for
Colposcopy and Cervical Pathology (ASCCP) HPV genotyping
update discusses the testing specifically for HPV 16/18 geno-
type in women over 30. Basically, HPV testing is recommended
for the purposes of triaging women >20 years of age with atypi-
cal squamous cells of undetermined significance (ASC-US) or
ASC-H (atypical squamous cells cannot exclude high grade
squamous intraepithelial lesion [HSIL]). Only testing for those
high-risk HPV types that are associated with cervical cancer is
appropriate. Follow-up testing for abnormal cytology and/or
positive HPV is complicated and readers are referred to the
ASCCP guidelines for management decisions. In addition, rec-
ommendations for testing for genotypes 16/18 HPV for women
over 30, where high risk HPV testing can be ordered in con-
junction with cytology, should be considered. In general, results
of cytology negative but HPV high risk positive warrant HPV
16/18 genotype determination for identification of patients at
higher risk for progression to invasive cervical cancer [171]. En-
docervical specimens in liquid cytology medium have a higher
sensitivity for detecting significant lesions (eg squamous intrae-
pithelial lesions (SIL) and can facilitate subsequent HPV testing
in patients since it can be done from the same specimen. Pa-
tients with a cervix remaining after hysterectomy, HIV positive
patients, and patients that have received the quadrivalent re-
combinant HPV vaccine (Gardasil from Merck and Co.)
should undergo routine Papanicolaou (Pap) and HPV screen-
ing and management. Pap and/or HPV testing should be post-
poned when a woman is menstruating [170, 172, 173].
In the United States, testing for syphilis traditionally has
consisted of initial screening with an inexpensive nontrepone-
mal test (rapid plasma reagin, RPR), then retesting reactive
specimens with a more specific, and more expensive, trepone-
mal test (eg T. pallidum particle agglutination [TP-PA]). If a
nontreponemal test is being used as the screening test, it should
be confirmed, as a high percentage of false positive results
occur in many medical conditions unrelated to syphilis. When
both test results are reactive, they indicate present or past infec-
tion. However, for economic reasons, some high-volume clini-
cal laboratories have begun using automated treponemal tests,
such as automated EIAs or immunochemoluminescence tests,
and have reversed the testing sequence: first screening with a
treponemal test and then retesting reactive results with a non-
treponemal test. This approach has introduced complexities in
test interpretation that did not exist with the traditional se-
quence [174]. Specifically, screening with a treponemal test
sometimes identifies persons who are reactive to the trepone-
mal test but nonreactive to the nontreponemal test. No formal
recommendations exist regarding how such results derived
from this new testing sequence should be interpreted, or how
patients with such results should be managed. To begin an as-
sessment of how clinical laboratories are addressing this
concern, CDC reviewed the testing algorithms used and the test
interpretations provided in four laboratories in New York City
[174]. Substantial variation was found in the testing strategies
used, which might lead to confusion about appropriate patient
management. A total of 3664 (3%) of 116 822 specimens had
test results (ie, reactive treponemal test result and nonreactive
nontreponemal test result) that would not have been identified
by the traditional testing algorithms, which obviate additional
testing if the nontreponemal test result is nonreactive. If they
have not been previously treated, patients with reactive results
from treponemal tests and nonreactive results from nontrepo-
nemal tests should be treated for late latent syphilis.
Treponema pallidum cannot be seen on Gram stain and
cannot be cultured in the routine laboratory. Darkfield
exam for motile spirochetes is unavailable in the majority of
laboratories.
Chancroid, caused by the gram-negative organism Haemo-
philus ducreyi, is the one genital lesion where a Gram stain may
be helpful in diagnosis. Communication with the laboratory
about the presumed diagnosis and specimen transport may
enhance recognition of organisms in the Gram stain and facili-
tate the appropriate culture technique. Samples must be ob-
tained after surface debridement and should be sent to a
referral laboratory familiar with this testing as many microbiol-
ogists have rarely seen chancroid. Lymphogranuloma venereum
(LGV) is caused by the intracellular pathogen Chlamydia tra-
chomatis (CT), specifically serovars L1, L2a, L2b and L3. LGV
is a diagnosis of exclusion of more common entities in context
with epidemiological information [168].
B. Vaginosis/Vaginitis
The diagnoses of bacterial vaginosis (BV), or altered vaginal
flora, and vaginitis caused by fungal organisms (vulvovaginal
candidiasis [VVC]) or Trichomonas vaginalis (TV), are often
considered clinically and diagnostically as a group because of
their overlapping nature. However, the mode of transmission
and/or acquisition is not necessarily that of an STI for BV or
VVC, but it is for TV. A number of point-of-care tests
(POCTs) can be performed from a vaginal discharge specimen
while the patient is in the healthcare setting. Although POCTs
are popular, the sensitivity and specificity of POCTs for making
a specific diagnosis varies widely and these assays, while rapid,
are often diagnostically poor. Some of the tests include a pH
strip test, scored Gram stain for BV, wet mount for TV, and
10% KOH microscopic examinations for VVC. For BV, use of
clinical criteria (Amsel’s diagnostic criteria) is equal to a scored
Gram stain of vaginal discharge. However, a scored Gram stain
is more specific than probe hybridization and POCT tests (that
only detect the presence of G. vaginalis as the hallmark organ-
isms for altered vaginal flora). For VVC and TV the presence of
pseudohyphae and motile trichomonads, respectively, allows a
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diagnosis. However, proficiency in microscopic examination is
essential given that infections may be mixed and/or present
with atypical manifestations. Unfortunately consistent micro-
scopic exam of vaginal specimens and interpretation are diffi-
cult for many laboratories to perform and wide variation of
sensitivities (40%–70%) for both TV and CVV using smear
exam exists relative to NAAT and culture, respectively. It
should be noted that recent publications utilizing NAATs high-
light the prevalence of Trichomonas as equal to or greater than
CT and GC and point to a growing trend toward screening for
TV, CT and GC simultaneously. Tests for the entities of vagino-
sis/vaginitis are shown in Table XI-2 [173, 175–178].
C. Urethritis/Cervicitis
Urethritis and cervicitis share common signs and symptoms
and infectious etiologies in male and female patients, respec-
tively. Table XI-3 combines the diagnostic tests used to identify
the pathogens common to both. In addition, because screening
for CT and GC has reduced the repercussions related to infec-
tions and subsequent PID, the following guidelines for screen-
ing women for CT and GC have been presented by the U.S.
Preventive Services Task Force [163, 179, 180].
Annual CT screening
• Sexually active women age ≤25 years and those pregnant
• Older women with new sex partner or multiple sex
partners
• Women who are incarcerated
GC Screening (consider local epidemiology and risk)
• Sexually active women age ≤25 years and those pregnant
• Women with previous GC infection or other STIs
• Women experiencing multiple sex partners
• Women who do not use condoms
• Commercial sex workers and those who use drugs
• Women who are incarcerated
For laboratory diagnosis of CT and GC, many methods exist
but nucleic amplification tests (NAATs) are the preferred assays
for detection because of increased sensitivity while retaining spe-
cificity in low prevalence populations (pregnant patients) and
the ability to screen with a noninvasive urine specimen [181].
Specifically, EIA tests for CT should not be used due to lack of
sensitivity. In general, retesting patients with a follow-up test for
CT or GC (test of cure) is not recommended unless special
Table XI-1. Laboratory Diagnosis of Genital Lesions
Common Etiologic Agents Diagnostic Procedures Optimum Specimen
Transport Issues; Optimal
Transport Time
Herpes simplex virus 1
and 2
Direct fluorescent antibody (DFA) Scraping of lesion base rolled
directly onto slidea
RT
Note: in children with
genital lesions, consider
atypical VZVa
Culture Scraping of lesion base and placed
in VTM//UTMb
RT, If >2 h, refrigerated or on ice
NAATc Scraping or aspirate Assay-specific; consult laboratory
Serologyd Serum Clot tube, RT
Human papilloma virus
(HPV)
DNA hybridization probe or NAAT
for high-risk HPV typese
Endocervical brush into liquid




Genital wartsf Histopathology; HR HPV testing
not done on warts
Biopsy or scraping Formalin container, RT, 2–24 h
Syphilis Darkfield microscopyg Cleanse lesion with gauze and
sterile saline
RT, immediately to laboratory
Test is not widely available and
specimenmust be transported
to laboratory immediately to
visualize motile spirochetes




Cleanse lesion with gauze and
saline
Slide should be dry before placing
in holder and/or transporting to
labSwab of lesion base directly to
slide
Serology Serum Clot tube, RT, 2 h
Non –Treponemal (VDRL or RPR)j
Treponemal Serology Serum Clot tube, RT, 2 h
EIA or TP-PA, FTA-ABSk,l
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circumstances exist (pregnancy, continuing symptoms).
However, patients that are at higher risk for STIs should be
screened within 3–12 months from the initial positive test for
possible re-infection because those patients with repeat infections
are at higher risk for PID. Requirements for testing practices
and/or need for confirmatory testing in pediatric patients may
vary from state to state. Appropriate providers or laboratories
that perform testing in children should be consulted [167].
NAATs on samples other than genital are currently not FDA-
cleared and require in-house laboratory validation.
Recently, prevalence studies using NAATs have shown that
Trichomonas is as common as CT and more common that GC
Table XI-1 continued.





Gram stain and Culturem Swab of lesion basewithout
surface genital skin




Cell culturen Swab of ulcer base, bubo
drainage, rectum
RT, immediately to laboratory
(Chlamydia serovars L1, L2,
L2a, L2b, L3)
Serology Serum RT, 2 h
Microimmunofluorescence (MIF)o
Serology Serum RT, 2 h
Complement fixation (CF)p
NAATq Swab of ulcer base, bubo
drainage, rectum




Giemsa or Wright stain in
pathology. Visualization of blue
rods with prominent polar
granules
Scraping of lesion base into
formalin
RT, 2 h
Scabies/lice Macro and microscopic
visualization
Collect parasite from skin
scrapings onto slide; place in a
sterile Petri dishr
RT, within 1 h
Abbreviations: EIA, enzyme immunoassay, NAAT, nucleic acid amplification test; RT, room temperature; VZV, Varicella zoster virus.
a Epithelial cells are required for adequate exam and used to assess quality of the specimen collection; Consider atypical VZV in children with genital lesions using
DFA. Typical 3-welled slide allows distinction between HSV -1, HSV-2 and VZV.
b VTM – viral transport medium or UTM – universal transport medium. Check with laboratory, some types can be maintained and shipped at RT.
c NAAT – nucleic acid amplification test; several NAATs are FDA-cleared. Specimen source and test availability are laboratory specific. Provider needs to check with
laboratory for allowable specimen source and TAT. More sensitive than culture or DFAwhen lesions are past vesicular stage.
d Serology can be nonspecific for HSV-1 and HSV-2 differentiation; should be limited to patients with clinical presentation consistent with HSV but with negative
cultures; for determination of asymptomatic carriers; request type-specific glycoprotein G (gG)-based assays that differentiate HSV-1 and HSV-2.
e High-risk (HR) HPV testing currently only recommended in women with Pap smear showing atypical squamous cells of undetermined significance (ASC-US) or
>30 years of age. HPV testing is not recommended for the diagnosis of HPV in a sexual partner or in patients <20 y/o (adolescents) with ASC-US. HPV 16/18
genotyping in cytology negative and HR HPV positive specific guidelines pending.
f The diagnosis of genital warts is most commonly made by visual inspection, high-risk HPV testing is not recommended.
g Darkfield microscopy not widely available.
h DFA-TPA - Limited availability, typically performed in public health laboratories.
i Viable organisms are not required for optimal test performance.
j Non-treponemal tests – (rapid plasma reagin (RPR) and Venereal Disease Research Laboratory (VDRL); less sensitive in early and late disease; become negative
after treatment; do not use to test pregnant patients due to potential for false-positive results.
k Treponemal tests – Enzyme immunoassay (EIA) formats, T. pallidum particle agglutination (TP-PA) and fluorescent treponemal antibody absorbed (FTA-ABS);
monitor titers using same type of test and/or same lab; positive for life; HIV positive patients may have unusual serologic responses.
l EIA – treponemal enzyme immunoassay test may be performed first with subsequent testing done with non-treponemal test such as RPR (reverse testing
algorithm). Confirmation with a TP-PA test may be required in positive EIA but negative RPR.
m Gram stain with chancroid organisms shows small rods or chains in parallel rows, “school of fish”; culture requires special media and sensitivity only 30%–70%.
Consider sending slide and culture to a referral laboratory familiar with this testing.
n Cell culture sensitivity about 30%; rectal ulcers in MSM.
oMIF titers ≥256 with appropriate clinical presentation suggests LGV.
p CF titers ≥64 with appropriate clinical presentation suggests LGV, sensitivity 80% at 2 weeks.
q NAATs for CT will detect L1-L3 but do not distinguish these from the other CT serovars.
r Place a drop of mineral oil on a sterile scalpel blade. Allow some of the oil to flow onto the papule. Scrape vigorously six or seven times to remove the top of the
papule. (Tiny flecks of blood should be seen in the oil.) Use the flat side of the scalpel to add pressure to the side of the papule to push the mite out of the burrow.
Transfer the oil and scrapings onto a glass slide (an applicator stick can be used). Do not use a swab, which will absort the material and not release it onto the slide.
For best results, scrape 20 papules.
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in most clinical and geographic settings, with a uniquely high
presence in women over 40 and incarcerated populations. In
addition, the ulcerative nature of the infection leads to sequelae
similar to those of CT and GC, including perinatal complica-
tions as well as susceptibility to HIV and HSV acquisition and
transmission. An FDA-cleared NAAT allows testing from the
same screening specimens used for CT and GC testing with sig-
nificantly improved sensitivity over wet mount.
Standardized tests for M. genitalium are not available or rec-
ommended. However, in patients with nonchlamydial, NGU
(nongonococcal) urethritis, 15%–25% infections may be due to
this organism. A NAAT may be the best option for detection of
M. genitalium, due to issues with culture and cross-reactivity
with serologic tests, but that test is neither FDA-cleared nor
widely available. Culture for Ureaplasma is not recommended
because of the high prevalence of colonization in asymptomat-
ic, sexually active people [182, 183].
D. Infections of the Female Pelvis
Pelvic inflammatory disease (PID) is a spectrum of disorders of
the upper female genital tract and includes any single or combi-
nation of endometritis, tubo-ovarian abscess, and salpingitis.
Table XI-2. Laboratory Diagnosis of Bacterial Vaginosis, Yeast Vaginitis, and Trichomoniasis
Common Etiologic Agents Diagnostic Procedures Optimum Specimens
Transport Issues; Optimal
Transport Time
Yeast (pH <4.5a) Saline wet mount and 10% KOHb,
c
Swab of vaginal discharge Submitted in 0.5 mL saline or
transport swabd, RT, 2 h
Culturee Swab of vaginal discharge Submitted in transport swab, RT, 12 h
DNA hybridization probef Swab of vaginal dischargef RT, 7 d
Bacterial vaginosis (BV) (pH
>4.5a)
Wet mount and 10% KOHg Swab of vaginal discharge Submitted in 0.5 mL saline or
transport swab, RT, 2 h
Quantitative Gram stainh Swab of vaginal discharge Place directly into transport swab
tube, RT, 12 h
DNA Hybridization probef Swab of vaginal dischargef RT, 7 d
Trichomoniasis (pH >4.5a) Saline wet mounti Swab of vaginal discharge Submitted in saline, RT, 30 min
(optimal) – 2 h
Rapid antigen testj Swab of vaginal epithelium/
discharge
Submitted in transport swab or saline,
RT, 24 h
DNA hybridization probef Swab of vaginal dischargef RT, 7 d
Culturek Swab of vaginal discharge Place directly into InPouch TV Culture
system, RT, 48 h




RT, 7 d (or manufacturer’s
recommendation)
Abbreviations: KOH, potassium hydroxide; NAAT, nucleic acid amplification test; RT, room temperature.
a pH of vaginal discharge for each condition listed when using pH strips as a point of care test.
b KOH – potassium hydroxide.
c Sensitivity of wet mount between 40% and 80%.
d Culturette (BD Microbiology Systems, Sparks, Md) or similar product.
e Consider culture in recurrent cases and when wet mount/KOH is negative.
f Affirm VP III Assay (Becton Dickinson, Sparks, Md); does not rely on viable organisms for optimal test performance; special transport tube required; detects G.
vaginalis as an organism associated with BV, yeast vaginitis (C. albicans only) and Trichomonas vaginalis. FDA-cleared for vaginal specimens from symptomatic
female patients only. Trichomonas sensitivity not as good as NAAT.
g Amine or fishy odor, “whiff test” positive when KOH added, lack of white blood cells and presence of clue cells.
h Quantitative Gram stain most specific procedure for BV; culture not recommended; testing and treatment recommended in symptomatic pregnant patients to
reduce postpartum endometritis [8].
i Wet mount for trichomonads requires live organisms to visualize movement and has poor sensitivity.
j OSOM Trichomonas Rapid Test (Genzyme, Diagnostics, Cambridge, MA); does not require live organisms for optimal test performance, sensitivity ranges from
62% to 95% compared to culture and NAAT in symptomatic and asymptomatic patients, with best results in symptomatic patients.
k InPouch TV culture system (Biomed Diagnostics, White City, OR) allows both immediate smear review by wet mount and subsequent culture; not widely
available, sensitivity approximately 70% compared to NAAT methods.
l NAAT- nucleic acid amplification test; APTIMA Trichomonas vaginalis (ATV) test (Gen-Probe, Inc. San Diego, CA) is a recently FDA-cleared test for both screening
as well as diagnosis of TV in women. Multiple specimen types can be used. Same specimen and collection device as currently used for Aptima CT/GC NAAT.
Testing for males and alternate sites has been validated by some laboratories. Provider needs to check with laboratory for availability. Some laboratories have
validated an in-house PCR method. Check laboratory for availability and specimen types allowed.
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PID can be clinically difficult to identify when patients present
with mild or nonspecific symptoms. Finding symptoms on
physical exam (cervical motion tenderness) as well as other cri-
teria (elevated temperature or mucopurulent discharge) in-
creases the specificity and positive predictive value of
laboratory tests. Diagnostic tests are dependent on the clinical
severity of disease, epidemiological risk assessment, and
whether invasive procedures, such as laparoscopy and/or endo-
metrial biopsy, are used. Bacterial tests performed on nonasep-
tically collected specimens (endocervical or dilatation and
curettage [D and C] have limited utility in diagnosing PID. Ac-
tinomyces spp can cause infections associated with intrauterine
devices; if suspected, the laboratory should be notified to
culture such samples anaerobically, including an anaerobic
broth that is held for 7 days. Patients with suspected PID
should be tested for CT, GC, TV and HIV. Both difficulty in di-
agnosis as well as significant potential sequelae should make
the threshold for therapy low [184, 185].
Postpartum endometritis should be suspected when the
patient presents with high fever (≥101°F or >100.4°F (38.0°C)
on more than two occasions >6 hours apart after the first 24
hours of delivery and up to 10 days post delivery).) after the
first 24 hours post-delivery, abdominal pain, uterine tenderness
and foul lochia. Usually a multi-organism syndrome, the infec-
tion is most commonly seen in patients with unplanned cease-
rean section because of the inability to introduce antibiotics
quickly. Postpartum endometritis can be reduced by testing
and treating for symptomatic BV late in pregnancy, which has
been associated with preterm labor and prolonged delivery.
Screening for colonization with group B streptococci (both
vaginal and anal swabs) at 35–37 weeks gestation and prophy-
laxis during labor and delivery can reduce the incidence of neo-
natal disease [186]. Although the role of culture in the setting
of endometritis is controversial, diagnostic tests to consider in
the diagnosis of PID and postpartum endometritis are shown
in Table XI-4.
E. Special Populations
Children for whom sexual assault is a consideration should be
referred to a setting or clinic that specifically deals with this sit-
uation. Readers are referred to the references by Jenny, Kellogg,
Girardet, and Black where NAAT and noninvasive specimens
have yielded excellent results [187–189].
In MSM, the typical genital sites are not always infected, eg
the urethra or urine. Recommendations from the CDC now
include screening in this population at a number of sites for
GC and CT, including rectum, pharynx and urethra. Readers
are referred to the CDC Treatment Guidelines for further rec-
ommendations [167].
In pregnant patients, screening for HIV, syphilis, hepatitis B
surface antigen (HBsAg), CT, GC (if in high risk group or high
GC prevalence area) is routine. Symptomatic patients with vag-
inosis/vaginitis should be tested for BV and Trichomonas.
Screening for Group B streptococci should occur at 35–37
weeks with both rectal and vaginal swab specimens submitted
to optimize identification of carriers. Laboratories typically use
an enrichment broth and selective media to enhance recovery
for both Trichomonas and Group B streptococci. While NAATs
are available for Group B streptococci, the sensitivity is optimal
only when performed from an enrichment broth specimen.
Group A streptococci are not detected by Group B PCR tests.
Past history of STIs, those in higher risk groups, and/or clinical
presentation consistent with infection, should be assessed for
other pathogens as warranted, eg HSV if vesicular lesions are
present. Although rare, Listeria infection in the pregnant
woman (usually acquired via ingestion of unpasteurized cheese
or other food) can be passed to the fetus, leading to disease or
death of the neonate. Due to nonspecific symptoms, diagnosis
is difficult, but blood cultures from a bacteremic mother may
allow detection of this pathogen in time for antibiotic prophy-
laxis [190]. Screening tests (serology, stool cultures) in pregnant
women are not appropriate.
XII. SKIN AND SOFT TISSUE INFECTIONS
Cutaneous infections, often referred to as skin and soft tissue
infections (SSTIs), occur when the skin’s protective mecha-
nisms fail, especially following trauma, inflammation, macera-
tion from excessive moisture, poor blood perfusion, or other
factors that disrupt the stratum corneum. Thus, any compro-
mise of skin and skin structure provides a point of entry for a
myriad of exogenous and endogenous microbial flora that can
produce a variety of infections. Infections of the skin and soft
tissue are often classified as primary pyodermas, infections as-
sociated with underlying conditions of the skin, and necrotiz-
ing infections. Representative primary cutaneous infections of
the skin include cellulitis, ecthyma, impetigo, folliculitis, furun-
culosis, and erysipelas and are commonly caused by a narrow
spectrum of pyogenic bacteria (Staphylococcus aureus and/or
Streptococcus pyogenes [Group A streptococcus]). Secondary
infections are often extensions of pre-existing lesions (traumat-
ic or surgical wounds, ulcers) which serve as the primary portal
of entry for microbial pathogens and are often polymicrobial
(mixed aerobic and anaerobic microorganisms) involving sub-
cutaneous tissue. Diabetic foot infections (DFI) typically origi-
nate in a wound, secondary to a neuropathic ulceration.
Anaerobic bacteria are important and predominant pathogens
in DFI and should always be considered in choosing therapeu-
tic options. The majority of DFIs are polymicrobial but gram-
positive cocci, specifically staphylococci, are the most common
infectious agents. Pseudomonas aeruginosa is involved in the
majority of chronic DFIs but its relevance related to treatment
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decisions is not clear. Surface cultures of such wounds, includ-
ing decubitus ulcers, are not valuable, as they usually represent
colonizing microbes, which cannot be differentiated from the
underlying etiologic agent. Tissue biopsies after thorough de-
bridement, or bone biopsies through a debrided site, are most
valuable. Necrotizing cutaneous infections, such as necrotizing
fasciitis, are usually caused by streptococci (and less often by
MRSA or Klebsiella species), but can also be polymcrobial. The
infection usually occurs following a penetrating wound to the
extremities, is often life-threatening, and requires immediate
recognition and intervention. On rare occasions, necrotizing fas-
ciitis occurs in the absence of identifiable trauma.
For the common forms of SSTIs, cultures are not indicated
for uncomplicated infections (cellulitis, subcutaneous abscess-
es) treated in the outpatient setting. Whether cultures are bene-
ficial in managing cellulitis in the hospitalized patient is
uncertain and the sensitivity of blood cultures in this setting is
low. Cultures are indicated for the patient who requires opera-
tive incision and drainage because of risk for deep structure
and underlying tissue involvement [191].












transport device, RT, 2 dEndocervical, vaginal and/
or urethral swab (rectum,
pharynx, conjunctiva,
liquid-based cytology)b,c
Hybridization probed,e Endocervical or urethral
swabd
Laboratory-provided




pharynx, or rectal swab
Laboratory-provided
transport device,
Refrigerate (4°C); <2 h
Direct fluorescent antibody
(DFA) testg
Conjunctival swab Transport medium, RT, 2 h
Neisseria
gonorrhoeae
Gram stainh Urethral discharge Smear on slide directly or




transport device, RT, 2 dEndocervical, vaginal and/




Hybridization probed Endocervical or urethral
swab
Laboratory-provided











Saline wet mountj Endocervical or urethral
swab
Submit in 0.5 mL saline,
30 min–2 h
Rapid antigen testk Endocervical swab Laboratory-provided
transport device, RT,
24 h
DNA hybridization probel Endocervical or vaginal
swab
Laboratory-provided
transport device, RT, 7 d





NAATc Vaginal , endocervical





transport device, RT, 2 d
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In this section, cutaneous infections, involving skin and soft
tissue, have been expanded and categorized as follows: trauma-
associated, surgical site, burn wounds, fungal, human and
animal bites, and device-related. Although the majority of these
infections are commonly caused by S. aureus and S. pyogenes,
other microorganisms, including fungi and viruses, are impor-
tant and require appropriate medical and therapeutic manage-
ment. It is important that the clinician be familiar with the
extent or limitation of services provided by the supporting lab-
oratory. For example, not all laboratories provide quantitative
cultures for the assessment of wounds, especially burn wounds.
If a desired service or procedure is not available in the local mi-
crobiology laboratory, consult with the laboratory so that ar-
rangements can be made to transfer the specimen to a qualified
reference laboratory with the understanding that turnaround
times (TAT) are likely to be longer, thus extending the time to
receipt of results.
A major factor in acquiring clinically relevant culture and as-
sociated diagnostic testing results is the acquisition of appropri-
ate specimens that represent the group of diseases discussed in
this section. Guidelines for obtaining representative specimens
are summarized as follows:
Key points for the laboratory diagnosis of skin and soft tissue
infections:
• Do not use the label “wound” alone. Be specific about
body site and type of wound (for example “human bite wound,
knuckle”).
• The specimen of choice is a biopsied sample of the
advancing margin of the lesion. Pus alone or a cursory
surface swab is inadequate and does not represent the disease
process.












DFAg Scraping of lesion base Apply to slide at bedside,
RT, 24 h
Culture Scraping of lesion base Place in VTM/UTM, RT or
on ice, 2 h






Abbreviations: NAAT, nucleic acid amplification test; RT, room temperature; UTM, universal transport media; VTM, viral transport media.
a Current FDA-cleared NAATs for CT and GC include: Roche Amplicor CT and GC (Roche Molecular Diagnostics, Indianapolis, IN); APTIMA Combo2 (Gen-Probe,
San Diego, CA), BD ProbeTec (Becton Dickinson, Sparks, Md), and Xpert CTNG (Cepheid, Sunnyvale, CA).
b Pharynx and rectal specimens in MSM (requires laboratory validation for those specimen types).
c NAAT- nucleic acid amplification test; APTIMA Trichomonas vaginalis (ATV) test (Gen-Probe, Inc. San Diego, CA) is a recently FDA-cleared test for both screening
as well as diagnosis of TV in women. Multiple specimen types can be used. Same specimen and collection device as currently used for Aptima CT/GC NAAT.
Testing for males and alternate sites has been validated by some laboratories. Provider needs to check with laboratory for availability. Some laboratories have
validated an in-house PCR method. Check laboratory for availability and specimen types allowed.
d FDA-cleared hybridization tests for CT/GC include: Digene Hybrid Capture II test CT/GC test (Digene, Silver Spring, Md) and PACE 2C (CT/GC) (Gen-Probe, Inc,
San Diego, CA). Neither test cleared for urine specimens; Digene test not cleared for males. Sensitivity not equal to NAAT.
e Not as sensitive as NAATs.
f Not widely available; reference test for some specimens; sensitivity approximately 70% compared to NAAT.
g Epithelial cells are required for adequate exam.
h Gram stain in males only; 10–15 WBC/HPF and intracellular gram-negative diplococci (gndc)- 95% specific for GC; no intracellular gndc seen- only 10%–29%
specific for GC.
i Culture allows for antimicrobial susceptibility testing; culture sensitivity may be better when direct inoculation of specimen to selective media with CO2 tablet at
patient bedside; vancomycin in media may inhibit some GC strains.
j Wet mount for trichomonads requires live organisms to visualize movement; sensitivity 60%.
k OSOM Trichomonas Rapid Test (Genzyme, Diagnostics, Cambridge, MA); does not require live organisms for optimal test performance, sensitivity ranges from
62% to 95% compared to culture and NAAT in symptomatic and asymptomatic patients, with best results in symptomatic patients.
l Affirm VP III Assay (Becton Dickinson, Sparks, MD); does not rely on viable organisms for optimal test performance; special transport tube required; detects G.
vaginalis as an organism associated with BV, yeast vaginitis (C. albicans only) and Trichomonas vaginalis. FDA-cleared for vaginal specimens and symptomatic
female patients only. Trichomonas sensitivity not as good as NAAT.
m InPouch TV culture system (Biomed Diagnostics, White City, OR) allows both immediate smear review by wet mount and subsequent culture; not widely
available. Sensitivity approximately 70% compared to NAAT methods.
n Check with laboratory, some can be maintained and shipped at RT.
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A. Burn Wound Infections
Reliance on clinical signs and symptoms alone in the diagnosis
of burn wound infections is challenging and unreliable. Sam-
pling of the burn wound by either surface swab or tissue biopsy
for culture is recommended for monitoring the presence and
extent of infection (Table XII-1). Quantitative culture of either
specimen is recommended; optimal utilization of quantitative
surface swabs requires twice weekly sampling of the same site
to accurately monitor the trend of bacterial colonization. A
major limitation of surface swab quantitative culture is that mi-
crobial growth reflects the microbial flora on the surface of the
wound rather than the advancing margin of the subcutaneous
or deep, underlying damaged tissue. Quantitative bacterial
culture of tissue biopsy should be supplemented with histo-
pathological examination to better ascertain the extent of mi-
crobial invasion. Be advised that quantitative bacterial cultures
may not be offered in all laboratories; quantitative biopsy cul-
tures should be considered for patients in which grafting is nec-
essary. Prior to any sampling or biopsy, the wound should be
thoroughly cleansed and devoid of topical antimicrobials that
can affect culture results. Blood cultures should be collected for
detection of systemic disease secondary to the wound.
The application of nucleic acid amplification tests (NAAT)
for detection of listed viruses is commonly restricted to blood
and/or body fluids. It is advisable that the clinician determine if
the local supporting laboratory has validated such assays and if
the laboratory has assessed the performance with tissue
specimens. This precaution would also apply to the molecular
detection of MRSA (except for one FDA-cleared test for S.
aureus and MRSA from SSTIs) and VRE [192, 193].
B. Human Bite Wound Infections
The human oral cavity contains many potential aerobic and an-
aerobic pathogens and is the primary source of pathogens that
cause infections following human bites. The most common of
these are Staphylococcus spp, Streptococcus spp, Clostridium
spp, pigmenting anaerobic gram-negative rods, and Fusobacte-
rium spp. Such infections are common in the pediatric age
group and are often inflicted during play or by abusive adults.
Bite wounds can vary from superficial abrasions to more severe
manifestations including lymphangitis, local abscesses, septic
arthritis, tenosynovitis, and osteomyelitis. Rare complications
include endocarditis, meningitis, brain abscess, and sepsis with
accompanying disseminated intravascular coagulation, espe-
cially in immunocompromised patients.
In addition to the challenge of acquiring a representative
wound specimen for aerobic and anaerobic culture, a major
limitation of culture is the potential for misleading information
as a result of the polymicrobial nature of the wound. It is im-
portant that a Gram stain be performed on the specimen to
assess the presence of indicators of inflammation (eg neutro-
phils), superficial contamination (squamous epithelial cells),
and microorganisms. Swabs are not the specimen of choice in
many cases (Table XII-2). Major limitations of swabs versus









Mixed anaerobic organisms Blood cultures and
antimicrobial
susceptibilities to assess
unusual causes of PID or
endometritis
Blood, 2 separate 20 mL
venipuncture collections
Inject into blood culture






Mycoplasma Gram stain Endometrium, tubo-ovarian
abscess and/or fallopian
tube contents





Histology for evidence of
endometritis
Endometrial biopsyc Sterile containe, RT, 30 min
Formalin container, RT,
30 min–4 h
Neisseria gonorrhoeae (GC) NAAT Urine, endocervical swab Laboratory-provided




HIV EIA-antibody Serum Clot tube, RT, 2 h
Abbreviations: NAAT, nucleic acid amplification test; RT, room temperature.
a Gram stain may aid in identification of significant pathogen.
b Limited identification and antimicrobial susceptibility testing (AST) when cultures show multiple mixed aerobic and anaerobic organisms.
c Invasive specimens obtained by laparoscopic exam.
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tissue biopsy or aspirates include: 1) greater risk of contamina-
tion with surface/colonizing flora; 2) limited quantity of speci-
men that can be acquired; 3) drying unless placed in appropriate
transport media, which in itself dilutes out rare microbes and
further limits the yield of the culture [194–196].
C. Animal Bite Wound Infections
As with human bite wounds, the oral cavity of animals is the
primary source of potential pathogens and thus the anticipated
etiological agent(s) is highly dependant upon the type of
animal that inflicted the bite (Table XII-3). Since dogs and cats
account for the majority of animal-inflicted bite wounds, the
two most prominent groups of microorganisms initially con-
sidered in the evaluation of patients are Pasteurella spp, namely
P. canis (dogs) and P. multocida subspecies multocida and sub-
species septica (cats) or Capnocytophaga canimorsus. Other
common aerobes include streptococci, staphylococci, Moraxel-
la spp and saprophytic Neisseria spp. Animal bite wounds are
often polymicrobial in nature and include a variety of anaer-
obes. Due to the complexity of the microbial flora in animals,
examination of cultures for organisms other than those listed
in Table XII-3 is of little benefit since these organisms are not
included in most of the commercial identification systems
(conventional and automated) data bases [3, 197–206].
D. Trauma-Associated Cutaneous Infections
Infections from trauma are usually caused by exogenous or en-
vironmental microbial flora but can be due to the individual’s
endogenous (normal) flora (Table XII-4). It is strongly recom-
mended that specimens not be submitted for culture within the
first 48 hours post-trauma since growth from specimens col-
lected within this time frame most likely represents environ-
mental flora acquired at the time of the trauma episode (motor
vehicle accident, stabbings, gunshot wounds, etc). The optimal
time to acquire cultures is immediately post-debridement of
the trauma site [207–210]. It is recommended that initial cul-
tures focus on common pathogens with additional testing
being reserved for uncommon or rare infections associated
with special circumstances (ex: detection of Vibrio spp follow-
ing salt-water exposure) or patients with chronic manifestations










Staphylococcus aureus Aerobic, quantitative
culture/AST
Blood culture RT, <12 h, aerobic
Coagulase-negative
staphylococci
Surface swab RT, <2 h, transport medium
Enterococcus spp Tissue (punch biopsy) No formalin, keep moist
Pseudomonas aeruginosa
Escherichia coli Histopathology Tissue (punch biopsy) Submit in formalin RT, 2 h
Klebsiella pneumoniae
Serratia marcescens Anaerobic culture Tissue biopsy or aspirate (swab
may not represent the disease
process)
Anaerobic transport tubes, pre-
reduced media; RT, <2 hProteus spp
Aeromonas hydrophilaa
Bacteroides spp and other
anaerobes
NAAT for MRSA and S.
aureus only
Swab frommanufacturerb Laboratory-provided transport
device, RT, <2 h
Fungi
Candida spp Fungal culture Tissue biopsy RT, <30 min, no formalin, keep
moistAspergillus spp
Fusarium spp
Alternaria spp Fungal blood culture Blood; 2–4 cultures per 24 h
period
Lysis-centrifugation tube or broth-




Herpes simplex virus Tissue culture Tissue (biopsy/aspirate) Viral transport medium or
laboratory-provided transport
device
Cytomegalovirus NAAT, where applicable
and laboratory-validatedVaricella-zoster virus
Abbreviations: AST, antimicrobial susceptibility tests; MRSA, methicillin-resistant Staphylococcus aureus; NAAT, nucleic acid amplification test; RT, room
temperature.
a Electrical burns; potential for transmission from leaches.
b Xpert MRSA/SA SSTI (Cepheid, Sunnyvale, CA).
e88 • CID 2013:57 (15 August) • Baron et al
of infection or who do not respond to an initial course of
therapy.
Although not considered in quite the same manner as exter-
nal trauma, intravenous drug users (IVDU) inject themselves
with exogenous substances that may include spores from soil
and other contaminants that cause skin and soft tissue infec-
tions, ranging from abscesses to necrotizing fasciitis. Agents are
similar to those in Table XII-4, with the addition of Clostridium
sordellii, C. botulinum (causing wound botulism), and the
agents of human bite wounds (Table XII-2) among skin
poppers who use saliva as a drug diluent.
E. Surgical Site Infections
Surgical site infections (SSIs) may be caused by endogenous
flora or originate from exogenous sources such as healthcare
providers, the environment, or materials manipulated during
an “incisional” or “organ/space” surgical procedure. Incisional
infections are further divided into superficial (skin and subcu-
taneous tissue) and deep (tissue, muscle, fascia). Deep incision-
al and organ/space infections are the SSIs associated with the
highest morbidity. The reader is referred to the Centers for
Disease Control and Prevention Guidelines for Prevention of
Surgical Site infections, 1999, for specific definitions of SSIs
(http://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf ).
Of the microbial agents listed below (Table XII-5), Staphylococ-
cus aureus, including methicillin-resistant S. aureus (MRSA),
coagulase-negative staphylococci, and enterococci are isolated
from nearly 50% of these infections [211]. Although nterococ-
cal species are commonly isolated from superficial cultures,
they are seldom true pathogens; regimens that do not include
coverage for enterococci are successful for surgical site infections.
The recommended IDSA therapeutic regimens for surgical site
infections are not reliably active against these organisms [191].
To optimize clinically relevant laboratory results, resist the use
of swabs during surgical procedures, and instead submit tissue,
fluids, or aspirates.
F. Interventional Radiology and Drain Devices
Common interventional devices that are used for diagnostic or
therapeutic purposes include interventional radiology and
surgical drains. The former consists of minimally invasive pro-
cedures (angiography, balloon angioplasty/stent, chemoemboli-
zation, drain insertions, embolizations, thrombolysis, biopsy,
radiofrequency ablation, cryoablation, line insertion, inferior
vena cava filters, vertebroplasty, nephrostomy placement,





















Abbreviation: RT, room temperature.
a No utility in collecting a specimen at the time of the bite; collect samples only
if infection occurs.
Table XII-3. Laboratory Diagnosis of Animal Bite Wound Infections




Actinobacillus spp Aerobic/anaerobic culture Tissue/biopsy/aspirate Anaerobic transport containerb
Capnocytophaga spp
Erysipelothrix rhusiopathiae Gram stain Be certain to provide sufficient
volume of sample for complete
culture and Gram stain
evaluation; RT, <2 h
Pasteurella spp
Streptobacillus spp
Blood culture Blood; 2–4 cultures per
24 h
Blood culture bottles, RT, <2 h
Mycobacterium fortuitum Aerobic culture Tissue/biopsy/aspirate Sterile container, RT, <2 h
M. kansasii Acid-fast culture
Acid-fast stain
Histopathology Tissue/biopsy/aspirate Transport in formalin, RT, 2 h–24 h
Abbreviation: RT, room temperature.
a Additional potential pathogens to consider: Staphylococcus intermedius, Bergeyella zoohelcum, Propionibacterium spp, Filifactor spp, Moraxella spp, Neisseria
spp, Kingella spp, Pseudomonas fluorescens, Halomonas venusta, CDC Group EF-4, CDC NO-1, Peptococcus spp, Rabies or other viruses (refer to Viral Section
XIV).
b Anaerobic transport media preserve all other organisms for culture.
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radiologically inserted gastrostomy, dialysis access and related
intervention, transjugular intrahepatic porto-systemic shunt,
biliary intervention, and endovenous laser ablation of varicose
veins) performed using image guidance. Procedures are re-
garded as either diagnostic, (eg angiogram) or performed for
treatment purposes, (eg angioplasty). Images are used to direct
procedures that are performed with needles or other tiny in-
struments (eg catheters). Infections as a result of such proce-
dures are rare but should be considered when evaluating a
patient who has undergone interventional radiology which
constitutes a risk factor for infection due to the invasive nature
of the procedure.
A variety of drainage devices are used to remove blood,
serum, lymph, urine, pus and other fluids that accumulate in
the wound bed following a procedure, (eg, fluids from deep
wounds, intracorporeal cavities, or intraabdominal postopera-
tive abscess). They are commonly used following abdominal,
cardiothoracic, neurosurgery, orthopedic and breast surgery.
Chest and abdominal drains are also used in trauma patients.
The removal of fluid accumulations helps to prevent seromas
and their subsequent infection. The routine use of postopera-
tive surgical drains is diminishing, although their use in certain
situations is quite necessary.
The type of drain to be used is selected according to quality
and quantity of drainage fluid, the amount of suction required,
the anatomical location, and the anticipated amount of time
the drain will be needed. Tubing may also be tailored according
to the aforementioned specifications. Some types of tubing
include: round or flat silicone, rubber, Blake/Channel, and
Triple-Lumen sump. The mechanism for drainage may depend
on gravity or bulb suction, or it may require hospital wall
suction or a portable suction device. Drains may be left in place
from one day to weeks, but should be removed if an infection is
suspected. The infectious organisms that may colonize a drain
or its tubing typically depend on the anatomical location and
position of the drain (superficial, intraperitoneal, or within an
organ, duct or fistula) and the indication for its use. Intrepreta-
tion of culture results from drains that have been in place for
more than 3 days may be difficult due to the presence of colo-
nizing bacteria and yeast.
Drains are characterized as Gravity, Low-Pressure Bulb Evac-
uators, Spring Reservoir, Low Pressure or High Pressure. Fluids
from drains are optimal specimens for collection and submis-
sion to the microbiology laboratory. All fluids should be col-
lected aseptically and transported to the laboratory in an
appropriate device such as blood culture bottle (aerobic),
sterile, leak proof container (ie, urine cup), or a citrate-contain-
ing blood collection tube to prevent clotting in the event that
blood is present. Expected pathogens from gravity drains origi-
nate from the skin or GI tract; for the remaining drain types,
skin flora represent the predominate pathogens.
G. Cutaneous Fungal Infections
The presence of fungi (moulds or yeasts) on the skin poses a
challenge to the clinician in determining if this represents con-
tamination, saprophytic colonization, or is a true clinical infec-
tion. For convenience, the fungi have been listed by the type of
mycosis they produce (Table XII-6), eg dermatophytes typically
produce tinea (ringworm)-type infections; dematiaceous
(darkly pigmented moulds and yeast-like fungi) cause both cu-
taneous and subcutaneous forms of mycosis; dimorphic fungi
generally cause systemic mycosis and the presence of cutaneous
lesions signifies either disseminated or primary (direct inocula-
tion) infection; yeast-like fungi are usually agents of opportu-
nistic-types of mycoses but can also manifest as primary or
disseminated disease as is true for the opportunistic moulds (eg
Aspergillus spp, Fusarium spp). In addition to the recommend-
ed optimal specimens and associated cultures, fungal serology
testing (complement fixation and immunodiffusion performed
in parallel, not independent of the other) is often beneficial in
diagnosing agents of systemic mycosis, specifically those caused
by Histoplasma and Coccidioides. In cases of active histoplas-
mosis and blastomycosis, the urine antigen test may be of value
in identifying disseminated disease.
The clinician should be aware that dematiaceous fungi
(named so because they appear darkly pigmented on laboratory
media), do not always appear pigmented in tissue but rather
hyaline in nature. To help differentiate the dematiaceous
species, a Fontana Mason stain (histopathology) should be per-
formed to detect small quantities of melanin produced by these
fungi. It is not uncommon for this group of fungi to be mistak-
enly misidentified by histology as a hyaline mould such as As-
pergillus spp. This highlights the importance of correlating
culture results with histological observations in determining
the clinical relevance since the observation of fungal elements
in histopathology specimens is most likely indicative of active
fungal invasion [212, 213].
XIII. TICKBORNE INFECTIONS
The clinical microbiology tests of value in establishing an etiol-
ogy of various tickborne diseases are presented below
(Table XIII-1). Borrelia species are responsible for relapsing
fever and Lyme borreliosis; both diseases are transmitted by
ticks to humans. Lyme borreliosis is a multisystem disease that
can affect the skin, nervous system, the joints, and heart; this
infection is the most frequently reported tickborne disease in
the northern hemisphere [151]. For the most part, early Lyme
disease is diagnosed on clinical grounds including the presence
of erythema migrans while early/disseminated and late/persis-
tent Lyme disease are diagnosed by two-tiered serological
testing (EIA followed by Western blot). Western blot should
not be performed except as a reflex test after an initial EIA has
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returned positive or equivocal. The IgMWestern blot is not clini-
cally interpretable after a patient has had 6–8 weeks of symp-
toms. Western blot IgG and IgM are based on testing 10 IgG
bands and 3 IgM bands. Criteria for positivity are at least 5 IgG
bands or at least 2 IgM bands (plus a positive or equivocal EIA)
[214]. A ‘post-treatment’ Lyme disease syndrome may occur
after appropriate antibiotic therapy for laboratory documented
B. burgdorferi infection. Persistent symptoms lasting more than
six months such as fatigue, musculoskeletal pains, and neurocog-
nitive dysfunction do not permanently respond to long-term an-
tibiotic therapy based on randomized-controlled trial data.”
Rickettsial diseases that are transmitted by ticks include
Rocky Mountain spotted fever, human granulocytotropic ana-
plasmosis, human monocytotropic ehrlichiosis, and others
including those caused by Ehrlichia ewingii [215, 216]. Al-
though clinically similar, these diseases are epidemiologically
and etiologically distinct illnesses. The diagnosis of patients
with these infections is challenging early in the course of their
clinical infection since signs and symptoms are often nonspe-
cific or mimic benign viral illnesses. In addition to Lyme borre-
liosis and rickettsial diseases, babesiosis and Colorado tick fever
virus are also transmitted by ticks.
Since the organisms transmitted by ticks are infrequently en-
countered in clinical specimens, most clinical microbiology lab-
oratories do not provide all of the services listed in the table
below. Of significance, tick borne relapsing fever, ehrlichiosis,
anaplasmosis, and babesiosis can all be rapidly diagnosed by
examining peripheral blood smears. However, a negative smear
Table XII-4. Laboratory Diagnosis of Trauma-Associated Cutaneous Infections













Blood culture Blood Aerobic/anaerobic blood







Histopathology Surgical tissue Formalin container, RT,
2 h–24 hBiopsy/aspirate
Mycobacterium spp Mycobacterial culture Tissue/biopsy/aspirate Sterile containerRT, <2 h
Nocardia spp Acid-fast smear
Histopathology Tissue/biopsy/aspirate Formalin container, RT,
2 h–24 h
Fungal
Aspergillus spp Fungal culture Surgical tissue Aerobic transport device




Penicilliummarneffei Histopathology Surgical tissue Formalin container, RT,






Abbreviations: KOH, potassium hydroxide; NAAT, nucleic acid amplification test; RT, room temperature.
a There is an FDA-cleared NAAT for direct detection of S. aureus and MRSA from swabs of wounds and pus.
b Potential Bioterrorism agent: if suspicious, notify laboratory in the interest of safety.
cClostridium tetani can also be an etiological agent of trauma-associated infections in rare cases.
Guide to Utilization of the Microbiology Lab • CID 2013:57 (15 August) • e91
result does not necessarily rule out a tick borne disease due to
the often low and variable sensitivity of peripheral blood smear
examination for these organisms. Therefore, clinical specimens
for culture, molecular analysis and the majority of serologic
assays are, for the most part, sent to reference laboratories. In
addition, because most NAATs for the diseases listed are not
FDA-cleared, such tests are not universally available. With these
limitations in the availability of and performance of various
testing formats (ie culture, molecular analysis, and the majority
of serologic assays), the provider needs to check with the labora-
tory for availability of testing, the optimum testing approach, ap-
propriate specimen source, and turn-around time.
Key points for the laboratory diagnosis of tickborne infections:
• Tick-borne diseases are difficult to diagnose because
symptoms are nonspecific, including fever, chills, aches, pains,
and rashes.
• Patient travel history, recent locations, and potential for
tick bite are important.
• Consultation with the microbiology laboratory is
normally required to determine the specimens accepted, the lo-
cation of the testing laboratory, and the turnaround time for
results.
Table XII-5. Laboratory Diagnosis of Surgical Site Infections




S. aureus Gram stain Tissue/biopsy/aspirate Keep tissue moist; aerobic
transport, RT, <2 hCoagulase-negative
staphylococci
Aerobic culture and AST
β-hemolytic streptococci
(Group A, B, C and G)
NAATa
Nonhemolytic streptococci Anaerobic culture (if
appropriate)
Tissue/biopsy/aspirate Anaerobic transport device
Enterococci RT, <2 h
Acinetobacter spp
















Tissue/biopsy/aspirate Special transport medium;








Candida spp Fungal culture Tissue/biopsy/aspirate Aerobic transport device
Calcofluor-KOH preparation Sterile container
RT, <2 h
Fungal blood culture Blood Lysis-centrifugation blood
culture tube or aerobic
blood culture bottles, RT,
<2 h
Histopathology Tissue/biopsy/aspirate Formalin container, RT, 2
h–24 h
Abbreviations: AST, antimicrobial susceptibility tests; KOH, potassium hydroxide; MRSA, methicillin-resistant Staphylococcus aureus; NAAT, nucleic acid
amplification test; RT, room temperature.
a There is an FDA-cleared NAAT for direct detection of S. aureus and MRSA from swabs of wounds and pus.
bM. hominis has caused infections post-joint surgery and post-abdominal surgery, particularly after caesarian sections. A series of sternal wound infections due to
Legionella spp were traced to contamination of the hospital water supply. A post-hip surgery Legionella infection occurred after skin cleansing with tap water.
Proper water treatment should remove the risk for such infections.
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XIV. VIRAL SYNDROMES
This section will cover viral infections most commonly encoun-
tered in the U.S., realizing that there are a myriad of viruses
that can cause illness in humans. Clinical microbiology labora-
tory tests of value in establishing a diagnosis of viral infections
are outlined below. Tests for human immunodeficiency virus
(HIV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), var-
icella-zoster virus (VZV), herpes simplex virus (HSV), human
herpes virus-6 (HHV-6), parvovirus (erythrovirus) B19,
measles, mumps, rubella, BK virus, JC virus, dengue, hepatitis
A virus, hepatitis B virus (and hepatitis D virus), hepatitis C
virus (HCV), enteroviruses, respiratory syncytial virus (RSV),
influenza virus, West Nile virus (and other encephalitides),
Table XII-6. Laboratory Diagnosis of Fungal Infections of Skin and Subcutaneous Tissue




Epidermophyton spp Fungal culture Skin scrapings/hair follicles/
nail scrapings
Sterile transport container Aerobic
conditions, RT, <4 hTrichophyton spp Calcofluor-KOH preparation
Microsporum spp Histopathology Tissue/biopsy Formalin container, RT, 2 h–24 h
Dematiaceous (darkly pigmented) Filamentous Fungi
Scedosporium/ Fungal culture Tissue/biopsy/aspirate Sterile transport container
Pseudallescheria spp Calcofluor-KOH preparation Aerobic conditions, RT, <2 h
Exophiala spp





Histoplasma capsulatum Fungal culture Tissue/biopsy/aspirate Sterile transport container
Blastomyces dermatitidis Urine Antigen (Histoplasma;
Blastomyces)
Urine Aerobic conditions




Sporothrix schenckii Fungal serology Serum Clot tube, RT, <2 h
Blood culture Blood; 2 sets Aerobic blood culture bottles, RT,
<2 h
Histopathology Tissue/biopsy/aspirate Formalin container, RT, 2 h–24 h
Yeast-like Fungi
Candida spp Fungal culture Tissue/biopsy/aspirate Sterile transport container
Cryptococcus neoformans Calcofluor-KOH preparation stain Blood; 2 sets Aerobic conditions
Trichosporon spp RT, <2 h
Geotrichum spp Aerobic blood culture bottles, RT,
<2 h
Malassezia spp Blood culture Blood; 2 sets Aerobic blood culture bottle or
lysis/centrifugation blood
culture, RT, <2 h
Histopathology Tissue/biopsy/aspirate Formalin container, RT, 2 h–24 h
Other Fungi
Aspergillus spp Fungal culture Tissue/biopsy/aspirate Sterile transport container
Fusarium spp Calcofluor-KOH preparation Aerobic conditions
Zygomycetes Blood; 2 sets(Fusarium
only)
RT, <2 h
Aerobic blood culture bottles or
lysis/centrifugation blood
cultures, RT, <2 h
Histopathology Tissue/biopsy/aspirate Formalin container, RT, 2 h–24 h
Abbreviations:KOH, potassium hydroxide; RT, room temperature.
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adenovirus, rabies virus and lymphocytic choriomeningitis virus
are specifically highlighted. Not all clinical microbiology labora-
tories provide all of the services outlined in the tables, especially
in the case of serologic and molecular tests. When the recom-
mended testing is not available in a local laboratory, it can
usually be referred to a reference laboratory with an ensuing pos-
sible increase in the time necessary to obtain results.
Specific IgM assays for a variety of viral agents may be associ-
ated with false positive results, especially with high titers of IgG
antibodies. Therefore, if the pretest probability of acute infec-
tion is low to moderate, it is good practice to measure IgG (or
total –IgG plus IgM) antibodies at disease presentation (“acute
phase”) and two to three weeks later (“convalescent phase”) to
assess for a four-fold or greater rise in antibody titer.
Many molecular diagnostic tests for viral pathogens are labo-
ratory developed tests, offered by Clinical Laboratory Improve-
ment Amendments (CLIA)-certified reference laboratories.
Although such tests require establishment of performance
characteristics prior to clinical use and appropriate quality
systems, performance may vary between laboratories. Through-
out this section, the term NAAT generally refers to polymerase
chain reaction (PCR) or reverse transcriptase PCR. Other
specific techniques may be substituted with appropriate
validation.
Table XIII-1. Laboratory Diagnosis of Tickborne Infections






Primary testb: Darkfield microscopy or
Wright’s, Giemsa or Diff-Quik stains of
peripheral thin or/and thick blood
smears. Can be seen in direct wet
preparation of blood in some cases.











NAAT Serum, blood, body fluids Clot tube for serum; sterile tube or
citrate tube for body fluids, RT,
within 2–4 h
Culturec





Early Lyme disease – presence of
erythema migrans:
Serum Clot tube, RT, ≤2 h





months after tick bite) or late/
persistent (months through years after
tick bite in untreated patients, almost
exclusively seen with B. afzeliig):
Borrelia afzelii (Europe,
Asia)
Primary test: Two-tier testing (acute- and
convalescent-phase sera
optimal) = EIA IgG and IgM antibody
screening. If EIA result is positive or
equivocal, confirm with IgG and IgM
Western blot (WB).h
NOTE: AWestern blot should NOT be
performed unless an initial EIA is
reported as positive or equivocal.
Serum and CSF Clot tube for serum, sterile tube
for CSF, RT, ≤1 h
Neuroborreliosisp
Paired serum/CSF antibody levels, ie,
CSF/serum antibody index.
NAATi Blood, biopsy specimens of
infected skin, synovial fluid or
tissue, CSF, etc.
Transport on ice; ≤1 h
If DNA not extracted shortly after
collection, store frozen at
−70°C.
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Table XIII-1 continued.








Primary Test: Wright or Giemsa stain of
peripheral blood or buffy coat
leukocytes during week first week of
infection.
Blood EDTA or citrate tube, RT, ≤1 h
Acute and convalescent IFA titers for
Anaplasma antibodies; specificity
ranges from 83% to 100%with cross-
reactivity among E. chaffeensis and A.
phagocytophilium antibodies, as well
as a number of clinical conditions such
as Rocky Mountain Spotted Fever,
typhus, Q fever, Lyme disease, etck
Serum Clot tube, RT, ≤2 h
NAAT Blood EDTA anticoagulant tube
Transport on ice; ≤1 h
Immunohistochemical staining of
Anaplasma antigens in formalin-
fixed, paraffin-embedded
specimens
Bone marrow biopsies or autopsy
tissues (spleen, lymph nodes,
liver and lung)




Primary Test: Wright or Giemsa stain of
peripheral blood or buffy coat
leukocytes smear during first week of
infection.
Blood EDTA anticoagulant tube, RT, ≤1 h
Ehrlichia ewingii j,k Serology: acute and convalescent IFA
titers for Ehrlichia antibodiesl
Serum Clot tube, RT, ≤2 h
NAAT (only definitive diagnostic test for
E. ewingii)
Whole blood Heparin or EDTA anticoagulant
tube Transport on ice; ≤1 h
If DNA not extracted shortly after
collection, store frozen.
Immunohistochemical staining of
Ehrlichia antigens in formalin-fixed,
paraffin-embedded specimens
Bone marrow biopsies or autopsy
tissues (spleen, lymph nodes,
liver and lung)




Serology: acute and convalescent IFA for
R. rickettsii IgM and IgG antibodiesl
Serum Clot tube, RT, ≤2 h
NAAT Skin biopsy (preferably a
maculopapule containing
petechiae or the margin of an
eschar) or autopsy tissues (liver,
spleen, lung, heart, and brain)
Sterile container
Transport on ice; ≤1 h
If DNA not extracted shortly after
collection, store frozen.
Immunohistochemical staining of
spotted fever group rickettsiae
antigens (up to first 24 h after
antibiotic therapy initiated) in
formalin-fixed, paraffin-embedded
specimens
Skin biopsy (preferably a
maculopapule containing
petechiae or the margin of an
eschar) or autopsy tissues (liver,
spleen, lung, heart and brain)
Formalin container, RT, ≤2 h
Protozoa
Babesia microti Primary Test: Giemsa, Wright’s, Wright-
Giemsa stains of peripheral thin and
thick blood smears (Giemsa preferred)
Whole blood For whole blood, prepare smears
immediately
Second choice EDTA vacutainer
tube
RT, ≤30 min
NAAT Blood EDTA anticoagulant tube, RT, ≤1 h
Serology: acute and convalescent IFA
titers for Babesia antibodies (IgM and
IgG)
Serum Clot tube, RT, ≤2 h
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Table XIII-1 continued.




Colorado Tick Fever Virus Virus-specific IFA-stained blood smears Blood EDTA anticoagulant tube, RT, ≤2 h
Serology: IFA titers or complement
fixationo
Serum Clot tube, RT, ≤2 h
Abbreviations: IFA, indirect fluorescent antibody; IgG, immunoglobulin G; IgM, immunoglobulin M; NAAT, nucleic acid amplification test; RT, room temperature.
a Other tick-borne diseases should be considered if patients have traveled to international destinations. Since travel between North America and Europe is
common, Lyme borreliosis caused by Borrelia garinii and Borrelia afzelii have been included in the table. Tick-borne rickettsial diseases such as African tick-bite
fever (ATBF) or Mediterranean spotted fever (MSF), occur world-wide and might have epidemiologic, seasonal and clinical features that differ from those observed
in the U.S. [215]. Of note, tick-borne disease caused by Rickettsia parkeri is emerging; this organism has a similar clinical presentation as ATBF and MSF with fever,
headache, eschars, and regional lymphadenopathy [217].
b Organisms are best detected in blood while a patient is febrile. With subsequent febrile epidsodes, the number of circulating spirochetes decreases. Even during
initial episodes, organisms are seen only 70% of the time.
c Special media and technical expertise is required for culture of Borrelia species that cause relapsing fever. A centrifugation-based enrichment method followed by
Giemsa staining is a rapid and viable approach [218].
d Not valuable for an immediate diagnosis, however, serologic testing is available through public health and some private laboratories. An acute serum (obtained
within 7 days of the onset of symptoms) and convalescent serum (obtained at least 21 days after the onset of symptoms) should be submitted for testing. Of
significance, early antibiotic treatment can blunt the antibody response and antibody levels may fall quickly during the months after exposure.
e To date, 18 genomic species are reported in the literature, three are confirmed agents of localized, disseminated and late manifestations of Lyme disease and are
listed in the table. Another 9 species have been described with possible pathogenic potential [219]. A “chronic” or “post” Lyme disease syndrome after initial
short-course antibiotic treatment has not been supported in a rigorous scientific study. Treatment of “chronic Lyme disease” is a controversial issue that has been
addressed by IDSA in a guideline available on its website (http://cid.oxfordjournals.org/content/43/9/1089.full#sec-36).
f Erythema migrans (EM) is the only manifestation of Lyme disease in the United States that is sufficiently distinctive to allow clinical diagnosis in the absence of
laboratory confirmation. Positive culture rates for secondary EM lesions, primary EM lesions, and large volume (≥9 mL) blood or plasma specimens are 90%, 60%,
and 48%, respectively [220]. If skin is biopsied, more than 1 biopsy sample should be taken for culture due to uneven distribution of spirochetes; disinfect the skin
prior to collection and submit tissues in sterile saline. Culture is rarely performed outside of research settings.
g Ixodes ticks have a broad host range, thereby increasing the chance of acquiring multiple pathogens from reservoir hosts. Thus, patients with one documented
tick-transmitted disease are at increased risk for infection with another tick-transmitted organism. Patients with a diagnosis of Lyme disease have demonstrated
immunoserologic evidence of coinfection with Babesia microti, Anaplasma phagocytophilum or Erlichia species; in Europe; coinfection with tick-borne encephalitis
virus should also be considered [221].
h Perform an IgM and an IgG WB during the first 4 weeks of illness on a patient with a positive EIA. An IgM WB is not interpretable after a patient has had
symptoms for greater than 1 month’s duration because the likelihood of a false-positive test result for a current infection is high in these persons; therefore, in
patients with symptoms longer than 4 weeks, only test an IgG WB (http://www.cdc.gov/lyme/healthcare/clinician_twotier.html). In addition, a positive IgM WB is
considered positive only if 2 of the following 3 bands are present: 24 kDa, 39 kDa and 41 kDa. Similarly, a positive IgG WB is considered positive only if 5 of the
following 10 bands are present: 18 kDa, 21 kDa, 28 kDa, 30 kDa, 39 kDa, 41 kDa, 45 kDa, 58 kDa, 66 kDa, and 93 kDa. Laboratories performing this testing are
strongly encouraged to report only the presence/absence of these specified bands since misinterpretation of Lyme disease WBs can otherwise possibly occur.
i Other Lyme-associated diseases can be diagnosed by NAAT (TAT 24–48 hours) or culture (TAT 3 days to 6–12 weeks). Acceptable specimens for multiple
erythemata or borrelial lymphocytoma, Lyme carditis, Lyme arthritis, and acrodermatitis are skin biopsy, endomyocardial biopsy, synovial fluid or biopsy, and skin
biopsy, respectively [221, 223]. Although Borrelia can be detected by NAAT in blood, biopsy specimens of infected skin, synovial tissue or fluid, or CSF, its
usefulness for the diagnosis of Lyme disease is limited at this time. For example, Borrelia DNA is detected in the blood of fewer than half of patients in the early
acute stage of disease when the erythema migrans rash is present, and if symptoms of Lyme disease have been present for a month or more, spirochetes can no
longer be found in blood. Similarly, NAAT testing of CSF specimens is positive in only about one-third of US patients with early neuroborreliosis, and is even less
sensitive in patients with late neurologic disease. The utility of testing synovial fluid and other specimen types is not well established and should be considered only
under special circumstances and skin biopsy is not generally recommended because patients with erythema migrans can be reasonably diagnosed and treated on
the basis of history and clinical signs alone.
j Communication with the laboratory is of paramount importance when ehrlichiosis is suspected to ensure that Wright-stained peripheral blood smears will be
carefully examined for intracytoplasmic inclusions (morulae) in either monocytes or neutrophils or bands.
k A newly discovered Ehrlichia species was reported to cause ehrlichiosis in Minnesota and Wisconsin; this Ehrlichia is closely related to Ehrlichia muris [224].
l Sensitivity of IFA antibody titers for tick-borne rickettsial diseases (RMSF, ehrlichiosis and anaplasmosis) is dependent on the timing of specimen collection; the
IFA is estimated to be 94% to 100% sensitive after 14 days of onset of symptoms and sensitivity is increased if paired samples are tested.
m Treatment decisions for tick-borne rickettsial diseases for acutely ill patients should not be delayed while waiting for laboratory confirmation of a diagnosis.
Fundamental understanding of signs, symptoms, and epidemiology of the disease is crucial in guiding requests for tests and interpretation of test results for
ehrlichiosis, anaplasmosis and Rocky Mountain spotted fever (RMSF). Misuse of specialized tests for patients with low probability of disease and in areas with a
low prevalence of disease might result in confusion.
n Antibiotic therapy may diminish the development of convalescent antibodies in RMSF.
o IgM antibodies develop 2 weeks after symptom onset.
p Laboratory assays for the diagnosis of neuroborreliosis are of limited clinical value [151, 222 ].
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Key points for the laboratory diagnosis of viral syndromes:
• Viral syndromes should be considered based on the pa-
tient’s age, immune status, history, and many other variables.
• Samples can be obtained and tested for the most likely
agents, with additional samples held frozen in the laboratory
for additional testing if necessary; it is not cost-effective to test
initial samples broadly for numerous viruses.
• Sample collection and handling are essential components
of obtaining a reliable viral test result; consult the microbiology
laboratory to determine which specimens should be obtained
and how to transport them to the laboratory.
• Many laboratories will not have virology capabilities and
tests will be sent out, resulting in longer turnaround times for
results.
• Cross-reactivity among some agents will result in non-
specific serologic results.
• Tests for immunity, previous virus infection (eg, tissue
donors), and new infection may have different formats, even
when the same virus is being considered.
A. Human Immunodeficiency Virus (HIV)
HIV-1 is an RNA virus with a genome consisting of three
major genes encoding capsid proteins (gag – p55, p24, p17);
reverse transcriptase, protease, and integrase (pol – p66, p51,
p31); and envelope glycoproteins (env – pg160, gp120, gp41).
HIV viruses are classified based on relatedness of genomic se-
quence into types 1 and 2, groups, and clades. HIV-1 and HIV-
2 proteins differ in molecular weight. HIV-1 is categorized into
groups M, O, non-M, non-O (N) and P, with M being most
common [225, 226]. HIV-1 is more common than HIV-2 in
the U.S.; the latter should be considered in persons who were
born in, have traveled to, have received blood products from, or
have had a sexual partner from West Africa, as well as those
who have been similarly exposed to HIV-2-infected persons in
any geographic area.
Antibodies are detectable in acute HIV infection, usually
within the first four weeks following exposure, preceded in pos-
itivity by p24 antigen, which is in turn preceded (by three to
five days) by HIV RNA positivity. Performing an HIV RNA
test after a negative initial antibody and/or antigen test in
persons suspected of acute infection may therefore be helpful.
Because of the time course of test positivity and the possibility
of seronegativity, the laboratory diagnosis of primary (acute)
HIV-1 infection is usually based on a high quantitative HIV-1
RNA (viral load) result (typically >105 copies/mL), or qualita-
tive detection of HIV-1 RNA and/or proviral DNA;
(Table XIV-1) [227]. Outside of the setting of acute HIV infec-
tion however, HIV viral load assays should be used with
caution for diagnosis of HIV infection because of the possibility
of false positive results. False positive results are generally of
low copy number (<5000 copies/mL); therefore, low copy
number results should prompt retesting of a second specimen.
Notably, because there is a 10- to 14-day period after infection
when no markers are detectable, testing another specimen two
to four weeks later should be considered if initial antibody,
antigen or RNA tests are negative. NAAT is not 100% sensitive
in individuals with established HIV infection due to viral sup-
pression, either naturally or therapeutically, or improper speci-
men collection/handling. If NAAT is used to make a diagnosis
of acute HIV-1 infection, it may be helpful to document subse-
quent HIV-1 seroconversion by conventional serologic testing.
In the neonate, serologic testing is unreliable due to persis-
tence of maternal antibodies; quantitative HIV-1 RNA (viral
load) testing is as sensitive as qualitative HIV-1 RNA and/or
proviral DNA testing for the diagnosis of HIV-1 infection
[228]. Serologic diagnosis has evolved since the 1980s. First and
second generation assays were indirect EIAs that used viral
lysate and recombinant/synthetic peptide antigens, respectively.
Third generation assays allowed detection of HIV IgM (in addi-
tion to IgG), enabling earlier diagnosis of infection. The most
recent—fourth generation—assays incorporate HIV p24 antigen
detection, allowing even earlier diagnosis of infection. Third
and fourth generation assays are generally positive seven to 14
and four to seven days, respectively, after detectable virus by
NAAT.
HIV p24 antigen may be detected in serum or plasma
between 14 and 22 days after infection (before antibody
becomes detectable); it typically decreases below detection
limits thereafter, limiting utility of p24 antigen testing alone.
Combined HIV antibody plus p24 assays (ie, fourth generation
assays) are in widespread use as initial screening assays and the
Association of Public Health Laboratories and the Centers for
Disease Control and Prevention now recommend them as
initial screening tests for diagnosis of HIV infection [225, 226].
The testing algorithm associated with their use does not require
Western Blot. Instead, individuals with reactive results are
further tested with an antibody immunoassay that distinguishes
HIV-1 from HIV-2 antibodies. If the differentiation assay is
negative, further testing with a qualitative or quantitative
NAAT is recommended to rule out acute HIV-1 infection. If
the differentiation assay is positive, viral load testing (and
usually also CD4 determination) is recommended to direct
management. An alternate approach is an initial HIV antigen/
antibody combination assay that discriminates detection of
antigen from antibody; p24 reactivity is subsequently con-
firmed by NAAT and antibody reactivity by an HIV-1/HIV-2
differentiation assay. The traditional laboratory diagnosis of
nonacute HIV-1 infection (Table XIV-1) begins with screening
for HIV-1/-2 antibodies. When testing by the screening assay
shows reactive results, confirmatory testing by Western blot is
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performed. (As an alternative, NAAT testing or a second anti-
body immunoassay—using different antigenic constituents or
based on different principles—may be considered.) An initial
positive HIV antibody immunoassay using an oral fluid speci-
men is followed by an immunoassay performed on blood,
serum or plasma, a positive result of which is followed by NAAT
or supplemental antibody testing to corroborate infection. A
negative blood, serum or plasma result requires follow-up testing
as previously described [225, 226]. Using the traditional algo-
rithm, if the Western blot result is positive, the patient is consid-
ered to be infected with HIV-1. If negative, testing for HIV-2
antibodies is recommended to rule out the possibility of HIV-2
infection causing the reactive combined HIV-1/-2 antibody
result. If the Western blot test is unreadable (ie, due to high back-
ground reactivity of the strip), testing with an HIV-1 antibody-
specific indirect immunofluorescence assay or qualitative or
quantitative testing for HIV-1 RNA or for proviral DNA should
be considered. According to Association of Public Health Labo-
ratories and the Centers for Disease Control and Prevention, an
HIV-1 antibody Western blot result is interpreted as positive
when at least 2 of the 3 following bands are present: p24, gp41,
and gp120/gp160. If only one of these bands is present, the result
is indeterminate, and additional supplemental testing with an
HIV-1 antibody-specific indirect immunofluorescence assay, an
EIA for HIV-2 antibodies alone, and a qualitative HIV-1 RNA
and/or proviral DNA assay should be considered. Causes of in-
determinate Western blots include evolving antibody profiles,
specimen contamination, antibody decline with immune system
failure (late stage infection), nonspecific reactivity due to viral or
cellular protein components, other infections (eg, syphilis, other
retroviruses, some parasites), immune-modulating conditions
(eg, pregnancy), and infection with groups N, O, or P HIV-1,
or HIV-2. High-risk patients with reactive serologic screening
test results and indeterminate Western blots but negative sup-
plemental tests should be considered for retesting two to four
weeks later. If this does not resolve the issue, additional supple-
mental testing (eg, NAAT) may be considered. Western blot
assay is less sensitive than third or fourth generation EIAs
during seroconversion with up to three weeks following a posi-
tive fourth generation assay before a positive Western blot
assay. Since as many as a third of healthy HIV-uninfected
blood donors have indeterminate HIV-1 Western blot assays,
they should not be ordered as the first test for HIV. Line immu-
noassays incorporating HIV-1 and HIV-2-specific recombinant
proteins and/or synthetic peptides (compared to purified pro-
teins separated by electrophoresis used in Western blotting) are
alternatives to Western blot assays.
Resistance testing is recommended for patients with acute or
chronic HIV infection prior to initiating therapy (including
treatment-naïve pregnant HIV-1-infected women), virologic
failure during combination drug therapy, and suboptimal sup-
pression of viral load after initiating therapy.
B. Epstein-Barr Virus
Epstein-Barr virus is a cause of mononucleosis and lymphopro-
liferative disease in immunocompromised patients.
Table XIV-1. Laboratory Diagnosis of Human Immunodeficiency
Virus (HIV)










Plasmaa RT, <2 h




















Plasmaa,b EDTA, RT, <2 h
HIV-1 proviral DNA,
qualitativec




HIV-1 RNA and proviral
DNA, qualitative




Plasmaa EDTA, RT, <2 h
HIV-2 RNA and proviral
DNA, qualitatived
Whole blooda EDTA, RT, <2 h
Abbreviation: RT, room temperature.
a Do not transport in plasma preparation tube. The specimen should be
collected in a lavender top (EDTA) tube.
bMethods used for quantification of HIV RNA include target amplification (eg,
reverse transcriptase polymerase chain reaction, transcription-mediated
amplification, and nucleic acid sequence-based amplification) and signal
amplification (eg, branched DNA) assays.
c Plasma should be promptly removed from cells after collection to prevent
leakage of proviral DNA from cells. Since PCR does not differentiate plasma
virion RNA from proviral DNA, leakage of proviral DNA from cells may result in
falsely elevated plasma HIV RNA viral load. Signal amplification assays (eg,
branched DNA assays) are not similarly affected.
d Consider HIV-2 in those with a clinical status suggestive of AIDS but a
nonreactive HIV-1 immunoassay result, discordant results between an HIV-1
and HIV-1/HIV-2 immunoassays, a reactive HIV-1/HIV-2 immunoassay result
with a negative or indeterminate HIV-1 Western blot assay, or confirmed HIV
infection by undetectable off-treatment HIV-1 viral load.
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An elevated white blood cell count with an increased per-
centage of atypical lymphocytes is common in EBV-associated
mononucleosis. Heterophile antibodies usually become detect-
able between the sixth and tenth day following symptom onset,
increase through the second or third week of the illness and,
thereafter, gradually decline over a year or longer. False-positive
results may be found in patients with leukemia, pancreatic car-
cinoma, viral hepatitis, CMV infection, etc. False-negative
results are obtained in approximately 10% of patients, and are
especially common in children younger than 10 years.
When rapid Monospot or heterophile test results are nega-
tive, additional laboratory testing (Table XIV-2) may be consid-
ered to differentiate EBV infection from a mononucleosis-like
illness caused by CMV, adenovirus, HIV, Toxoplasma gondii,
etc. In this situation, EBV antibody testing for IgG and IgM to
viral capsid antigen (VCA) and Epstein-Barr nuclear antigen
(EBNA) are recommended. The presence of VCA IgM (with or
without VCA IgG) antibodies in the absence of antibodies to
EBNA indicates recent primary infection with EBV. The pres-
ence of EBNA antibodies indicates infection more than 6 weeks
from the time of the sample and therefore not likely implicating
EBV as a cause. Antibodies to EBNA develop one to two or
more months after primary infection and are detectable for life.
Over 90% of the normal adult population has IgG class anti-
bodies to VCA and EBNA antigens, although approximately
5%–10% of patients who have been infected with EBV fail to
develop antibodies to the EBNA antigen.
EBV is associated with lymphoproliferative disease in pa-
tients with congenital or acquired immunodeficiency, including
patients with severe combined immunodeficiency, recipients of
organ or peripheral blood stem cell transplants, and patients in-
fected with HIV. Increases in EBV viral load detected by NAAT
in peripheral blood may be present in patients before the devel-
opment of EBV-associated lymphoproliferative disease; these
levels typically decrease with effective therapy. Tissues from pa-
tients with EBV-associated lymphoproliferative disease may
show monoclonal, oligoclonal, or polyclonal lesions. The diag-
nosis of EBV-associated lymphoproliferative disease requires
demonstration of EBV DNA, RNA or protein in biopsy tissue.
NAAT may be used to detect EBV DNA in CSF of patients
with acquired immunodeficiency syndrome-related central
nervous system lymphoma, however EBV DNA may also be
present in cerebrospinal fluid with other abnormalities (eg,
central nervous system toxoplasmosis, pyogenic brain abscess-
es) and therefore positivity is nonspecific. Detection of anti-
body in CSF may indicate central nervous system infection,
blood contamination, or transfer of antibodies across the
blood-brain barrier. Calculation of the CSF to serum antibody
index may be helpful.
C. Cytomegalovirus
In immunocompetent individuals suspected of having acute
CMV infection, testing for CMV-specific antibodies is recom-
mended as the first line laboratory diagnostic test (Table XIV-
3). In the immunocompetent host, the presence of IgM class
antibodies indicates recent infection; however, false positive
CMV IgM results may occur in patients infected with EBV or
with activated immune systems due to other causes. The pres-
ence of IgG antibodies alone indicates past exposure to CMV.












Serum Clot tube, RT,
<2 h





Serum Clot tube, RT, <2
h














Cerebrospinal fluid Sterile tube, RT,
<2 h
Abbreviations: EBV, Epstein-Barr virus; IgG, immunoglobulin G; IgM,
immunoglobulin M; NAAT, nucleic acid amplification test; RT, room
temperature.








Serology Serum Clot tube, RT, <2 h














Plasma, whole blood EDTA anticoagulant
tube, RT, <2 h











Culture Urine Sterile container, RT,
<2 h
Abbreviation: RT, room temperature.
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In recipients of organ or peripheral blood stem cell trans-
plants, CMV viral load by NAAT or antigenemia (performed
by fewer laboratories as NAATs gain favor) is used as a marker
for preemptive therapy, to diagnose CMV-associated signs and
symptoms, and to monitor response to antiviral therapy. Stan-
dard Reference Material (SRM) is available from the National
Institute of Standards and Technology (NIST) for CMV viral
load measurement. SRM 2366, which consists of a bacterial ar-
tificial chromosome that contains the genome of the Towne
strain of CMV, is used for assignment of the number of amplifi-
able genome copies of CMV/volume (eg, copies/microliter).
Cytomegalovirus can be cultured from peripheral blood
mononuclear cells (and other clinical specimens). However,
isolation is labor-intensive and can take up to 14 days; the
waiting time can be shortened to 1–2 days with the use of the
shell vial assay. In addition to a long turnaround time, culture-
based assays have poor sensitivity. Because viral load is typically
high and CMV is shed in the urine of newborns, urine culture
for CMV continues to be used at some institutions for the diag-
nosis of congenital CMV infection.
Cytomegalovirus antigens can be demonstrated by immuno-
histochemical or in situ hybridization tests of formalin-fixed,
paraffin-embedded tissues. Cytomegalovirus DNA, detected
using NAAT in a variety of clinical specimens, may be useful in
diagnosing CMV disease.
Among immunocompromised patients with CMV infection,
the potential exists for the emergence of resistance to antiviral
agents. A variety of assays can be used to assess antiviral resis-
tance; most commonly sequencing of UL97 (phosphotransfer-
ase gene) with or without UL54 (DNA polymerase gene) is
utilized in such situations. Sequencing-based assays are per-
formed on DNA amplified directly from clinical specimens,
provided they contain a sufficient quantity of CMV DNA. Alter-
natively, the virus can first be isolated in cell culture. Ganciclovir
resistance most commonly emerges due to point mutations or de-
letions in UL97 (with foscarnet and cidofovir unaffected) with
mutations at three codons (460, 594, 595) being most common.
UL54 point mutations or deletions occur less frequently. If UL54
mutations are selected by ganciclovir or cidofovir, there is typical-
ly cross-resistance to both ganciclovir and cidofovir but not fos-
carnet; but if mutations are selected by foscarnet, there is usually
no cross-resistance to ganciclovir or cidofovir.
NAATs may be used to detect CMV DNA in CSF of patients
with suspected CMV-central nervous system infection, but
false positive results may occur (eg, in patients with bacterial
meningitis in whom CMV DNA in blood crosses the inflamed
blood-brain barrier and contaminates cerebrospinal fluid). De-
tection of antibody in cerebrospinal fluid may indicate central
nervous system infection, blood contamination, or transfer of
antibodies across the blood-brain barrier. Calculation of the
CSF to serum CMV antibody index may be helpful.
D. Varicella-Zoster Virus
The presence of VZV IgG and IgM typically indicates recent in-
fection with VZV; however, these results may also be observed
in patients with recent immunization to VZV. A positive VZV
IgG with a negative VZV IgM result indicates previous expo-
sure to VZV and/or response to vaccination. A negative IgG
result coupled with a negative IgM result indicates the absence
of prior exposure to VZV and no immunity, but does not rule
out VZV infection, as the specimen may have been drawn
before the appearance of detectable antibodies. Negative results
in suspected early VZV infection should be followed by testing
a new serum specimen in two to three weeks.
The most sensitive and specific test for diagnosis of VZV-
associated skin lesions is NAAT (Table XIV-4). A culture trans-
port swab is vigorously rubbed on the base of the suspect skin
lesion; the vesicle may be unroofed to expose the base. A less
sensitive method for diagnosis is detection of viral antigens by
direct fluorescent antibody stain of lesion scrapings. VZV
culture is not recommended since this virus is difficult to grow
in routine cell lines and may take two weeks to isolate (unless
using shell vial assay). Suspected VZV-associated skin lesions
must be clinically differentiated from smallpox as described in
the algorithm developed by the Centers for Disease Control
and Prevention (http://www.bt.cdc.gov/agent/smallpox/diagnosis/
riskalgorithm/index.asp); information about laboratory testing
for smallpox is available at http://www.bt.cdc.gov/agent/smallpox/
lab-testing.
VZV NAATs can be performed on CSF as an aid to the diag-
nosis of VZV central nervous system infection. CSF IgM or in-
trathecal antibody synthesis distinguishes meningoencephalitis
from a post-infectious immune-mediated process.
E. Herpes Simplex Virus
The presence of IgG antibodies specific to the glycoprotein G
antigen from HSV type 1 or 2 indicates previous exposure to








Serology Serum Clot tube, RT, <2 h











Vesicle fluid on slide Place in sterile
container, RT, <2 h
Abbreviations: NAAT, nucleic acid amplification test; RT, room temperature.
a M4 or M5 media acceptable; do not use calcium alginate-tipped swab, swab
with wood shaft, or transport swab containing gel.
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the corresponding serotype of the virus. Positive IgG results do
not differentiate past from current, active infection unless sero-
conversion is determined by testing, in parallel, acute and con-
valescent phase specimens. A fourfold increase in IgG results
may also suggest recent exposure; however, most commercial
assays no longer yield a titered result that can be used quantita-
tively. The presence of IgM antibodies to HSV suggests active,
primary infection with this virus.
NAAT is the most sensitive, specific and rapid test for diag-
nosis of HSV-associated skin or mucosal lesions and should
detect and distinguish HSV types 1 and 2 (Table XIV-5). A
viral culture transport swab is vigorously rubbed over the base
of the suspect skin or mucosal lesion; the vesicle may be un-
roofed to expose the base. Older, dried and scabbed lesions are
less likely to yield positive results. Culture and direct fluores-
cent antibody testing are less sensitive than NAATs.
HSV NAATs performed on CSF are used to diagnose HSV
central nervous system disease [229]. The assay should detect
and distinguish HSV types 1 and 2; type 1 is most commonly
associated with encephalitis and type 2 with meningitis. Viral
culture of cerebrospinal fluid is insensitive for diagnosis of
HSV central nervous system disease.
F. Human Herpes Virus-6
Human herpes virus-6 causes roseola infantum in children and
can cause primary or reactivation infection in immunocompro-
mised patients. IgG seroconversion, the demonstration of anti-
HHV-6 IgM, or a four-fold rise in IgG antibodies from paired
sera may indicate recent infection with HHV-6. Commercial
assays do not typically distinguish between variants A and
B. Because of the ubiquitous nature of HHV-6, most people
have been exposed to the virus by two years of age. Therefore, a
single HHV-6 IgG serologic test result may not be clinically rel-
evant. Five percent of asymptomatic adults may be IgM positive
at any given time.
The most commonly used molecular test for the laboratory
diagnosis of HHV-6 is NAAT (none FDA-cleared), some
formats of which differentiate variants A and B (Table XIV-6).
NAAT does not differentiate replicating from latent virus.
HHV-6 DNA quantification may be useful in this regard, as
well as in monitoring response to antiviral therapy. HHV-6
may be shed intermittently by healthy and immunocompro-
mised hosts. Therefore detection of HHV-6 in blood, body
fluids or even tissue does not definitively establish a diagnosis
of disease caused by HHV-6. Chromosomally integrated HHV-
6, which results in high HHV-6 levels in whole blood, may lead
to an erroneous diagnosis of active infection. HHV-6 can be
cultured from peripheral blood mononuclear cells (and other
clinical specimens) [230]. However, viral isolation is labor-
intensive, taking up to 21 days; the detection time can be short-
ened to 1–3 days with the shell vial culture assay. In addition to
a long processing time, culture-based assays suffer from poor
sensitivity and do not differentiate between variants A and
B. HHV-6 antigens can be demonstrated by immunohisto-
chemical or in situ hybridization tests in formalin-fixed, paraf-
fin-embedded tissues.
G. Parvovirus (Erythrovirus) B19
In immunocompetent individuals with erythema infectiosum
or arthralgia/arthritis, testing for parvovirus (erythrovirus)
B19-specific antibodies is recommended as the first line lab-
oratory diagnostic method for parvovirus B19 infection
(Table XIV-7). The presence of IgM class antibodies suggests
recent infection. IgM antibodies can be detected 10 to 14 days
post infection and may persist for five months, and occasionally
even longer [231]. IgG and IgM reach peak titers within one








Serology Serum Clot tube, RT, <2 h











Vesicle fluid on slide Place in sterile
container
RT, <2 h






RT or on wet ice,
<2 h
Abbreviations: NAAT, nucleic acid amplification test; RT, room temperature.
a M4 or M5 media acceptable; do not use calcium alginate-tipped swab,
wooden shaft swab, or transport swab containing gel.







Serology Serum Clot tube, RT, <2 h
NAAT Serum Serum: Clot tube RT, <2 h
Plasma Plasma or whole blood:
EDTA tube, RT, <2 hWhole blood
Peripheral blood
mononuclear cells
Saliva Sterile container, RT, <2 h
Cerebrospinal fluid Sterile container, RT, <2 h
Abbreviations: NAAT, nucleic acid amplification test; RT, room temperature.
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month. IgG antibodies may persist for years. The presence of
IgG antibodies alone is indicative of past exposure and suggests
immunity; this test may be helpful for women in the first tri-
mester of pregnancy. Serologic tests may be negative in the im-
munocompromised host despite prior exposure to the virus.
Parvovirus B19 DNA-based assays may be used for the diag-
nosis of parvovirus B19 infection presenting as transient aplas-
tic crisis or chronic anemia in immunosuppressed patients.
NAAT is the most sensitive noninvasive technique for the labo-
ratory diagnosis of parvovirus B19-related anemia in solid
organ transplant recipients, although current tests are laborato-
ry-validated and not FDA-cleared. A caveat regarding NAAT
for diagnosis of parvovirus B19-related anemia is that parvovi-
rus B19 DNA has been anecdotally detected for extended
periods in serum, even in healthy individuals. The presence of
giant pronormoblasts in bone marrow is suggestive of parvovi-
rus B19 infection, although such cells are not always detected.
H. Measles (Rubeola) Virus
Individuals who are immune to measles should yield a positive
result for IgG antibody to the virus. Those who are not immune
have negative IgG and IgM results. Recent infection with measles
virus is typically indicated by a positive IgM antibody result in
the absence of IgG. IgM is often positive on the day of onset of
rash; however, in the first 72 hours after rash onset, up to 20% of
tests for IgM may be falsely negative. Therefore, if the acute IgM
is negative, a second serum specimen, collected 72 hours after
rash onset, should be tested for IgM. IgM is detectable for a
month or longer after rash onset. IgMmay be positive in individ-
uals with recent immunization to measles virus. A serologic di-
agnosis of acute measles requires demonstration of a four-fold
rise in IgG antibody titer (Table XIV-8). Two serum specimens
are collected, with the first specimen being obtained as soon as
possible after rash onset, and the second specimen being collect-
ed 10 to 30 days later; both should then be tested concurrently
by the same method. Criteria for documenting an increase in
titer depend on the specific test used.
Measurement of measles-specific antibodies in CSF is used
in the diagnosis of subacute sclerosing panencephalitis (SSPE);
levels of rubeola antibody are highly elevated in the cerebrospi-
nal fluid of SSPE patients compared to those without the
disease.
Measles virus can be isolated from throat or nasopharyngeal
swabs or urine. Specimens should be collected soon after rash
onset. NAAT also can be considered as a diagnostic test op-
tion [232].
1Place the swab in viral transport medium, cell culture
medium or other sterile isotonic solution (eg, saline).
I. Mumps Virus
Several types of tests are used for mumps diagnosis
(Table XIV-9). Laboratory criteria for the diagnosis of mumps
include a positive serologic test for mumps IgM antibody, a
four-fold rise in serum mumps IgG antibody levels between
acute- and convalescent-phase paired sera, isolation of mumps
virus from clinical samples, or detection of mumps RNA in a
clinical specimen.
Sera for acute phase IgG testing should be collected within 5
days after symptom onset (ie, at the time of diagnosis); conva-
lescent sera should be collected approximately two weeks after
symptom onset. IgM antibodies typically become detectable
during the first few days of illness and reach a peak about a
week after onset. Receipt of one or more doses of the mumps
vaccine may result in an absent, delayed or transient IgM re-
sponse. If the acute IgM is negative, a second specimen should
be collected for IgM testing 2–3 weeks after onset of symptoms.










Bone marrow Sterile container, RT, <2 h
Formalin container, RT, 2
h–24 h
Serology Serum Clot tube, RT, <2 h




Plasma or whole blood:
EDTA tube, RT, <2 h
Abbreviations: NAAT, nucleic acid amplification test; RT, room temperature.







Serology Serum Clot tube, RT, <2 h
Cerebrospinal fluid Sterile tube, RT, <2 h




Viral transport media, RT or
on wet ice, <2 h
Blood EDTA, RT, <2 h
Cerebrospinal fluid Sterile tube, RT, <2 h
NAAT Oropharyngeal swab,
oral fluid
Sterile container, RT, <2 h
Urine Sterile container, RT, <2 h
Blood EDTA tube, RT, <2 h
Cerebrospinal fluid Sterile tube, RT, <2 h
Abbreviations: NAAT, nucleic acid amplification test; RT, room temperature.
a Place the swab in viral transport medium, cell culture medium or other sterile
isotonic solution (eg, saline).
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Among previously immunized suspected cases, mumps virus
detection is a particularly important method of confirming the
case. The preferred sample for viral isolation is a swab from the
parotid duct, or from the duct of another affected salivary
gland. Mumps virus can also be detected by molecular tech-
niques (no FDA-cleared tests) [233]. Mumps viral RNA may be
detected prior to onset of parotitis until five to nine days after
onset.
Detection of antibody in CSF may indicate central nervous
system infection, blood contamination, or transfer of antibodies
across the blood brain barrier. Calculation of the CSF to serum
antibody index to mumps virus may be helpful.
J. Rubella Virus
Serology is the most common method of confirming the diag-
nosis of rubella (Table XIV-10). The presence of antibodies to
rubella virus in a single serum specimen is evidence of immuni-
ty. Acute rubella infection can be serologically confirmed by a
four-fold rise in rubella IgG antibody titer between acute and
convalescent serum specimens or by the presence of serum
rubella IgM. If testing is performed, serum should be collected
as early as possible (within 7 to 10 days) after onset of illness,
and again 14 to 21 days (minimum of 7) days later. Caution
should be taken in interpreting positive rubella IgM results, as
false positive results can occur. Rubella is no longer endemic in
the United States; therefore, IgM testing should only be per-
formed in patients with a clinical presentation suggestive of
acute rubella. Prenatal screening for rubella immunity should
only be performed using an IgG-based assay.
K. BK Virus
BK virus causes allograft nephropathy in renal transplant recip-
ients, a definitive diagnosis of which requires renal allograft
biopsy with in situ hybridization for BK virus. BK virus may
also cause hemorrhagic cystitis, especially in stem cell trans-
plant recipients.
Detection of certain levels of BK viral load by NAAT in
plasma may provide an early indication of allograft nephropa-
thy, although there are no FDA-cleared NAATs (Table XIV-11)
[234]. Urine cytology or quantitative NAAT may be used as a
screening test, followed by BK viral load testing by NAAT, if
positive. Urine NAAT for BK virus may be more sensitive than
urine decoy cell (virus-infected cells shed from the tubules or
urinary tract epithelium) detection; BK virus DNA may be
present earlier in the urine than are decoy cells. However,
urinary shedding of BK virus is a common occurrence; if used
as a screening test, only high levels (ie, above a laboratory estab-
lished threshold that correlates with disease) should be consid-
ered significant. Urine testing for BK virus places the laboratory
at risk for specimen cross-contamination as extremely high
levels of virus in the urine may lead to carryover between speci-
mens and false positive results.
L. JC Virus
JC virus is the etiologic agent of progressive multifocal leu-
koencephalopathy (PML), an often fatal demyelinating disease of
the central nervous system that occurs in immunocompromised







Serology Serum Clot tube, RT, <2 h
Cerebrospinal fluid Sterile tube, RT, <2 h
Culture Parotid (Stensen’s) duct/
buccal swaba
Sterile container, RT but




Cerebrospinal fluid Sterile tube, RT but best on
wet ice, <2 h
NAAT Parotid gland duct/buccal
swaba




Viral transport medium, RT,
<2 h
Cerebrospinal fluid Sterile tube, RT, <2 h
Abbreviations: NAAT, nucleic acid amplification test; RT, room temperature.
a Massage parotid gland for 30 seconds and then swab parotid (Stensen’s)
duct using a viral culture transport swab.
b Place the swab in viral transport medium, cell culture medium or other sterile
isotonic solution (eg, saline).







Serology Serum Clot tube, RT, <2 h
Abbreviation: RT, room temperature.







Urine cytology Urine’ 100 mL urine in 250 mL clear plastic
collection bottle containing 50 mL
of 2% carbowax solution
(Saccomanno’s fixative) or
alternative fixative 50% ethyl





Plasma EDTA tube, RT, <2 h
Serum Clot tube, RT, <2 h
Urine Sterile container, RT, <2 h
Abbreviations: NAAT, nucleic acid amplification test; RT, room temperature.
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hosts. Histologic examination of brain biopsy tissue reveals
characteristic pathologic changes. In situ hybridization for JC
virus may be performed on brain tissue. Detection of JC virus
DNA by NAAT in CSF specimens of patients with suspected
progressive multifocal leukoencephalopathy has largely re-
placed the need for tissue biopsy for laboratory diagnosis
(Table XIV-12).
M. Dengue Virus
Dengue is a mosquito-borne febrile illness. In travelers from
certain areas, Chikungunya and yellow fever should be consid-
ered in the differential diagnosis, along with malaria. Dengue
diagnosis requires laboratory confirmation by culture, NAAT
or testing for dengue specific antibodies (Table XIV-13) [235].
Serologic testing represents the most common method for diag-
nosis of dengue infection. An acute-phase serum specimen
should be collected within five days after onset of fever. Patients
in the early stage of dengue fever virus infection may not have
detectable IgG antibodies; IgG antibodies typically take at least
six days after onset of symptoms to develop. IgG antibodies to
dengue may persist for decades. If a negative test result is re-
ported for a patient for whom dengue fever is strongly suspect-
ed, a second serum specimen should be drawn 7 to 10 days
after disease onset and tested for IgM and IgG antibodies.
While detection of dengue IgM may indicate recent infection,
seroconversion of dengue IgG should also be demonstrated to
confirm the diagnosis. Tests for anti-dengue antibodies may
detect antibodies to other flaviviruses, including West Nile and
St. Louis encephalitis viruses. Molecular testing for dengue
virus is available upon special request from the Centers for
Disease Control and Prevention and selected reference labora-
tories.
N. Hepatitis AVirus
Diagnosis of acute hepatitis A virus infection is confirmed by
detecting hepatitis A-specific IgM antibodies (Table XIV-14).
The presence of hepatitis A virus-specific total antibodies (ie,
IgM and IgG combined) in an asymptomatic patient with
normal liver tests indicates either past hepatitis A infection or
immunity to this viral infection from vaccination. Currently,
there is no commercially available laboratory test for detecting
only hepatitis A-specific IgG antibodies.
O. Hepatitis B, D, and C Viruses
Hepatitis B surface antigen may be detected in the presence of
acute or chronic hepatitis B virus infection [236]; it indicates
that the person is infectious. In acute infection, its appearance
predates clinical symptoms by four weeks and it remains de-
tectable for one to six weeks. The tests for hepatitis B and D
disease detection are primarily serologic and molecular
(Table XIV-15). Check with the laboratory about minimum
volumes of blood needed, as some molecular platforms require
more blood than others.
The presence of hepatitis B surface antibodies indicates re-
covery from and immunity to hepatitis B infection, as a result
of either natural infection or vaccination. In most patients with
self-limited acute hepatitis B infection, hepatitis B surface
antigen and antibodies are not detectable simultaneously in
serum or plasma.
Hepatitis B core IgM antibodies appear during acute or
recent hepatitis B virus infection and remain detectable for
about six months. A serologic “window” occurs when hepatitis
B surface antigen disappears and hepatitis B surface antibody is
undetectable. During this “window” period, infection can be di-
agnosed by detecting hepatitis B core IgM antibodies, which
can remain detectable for up to six months.
Hepatitis B core total antibodies appear at the onset of symp-
toms of acute hepatitis B infection and persist for life; their
presence indicates acute (mainly virus-specific IgM antibodies),
recent (both hepatitis B core-specific IgM and IgG antibodies),









Sterile tube, RT, <2 h
Abbreviations: NAAT, nucleic acid amplification test; RT, room temperature.







Serology Serum Clot tube, RT, <2 h
Culture Serum Clot tube, RT, <2 h
NAAT Serum Clot tube, RT, <2 h
Plasma EDTA tube, RT, <2 h
Cerebrospinal
fluid
Sterile tube, RT, <2 h
Abbreviations: NAAT, nucleic acid amplification test; RT, room temperature.













Plasma EDTA tube, RT, <2 h
Abbreviation: RT, room temperature.
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or previous (hepatitis B core-specific IgG antibodies) hepatitis
B infection.
A chronic hepatitis B virus carrier state is defined by persis-
tence of hepatitis B surface antigen for at least 20 weeks. In pa-
tients with chronic hepatitis B infection, the presence of
hepatitis B e antigen in serum or plasma is a marker of high
viral replication levels in the liver. Loss of hepatitis B e antigen
and emergence of antibody to hepatitis B e antigen is usually
associated with improvement of underlying hepatitis and a re-
duction in the risk of hepatocellular carcinoma and cirrhosis.
Alternatively, disappearance of hepatitis B e antigen may
denote the emergence of a precore mutant virus; high concen-
trations of HBsAg and HBV DNA, in the absence of hepatitis B
e antigen and presence of antibody to hepatitis B e antigen
suggest the presence of a precore mutant virus. Hepatitis B viral
DNA is present in serum or plasma in acute and chronic hepa-
titis B infection [237]. Quantification of hepatitis B viral DNA
(by PCR or branched-DNA assay methods) may be included in
the initial evaluation and management of chronic hepatitis B
infection, especially when deciding treatment initiation and
monitoring patient’s response to therapy. Other molecular lab-
oratory tests used in the diagnosis and management of hepatitis
B infection have been reviewed and include assays for
determining viral genotype, detection of genotypic drug resis-
tance mutations, and core promoter/precore mutations [237].
Detection of hepatitis B surface antibodies in the absence of
hepatitis B core total antibodies distinguishes vaccine-mediated
immunity from immunity acquired by natural infection (in
which hepatitis B surface and hepatitis B core total antibodies
are both present). Current commercially available assays for de-
tecting hepatitis B surface antibody yield positive results (quali-
tative) for antibody levels of ≥10 mIU/mL in serum or plasma,
indicating post-vaccination immunity (protective antibody
level). Quantitative hepatitis B surface antibody results are used
to monitor adequacy of hepatitis B immune globulin therapy in
liver transplant recipients receiving such therapy during the
post-transplant period.
In acute hepatitis D superinfection of a patient with known
chronic hepatitis B, hepatitis D antigen, hepatitis D-specific
IgM and total antibodies are present (Table XIV-15). In acute
hepatitis B and D co-infection, the same serologic markers (ie,
hepatitis D antigen, hepatitis D-specific IgM and total antibod-
ies) are present, along with hepatitis B core IgM antibodies.
The diagnosis of HCV usually begins with a screening test
for HCV-specific IgG antibodies using EIA or chemilumines-
cent immunoassay (CIA). Antibodies may not be detectable,
however, until six to ten weeks after the onset of clinical illness.
Individuals with negative screening test results do not need
further testing for HCV (Table XIV-16). Those with positive
screening test results should undergo confirmatory or supple-
mental testing for HCV RNA by molecular test methods.
Signal-to-cut-off ratios (calculated by dividing the optical
density value of the sample tested by the optical density value
of the assay cut-off for that run) are an alternative to supple-
mental testing (http://www.cdc.gov/hepatitis/HCV/LabTesting.
htm). Hepatitis C virus RNA can be detected by NAATs soon
after infection as well as in chronic infection. NAAT for HCV
can be performed qualitatively (by reverse-transcription PCR
or transcription-mediated amplification) or quantitatively (by
reverse-transcription PCR or branched DNA). Prior to and
during treatment, quantification of HCV RNA (by PCR or
branched-DNA assay methods) is necessary to monitor rapid
and early virologic response to antiviral therapy, while qualita-
tive or quantitative HCV RNA detection is used to determine
end-of-therapy and sustained virologic response to therapy.
The recombinant immunoblot assay (RIBA) has similar sen-
sitivity to, but higher specificity than, screening tests, and was
formerly used as a confirmatory test in patients with a positive
screening antibody test for HCV. Patients with a positive
screening test but negative RIBA results are considered not to
have HCV infection (ie, falsely reactive screening test). Positive
RIBA results (≥ two bands present) are indicative of chronic or
resolved HCV infection, whereas those with a single band de-
tected are considered indeterminate. Hepatitis C virus







Hepatitis B surface antigen
(HBsAg)
Serum Clot tube, RT,
<2 h
Plasma EDTA, RT, <2 hHepatitis B surface
antibody (anti-HBs)
Hepatitis B core total
antibodies (anti-HBc
total)
Hepatitis B core IgM
antibody (anti-HBc IgM)
Hepatitis B e antigen
(HBeAg)
Hepatitis B e antibody (anti-
HBe)
Hepatitis D total antibodies
(anti-HDV total)
Hepatitis D IgM antibody
(anti-HDV IgM)
Hepatitis D IgG antibody
(anti-HDV IgG)
Hepatitis D antigen
Hepatitis B virus DNA
quantification (viral load)
Abbreviations: IgG, immunoglobulin G; IgM, immunoglobulin M; RT, room
temperature.
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genotyping is used to guide the choice and duration of antiviral
therapy and predict the likelihood of response to therapy, as
different genotypes have varying susceptibilities to current
treatment regimens.
A human genomic polymorphism interleukin-28B (IL-28B)
genotype CC (within an interferon gamma promoter region), is
associated with increased likelihood of sustained viral response
in individuals with chronic hepatitis C virus infection undergo-
ing treatment with pegylated interferon and ribavirin, and has
strong predictive value for spontaneous resolution of infection.
The Centers for Disease Control and Prevention has recently
recommended that adults born during 1945 and 1965 receive
one-time testing for hepatitis C virus.
P. Enterovirus and Parechovirus
The enteroviruses that most often cause meningitis include
certain echovirus and coxsackievirus serotypes and enterovirus-
es 70 and 71. NAAT of CSF is more sensitive than culture for
the diagnosis of enteroviral central nervous system infection
(Table XIV-17). Plasma or serum is useful for diagnosis of
sepsis syndrome of the newborn due to enterovirus, but testing
is less reliable outside of the newborn period. In the right clini-
cal scenario, recovery of enterovirus from throat or stool may
provide circumstantial etiologic evidence of central nervous
system infection.
Serologic evaluation involves assessment of acute and conva-
lescent titers, and is not typically useful in real-time clinical
practice.
Parechoviruses have clinical presentations similar to entero-
viruses, but are classified as a different genus and require a spe-
cific NAAT (laboratory validated only, no FDA-cleared tests)
for detection.
1A commercial FDA-cleared product is available for rapid
PCR testing for enteroviruses in CSF.
Q. Respiratory Syncytial Virus
Respiratory syncytial virus causes bronchiolitis and/or pneu-
monia and is most common in infants and young children, al-
though it can present in older individuals and cause severe
disease in the immunocompromised. It is ideally detected by
NAAT testing of secretions obtained by washing, suctioning, or
swabbing the nasopharynx (Table XIV-18). Several FDA-
cleared NAAT platforms exist. Culture is more time-consuming
and less sensitive.
The presence of IgG generally indicates past exposure and
immunity. The presence of IgM class antibodies or a 4-fold or
greater rise in IgG titer between acute and convalescent sera
suggests recent infection.
R. Influenza Virus Infection
Rapid diagnosis of influenza virus infection (≤48 hours follow-
ing the onset of symptoms) is needed to facilitate early admin-
istration of antiviral therapy. The virus may be rapidly detected
by NAAT or direct antigen detection from nasopharyngeal
swabs (Table XIV-19). Sensitivity is higher for NAAT than
rapid antigen detection. Rapid screening tests may perform
poorly during influenza season (especially for detection of pan-
demic H1N1 and swine-associated H3N2 strains) and negative
tests may need to be confirmed by NAAT or culture. During
seasons of low prevalence of influenza, false positive tests are
more likely to occur with rapid screening procedures. Perfor-
mance of influenza assays varies depending on the assay and
the circulating strains. NAAT is now considered the gold










Sterile tube, RT, <2 h
Serum Clot tube, RT, <2 h
Plasma (Blood is
less reliable)
EDTA tube, RT, <2 h
Urine Sterile container, RT, <2 h
Culture Throat Sterile container or viral
transport medium, RT,
<2 h
Stool Sterile container, RT, <2 h
Plasma (Blood is
less reliable)
EDTA tube, RT, <2 h
Abbreviations: NAAT, nucleic acid amplification test; RT, room temperature.
a A commercial FDA-cleared product is available for rapid PCR testing for
enteroviruses in CSF.







HCV IgG antibody (anti-
HCV IgG) screen











Abbreviations: IgG, immunoglobulin G; IgM, immunoglobulin M; RT, room
temperature.
e106 • CID 2013:57 (15 August) • Baron et al
standard for detection of influenza virus in clinical samples.
Several FDA-cleared NAAT platforms exist.
Serologic evaluation involves assessment of acute and conva-
lescent titers, but is not typically useful in real-time clinical
practice.
S. West Nile Virus
West Nile virus (and Eastern equine, Western equine, Saint
Louis and California encephalitis viruses) cause central nervous
system infections.
The laboratory diagnosis of West Nile virus is typically accom-
plished by detecting virus-specific IgM antibodies in serum
(Table XIV-20). West Nile virus IgM antibodies may persist in
serum for ≥6 months and false positive results may occur follow-
ing recent yellow fever immunization or natural infection with
other flaviviruses (eg, dengue, Saint Louis encephalitis). Acute (3–
10 days after symptom onset) and convalescent (2–3 weeks later)
serum for IgG serology may also be helpful. Positive antibody
titers to West Nile virus are commonly present in older individu-
als, especially those from the Indian subcontinent (who presum-
ably have been exposed to flaviviruses during their lifetimes).
Therefore in patients where the pretest probability of infection
with West Nile virus is low, the presence of West Nile virus anti-
bodies in plasma or serum should be interpreted cautiously.
Serologic diagnosis of West Nile virus central nervous system
infection is based on assessing the CSF to serum antibody
index or the detection of West Nile virus IgM in cerebrospinal
fluid. However, detection of antibody in cerebrospinal fluid
may indicate central nervous system infection, blood contami-
nation, or transfer of antibodies across the blood-brain barrier.
West Nile virus NAAT is insensitive in immunocompetent
hosts, but more sensitive in immunocompromised hosts. Viremia
typically drops to levels that may be undetectable by NAAT at the
time of symptom onset. West Nile Virus NAAT testing is insensi-
tive for central nervous system disease. Viral culture may be avail-
able in specialized laboratories but is also insensitive.
Eastern and Western equine, Saint Louis and California en-
cephalitis virus infection may be diagnosed serologically fol-
lowing the same strategy used for West Nile virus.
T. Adenovirus
In otherwise healthy individuals, adenoviruses usually cause
mild, self-limiting respiratory illnesses with most cases being
Table XIV-20. Laboratory Diagnosis of West Nile Virus (and








Serology Serum Clot tube, RT, <2 h
NAAT Cerebrospinal
fluid
Sterile tube, RT, <2 h
Serum Clot tube, RT, <2 h
Plasma EDTA tube, RT, <2 h
Abbreviations: NAAT, nucleic acid amplification test; RT, room temperature.














































Serology (IgM and IgG) Serum Clot tube, RT, <2 h
Abbreviations: IgG, immunoglobulin G; IgM, immunoglobulin M; NAAT,
nucleic acid amplification test; RT, room temperature.
a Commercial products are available for rapid PCR testing for respiratory
viruses.




















Sterile container or viral
transport medium, RT
or ideally on wet ice,
<2 h
Serology Serum Clot tube, RT, <2 h





Sterile container or viral
transport medium,
RT, <2 h
Abbreviations: NAAT, nucleic acid amplification test; RT, room temperature.
a Commercial products are available for rapid NAAT testing for respiratory
viruses
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diagnosed on clinical grounds alone. Occasionally, adenovirus
infections in immunocompetent hosts can be deadly, especially
in children with asthma. In immunocompromised patients,
adenoviruses may cause pneumonia, disseminated infection,
gastroenteritis, hemorrhagic cystitis, meningoencephalitis,
hepatitis, etc.
Diagnosis is based on NAAT, culture and/or compatible his-
topathology (Table XIV-21). Viral culture has a long turn-
around time but is reduced if using shell vial technology.
Plasma viral load (assessed by quantitative NAAT) may be
useful as a marker for preemptive therapy, to diagnose adenovi-
rus-associated signs and symptoms, and to monitor response to
antiviral therapy in some immunocompromised populations.
Serologic testing relies on demonstration of antibodies to
group-specific antigens, and often requires analysis of acute
and convalescent sera. Serologic diagnosis of central nervous
system infection is based on CSF to serum antibody index,
four-fold rise in acute to convalescent IgG titer, or a single posi-
tive IgM. Detection of antibody in CSF may indicate central
nervous system infection, blood contamination, or transfer of
antibodies across the blood-brain barrier.
U. Rabies Virus
Rabies virus infects the central nervous system and is most
often transmitted through the bite of a rabid animal. State
Health Departments should be consulted immediately in cases
of suspected rabies.
No single test is sufficient to diagnose rabies ante-mortem
(Table XIV-22). Testing is performed on samples of saliva,
serum, spinal fluid and skin biopsies of hair follicles at the nape
of the neck. Saliva and CSF may be tested by culture and NAAT
(laboratory-validated). Serum and CSF may be tested for anti-
bodies to rabies virus. Skin biopsy specimens may be examined
for rabies antigen in the cutaneous nerves at the base of hair folli-
cles. Histopathologic evaluation and direct fluorescent antibody
testing of brain biopsy material are helpful, if available.
Serologic testing may be used to document post-vaccination
seroconversion in the immunocompromised, if there is signifi-
cant deviation from a prophylaxis schedule or if an individual
initiated treatment internationally with a non-cell culture
vaccine.
V. Lymphocytic Choriomeningitis Virus
Lymphocytic choriomeningitis virus is a rodent-borne virus
that can cause meningoencephalitis and may be life-threatening
in immunosuppressed persons. Serologic diagnosis is based on
a four-fold rise in acute to convalescent IgG titer, or a single
positive IgM (Table XIV-23). Detection of antibody in CSF
may indicate central nervous system infection, blood contami-
nation, or transfer of antibodies across blood-brain barrier; CSF
to serum antibody index may be helpful in interpreting CSF an-
tibody results.










































Serology Serum Clot tube, RT, <2 h
Cerebrospinal fluid Sterile tube, RT,
<2 h
Abbreviations: NAAT, nucleic acid amplification test; RT, room temperature.













Sterile container, RT, <2 h
Serology Serum Clot tube, RT, <2 h
Cerebrospinal
fluid
Sterile tube, RT, <2 h
Abbreviations: NAAT, nucleic acid amplification test; RT, room temperature.








Serology (IgG, IgM) Serum Clot tube, RT, <2 h
Cerebrospinal
fluid
Sterile tube, RT, <2 h
Abbreviations: IgG, immunoglobulin G; IgM, immunoglobulin M; RT, room
temperature.
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XV. BLOODAND TISSUE PARASITE
INFECTIONS
Blood and tissue parasites comprise a large number of protozoa
and helminths found in tropical and temperate climates world-
wide [238]. Certain parasites cause infections with associated
high morbidity and mortality (eg malaria, amebic encephalitis)
while others may cause mild or asymptomatic disease (eg filaria-
sis due to Mansonella spp, toxoplasmosis in immunocompetent
adults). As expected, the most commonly submitted specimens
for laboratory identification of these parasites are whole blood,
tissue aspirates/biopsies, and serum for serologic studies.
Microscopy remains the cornerstone of laboratory testing for
the diagnosis of most blood and tissue parasitic infections [239,
240]. Expert microscopic examination of Giemsa stained thick
and thin peripheral blood films is used for detection and identi-
fication of the protozoan blood parasites Plasmodium, Babesia,
and Trypanosoma, and the filarial nematodes, Brugia, Wu-
chereria, and Mansonella, whereas microscopic examination
and/or culture of ulcer samples, bone marrow, tissue aspirates,
and biopsies are useful in the diagnosis of African trypanoso-
miasis, onchocerciasis, trichinosis, toxoplasmosis, and leish-
maniasis. Although requiring a minimal amount of reagents
and equipment, the accuracy of microscopic methods requires
well-trained and experienced technologists. Even in the best
hands, diagnosis may be hampered by sparseness of organisms
on the slide and the subjective nature of differentiating similar
appearing organisms (Plasmodium vs. Babesia; various microfi-
lariae) or in identifying the species of Plasmodium present. The
laboratory can enhance the sensitivity of these methods by em-
ploying a number of concentration procedures such as buffy
coat examination, centrifugation, and filtration. In all of these
procedures, samples must be properly obtained, transported to
the laboratory as quickly as possible and processed in a timely
fashion to preserve organism viability and/or morphology.
Serologic assays for detection of antibodies are available as
adjunctive methods for the diagnosis of a number of blood and
tissue parasite infections. Unfortunately, none are sensitive or
specific enough to be used to establish the diagnosis on their
own. In particular, assays for infection with one helminth will
often cross-react with antibodies to a different helminth [239].
When available, antibody titers may be used to determine the
strength of the immune response or detect a trend in antibody
levels over time. Indirect fluorescent antibody assays (IFA) can
provide quantitative titer results but reading the slides is subjec-
tive and inherently prone to varying results. In contrast, EIAs
typically provide only qualitative positive or negative results de-
termined by an arbitrarily set breakpoint. Thus, clinicians will
not be able to determine if a positive result was a very strong
positive or a very weak one without calling the laboratory for
more information. This can have important implications for
interpretation of results which are not entirely consistent with
the clinical picture.
Laboratory methods that detect parasite antigens and/or
DNA provide an attractive alternative to traditional morpho-
logic and serologic techniques. For example, a simple rapid
immunochromatographic card assay for the detection of Plas-
modium has recently been approved by the FDA [241, 242]. It
may find use in acute care settings such as emergency depart-
ments (EDs) or out-patient clinics to establish a diagnosis of
malaria quickly while awaiting results of confirmatory blood
films. This assay is adequately sensitive in typical patients with
symptomatic malaria (“fever and chills”) but loses sensitivity if
the parasitemia is very low or infection is due to non-falciparum
species [241]. This is especially important in nonendemic set-
tings such as the U.S. where patients often present with low
parasitemia.
Finally, the Centers for Disease Control and Prevention
(CDC) and a number of reference laboratories in the U. S. and
Canada perform extremely sensitive nucleic acid detection
methods such as real-time PCR assays for certain blood and
tissue parasites, including Plasmodium, Babesia, Toxoplasma,
and the agents of amebic encephalitis. Clinicians should
consult their microbiology laboratory to determine if their ref-
erence laboratory or other entity offers the desired testing. Mo-
lecular assays may be of particular use in patients with very low
parasitemias or in specifically identifying organisms that
cannot be differentiated microscopically. However, DNA may
persist for days or weeks after successful treatment and detec-
tion does not necessarily correlate with the presence of viable
organisms. In addition, the current restriction to the reference
laboratory setting means that the time from specimen collec-
tion to receipt of result may be longer than desired for optimal
patient care. In situations where infection is potentially life
threatening, empiric treatment should be considered while
awaiting results from the outside laboratory.
Key points for the laboratory diagnosis of blood and tissue par-
asites:
• Microscopy is the cornerstone of laboratory identification
but is highly subjective and dependent on technologist experi-
ence and training.
• Proper specimen collection and transport are essential
components of morphology and culture based techniques.
• Serology shows significant cross-reactivity among hel-
minths, including filaria.
• There are a limited number of antigen detection methods
available for blood and tissue parasites in the United States.
• Automated hematology analyzers may fail to detect
malaria or babesiosis parasites; request manual evaluation if
either agent is suspected.
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Table XV-1. Laboratory Diagnosis of Blood and Tissue Parasitic Infectionsa,b
Disease/Organism Main Diagnostic Tests Remarks





Microscopy and culture of CSF or brain tissue Specimens for culture should not be
refrigerated. Balamuthia mandrillaris does
not grow on standard agar (requires
specialized cell-culture).
PCR from unfixed tissue or CSF is available from
the CDC. Stained and unstained tissue slides
may also be sent.
Angiostrongyliasis and
Gnathostomiasis
Serology from CDC or Faculty of Tropical
Medicine, Mahidol University, Bangkok
Thailand (http://www.tm.mahidol.ac.th/en/
special)
In eosinophilic meningitis, larvae may be rarely
seen in CSF. Larvae may also be seen in




B. duncani and Babesia
spp MO-1 strain
Microscopy of Giemsa stained thick and thin
blood films
Most commercially available NAAT assays
detect B. microti only. Serology does not
distinguish between acute and past infection.Real time PCR available from CDC and
reference labs.
Baylisascaris Encephalitis Serology from the CDC Division of Parasitic
Diseases, Parasite Serology Laboratory
Turnaround time can be long.




Serology from the CDC or referral laboratories.
Cross-reactivity may be observed between
tests for either organism.
Serology is confirmatory to radiologic and scan
studies.
Encysted larvae and/or hooklets can be seen in
tissue biopsies or aspirates of cysts
(echinococcosis).
Filariasis due to species of
Wuchereria, Brugia, and
Mansonella
Microscopy of Giemsa stained thick and thin
blood films. Examination of concentrated
blood specimens (Knott’s, Nuclepore filtered
blood or buffy coat) increases sensitivity.
Antibody and/or antigen detection EIA
(Wuchereria bancrofti and Brugia malayi) in
blood by the CDC or reference lab
Blood films forW. bancrofti and B. malayi
should be collected at night when
microfilariae are circulating. Repeat exams
may be necessary due to low parasitemia.





Microscopy of “skin snip” after incubation in
saline at 37°C [243]
“Skin snips” should be from areas near
nodules and should be “razor thin”with
no visible blood. Histopathologic
examination of skin biopsy or resected nodule
(onchocercoma) can identify microfilariae and/
or adults. Serology available from reference





Microscopic exam of Giemsa stained smears of
biopsy touch impressions or aspirate from
leading edge of ulcer; culture may be available
using special media (NNN and others)
Histopathology of leading edge ulcer biopsies is
less sensitive than impression smears.
PCR and isoenzyme analysis are available at the
CDC for speciation, which may be important
for treatment considerations [244]




Microscopic exam of Giemsa stained bone
marrow aspirate/biopsy, splenic aspirate;
culture may be available using special media
(NNN and others). Contact laboratory for
availability of special media.
Positive rK39 serology reported to be both
sensitive and specific for the diagnosis of
visceral leishmaniasis in various endemic
areas of the world.
Serology from the CDC or reference laboratory
[244]
Malaria due to Plasmodium
falciparum, P. ovale,
P. vivax, P. malariae,
P. knowlesi
Microscopy of Giemsa stained thick and thin
blood films (3 sets obtained during febrile
episodes); antigen (HR-2, aldolase, pLDH)
detection tests (BinaxNow is FDA approved in
US)
Antigen strip tests lack sensitivity in low
parasitemia and non-falciparummalaria
and do not differentiate all species.
NAAT from some reference laboratories will
detect and differentiate all species.
Toxocariasis (visceral larva
migrans)
Serology from CDC or referral laboratories Larvae may be seen in histopathologic sections
of biopsies of liver or other infected tissues.Histopathology
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• NAATs are useful for detection of low parasitemia or in
specifically identifying organisms which cannot be differentiat-
ed microscopically.
• NAATs should not be used to monitor response to
therapy, since DNA may be detectable for days to weeks after
successful treatment.
• Nucleic acid detection of blood and tissue parasites is
currently available only from specialized laboratories and turn-
around time may be prolonged.
Table XV-1 presents an inclusive overview of the approach
to the diagnosis of blood and tissue parasitic infections [238–
240]. Important points are bolded. Subsequent sections A and
B provide more detailed information on the diagnosis of para-
sitic infections which are of particular concern to practitioners
in North America (babesiosis and American trypanosomiasis)
or in which rapid and accurate diagnosis is crucial because of
the life-threatening nature of the infection (malaria and babe-
siosis). With all testing, it is important to note that results are
only as reliable as the experience, resources, and expertise of
the laboratory performing the tests. In general, large public
health laboratories such as those of the CDC and World Health
Organization (WHO) are more likely than commercial labora-
tories to have the experience and volume of specimens to prop-
erly validate the more esoteric tests, while turnaround time for
results is often faster with commercial reference labs. Direct
communication by phone or e-mail will sometimes hasten
specimen processing and result reporting from public health
Table XV-1 continued.
Disease/Organism Main Diagnostic Tests Remarks
Toxoplasmosis due to
Toxoplasma gondii
Serology (IFA, EIA, enzyme linked fluorescent
assay) from CDC or reference laboratory for
detection of IgM and IgG; Positive IgG seen
in up to 15% to 40% of US population due
to previous exposure. IgG avidity test and
serial titers may distinguish between recent
and past infection.
Cysts and tachyzoites can be seen in specimens
from immunocompromised patients (eg
bronchoalveolar lavage, brain biopsy).





Serology (EIA) from the CDC or reference
laboratory [245]
Encysted larvae can be seen in histopathologic







T. b. rhodesiense (East
African)
Microscopy of Giemsa stained thick and thin
blood films or buffy coat preps. Parasitemia
is often low, requiring repeated exams.
Centrifuged CSF may be examined but
organisms are rarely seen. Aspirates of
chancres and lymph nodes may also be
examined. There is an infection hazard
from live organisms in blood specimens.
[246, 247]
Morula cells of Mott (plasma cells with large
eosinophilic antibody globules) may be seen
in CSF and brain biopsy. Card agglutination
test for trypanosomiasis (CATT) is available in
endemic settings for detection of
T. b. gambiense infection. Contact the CDC or
Parasite Diagnosis Unit, (Prince Leopold
Institute of Tropical Medicine, Antwerp,
Belgium Phone: +32 3 247.66.66 - Fax: +32 3






Microscopy of Giemsa stained thick and thin
blood films or buffy coat preps.
Parasitemia is very low in chronic infection.
IgG antibody may persist for decades and its
presence is considered evidence of chronic
infection.
Serology available for donor and diagnostic
testing.
An FDA-approved test is available for screening
blood donors and is different from the test
used for diagnostic purposes.Culture of blood may be available using special
media (NNN and others). Contact the
laboratory for availability of special media.
There is an infection hazard from live
organism in blood specimens [246, 248, 249].
Abbreviations: HRP2, histidine rich protein 2; IFA, immunofluorescence assay; NIH, National Institutes of Health; NAAT, nucleic acid amplification test; NNN, Novy-
MacNeal-Nicolle medium; PCR, polymerase chain reaction.
a
“CDC” refers to the Division of Parasitic Diseases at the Centers for Disease Control and Prevention, Atlanta GA, (770) 488-4431. Central Telephone for the CDC:
(404) 639-3311 and web: http://www.cdc.gov/ or http://www.dpd.cdc.gov/dpdx/.
b
“Reference Laboratories” refers to any laboratory that performs esoteric testing not usually done in routine hospital labs; examples include Toxoplasma
Serology Laboratory (http://www.pamf.org/serology/); 650-853-4828, ARUP (800) 522-2787), FOCUS Diagnostics ((703) 480-2500), and Mayo Medical Laboratories
(800-533-1710). All have their own web sites.
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laboratories, especially when there is an urgent clinical situa-
tion. The DPDx website at CDC (http://www.dpd.cdc.gov/
dpdx/HTML/DiagnosticProcedures.htm) provides a list of cur-
rently available diagnostic tests for parasitic infections available
from the CDC. The CDC also provides a valuable consultation
service that can be accessed through the DPDx website for both
the laboratorian and clinician. The availability of rapid ship-
ping methods (FedEx, UPS, etc.) and e-mail or other electronic
communication allow reporting of results from specialty labo-
ratories, including those in Europe and Asia, in surprisingly
short periods of time. It is useful to obtain shipping informa-
tion from such laboratories to avoid unnecessary delays because
of customs or airline regulations or other delivery problems.
A. Babesia and Malaria
Babesiosis is caused primarily by Babesia microti in the U.S.
and B. divergens in Europe. More recently, a small number of
infections occurring in California and Washington have been
attributed to B. duncani, while an unnamed species (MO-1
strain) has been detected from a fatal case in Missouri. Malaria
is caused by Plasmodium falciparum, P. vivax, P. ovale,
P. malariae, and P. knowlesi; the latter is primarily a simian
parasite in Southeast Asia which has recently been recognized
in an increasing number of human patients. Table XV-2 sum-
marizes the laboratory tests available for these agents.
The standard method for diagnosis of both parasites is mi-
croscopic examination of Giemsa stained thick and thin blood
films. Although this method requires a minimum amount of
resources (staining materials and high quality microscopes),
well trained and experienced technologists must be available to
obtain maximum accuracy and efficiency [250]. Because both
babesiosis and malaria are serious infections which can pro-
gress to fatal outcomes if not diagnosed and treated accurately,
it is necessary for health care facilities to have ready access to
rapid accurate laboratory testing. Ideally, samples are obtained
from fresh capillary (or venous) blood and slides are prepared
immediately. However, it is typically more practical to obtain
EDTA (preferred) or heparin anticoagulated blood and trans-
port the sample to the laboratory for slide preparation.
Thick blood films are essentially lysed concentrates which
allow rapid detection of the presence of parasites consistent
with either Plasmodium or Babesia but generally do not allow
definitive identification. The thick film is made using 2–3 drops
of blood that have been “laked” (lysed) by placement into a hy-
potonic staining solution. This releases the intracellular para-
sites and allows for examination of multiple (20–30) layers of
blood simultaneously. For this reason, it is the most sensitive
method for microscopic screening and allows detection of very
low levels of parasitemia (less than 0.001% of RBCs infected).
In contrast, the thin films are prepared like a hematology pe-
ripheral smear and are fixed in ethanol before staining. Fixation
retains the structure of the RBCs and intraerythrocytic parasites
and provides ideal morphology for Plasmodium speciation. It
also allows for optimal evaluation and differentiation of
malaria from Babesia parasites, although the different Babesia
species cannot be distinguished from one another by morphol-
ogy alone. Staining is best performed with Giemsa at a pH of
7.2 to highlight the microscopic features of the parasites.
Wright-Giemsa and rapid field stains are also acceptable.
Both thick and thin films should be screened manually, since
automated hematology analyzers may fail to detect Plasmodium
and Babesia species parasites. The slides should first be screened
at low power (100 times final magnification) for identification of
larger microfilariae, followed by examination under oil immer-
sion. The laboratorian should examine a minimum of 300 micro-
scopic fields at 500 to 1000 times total magnification on the thick
and thin films before reporting a specimen as negative. It is im-
portant to remember that Babesia and Plasmodiummay at times
be indistinguishable on blood films and that both can be trans-
mitted by transfusion so each can occur in atypical clinical set-
tings. Clinical and epidemiologic information must be
considered and additional testing may be required.
If parasites are identified and the laboratory does not have
expertise for species identification, then a preliminary diagnosis
of “Plasmodium or Babesia parasites” should be made, followed
by confirmatory testing at a reference lab. In this situation, the
primary laboratory should relay the message to the clinical
team that the deadly parasite, P. falciparum, cannot be excluded
from consideration. Repeat blood samples (3 or more speci-
mens drawn during febrile episodes) are indicated if the initial
film is negative, and malaria or babesiosis is strongly suspected.
When Plasmodium species are identified, one can enumerate
the number of infected RBCs and divide by the total number of
RBCs counted to arrive at the percent parasitemia. This is best
determined by using the thin film. Quantification can also be
performed using the thick film, but this method is less precise.
Quantification may be used to guide initial treatment decisions
and to follow a patient’s progress during treatment.
An alternative to Giemsa-stained blood films for morpholog-
ic examination is the Quantitative Buffy Coat (QBC) method.
This test detects fluorescently stained parasites within RBCs
and requires specialized equipment. It acquires maximum effi-
ciency for the laboratory if multiple specimens are being pro-
cessed at the same time which is seldom the case in
U. S. laboratories. In addition it requires preparation of a thin
blood smear if a QBC sample is positive, since specific identifi-
cation and rate of parasitemia will still need to be determined
by the latter method. For these reasons, the QBC method is
seldom used in the U.S. at this time.
Although morphologic examination is the conventional
method for diagnosis of malaria, it requires considerable time
and expertise. Rapid antigen detection tests (RDTs) for malaria
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provide cost effective, rapid alternatives and can be used for
screening when qualified technologists are not available. The Bi-
naxNow rapid diagnostic test has recently been approved by the
FDA. It is a rapid immunochromatographic card (or “dipstick”)
assay which requires no specialized equipment or special training
for qualified technologists. This RDT uses monoclonal antibod-
ies to detect the HRP-2 antigen of P. falciparum and an aldolase
common to all species of Plasmodium. Positive RDTs should be
confirmed by examination of thick and thin blood films which
are also necessary to determine which species other than P. fal-
ciparum (if the assay is aldolase positive but HRP-2 negative) is
present and to determine the rate of parasitemia.
This RDT is somewhat less sensitive than a thick blood film
and may be falsely negative in cases with very low rates of para-
sitemia. However, the sensitivity is comparable to blood smear
in symptomatic malaria patients with P. falciparum infection.
In addition, RDTs may be falsely positive for several days after
eradication of intact parasites, since antigens may still be de-
tected. Therefore, the assay should not be used to follow pa-
tients after adequate therapy has been given. The RDT should
not be viewed as a replacement for blood films but rather as a
substitute in situations where reliable blood films will not be
readily available (off hours in the laboratory when skilled per-
sonnel are not available) or when the clinical situation is critical
and an immediate diagnosis is required (stat laboratory in the
emergency department). Such RDT testing should be followed
as soon as possible by good quality thick and thin blood films.
Serology plays little role in diagnosis of acute babesiosis and
malaria, since antibodies may not appear early in infection and
titers may be too low to determine the status of infection. The
primary use of antibody detection is for epidemiologic studies
and as evidence of previous or relapsing infection. Indirect im-
munofluorescent antibody (IFA) is the most readily available
commercial assay for Babesia (Focus Diagnostics, Cypress CA,
Table XV-2. Laboratory Diagnosis of Babesiosis and Malaria Infection








Drop of blood from finger stick or
venipuncture needle placed directly
on glass slides and blood films
made immediately
Slides should be made from blood
within 1 h. If transport time is
longer, thick and thin blood
should be made at bedside but
blood in EDTA tube may be
refrigerated. Prolonged
exposure to EDTA can alter
parasite morphology.
2–4 h
Thick blood films dry slowly and
should be protected from





Buffy coat concentrate of RBCs from
venous blood in acridine orange
containing capillary tubes
QBC concentrates and slides
should be made from blood







Rapid Diagnostic Test or
RDT)
Drop of blood from finger stick or
venipuncture needle placed directly
on RDT test pad
Test should be performed as soon
as possible but blood may be
stored at 2°–30°C for up to 3 d
for some commercial assays
15–30 min
Serologic detection of
antibody to B. microti
and Plasmodium spp
1.0 mL of serum from clotted blood
tube
Serum should be separated from
blood within several hours.
Store serum refrigerated or
frozen if not tested within 4–6 h
to preserve antibody and
prevent bacterial growth. Avoid
use of hyperlipemic or
hemolyzed blood.
4–6 h
NAAT Typically 1.0 mL venipuncture blood
in EDTA tube
Test should be performed as soon
as possible but blood may be
transported refrigerated if
storage will be >48 h
1–2 h
Abbreviations: NAAT,nucleic acid amplification test; RBC, red blood cell; TAT, turnaround time.
a Transportation time is not included in this estimate.
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and other reference laboratories). IgM titers ≥1:16 and IgG
titers ≥1:1024 indicate acute infection as does a 4-fold rise in
titer. IgG titers of 1:64–1:512 with negative IgM and no titer
rises in serial specimens suggests previous infection or expo-
sure. There is insufficient evidence for use in diagnosis of
B. divergens, B. duncani, or MO-1 infections. Serology for Plas-
modium spp is available through CDC.
Rapid NAAT assays have recently been developed for
malaria and babesiosis and are available from some commercial
reference laboratories and the CDC although none are FDA-
cleared. These methods are comparable in sensitivity to the
thick blood film and require no specialized parasitologic exper-
tise. NAATs may be useful in accurate diagnosis of acute infec-
tion if blood films are negative or difficult to obtain and in the
differentiation of malaria parasites from Babesia or nonparasit-
ic artifacts. Finally, NAAT may provide diagnostic confirmation
in cases empirically treated without prior laboratory diagnosis
by detection of remnant nucleic acid. Because residual DNA
can be detected days (or even weeks to months in asplenic
persons) after intact parasites have been eradicated, NAATs
should not be used to monitor response to therapy. When a
NAAT is positive for Plasmodium or Babesia parasites, thin
blood films must still be examined to determine the percent
parasitemia.
It is important to stress that requests for malaria and babe-
siosis diagnosis should be considered “STAT” and testing per-
formed as rapidly as possible. NAAT assays may be rapid but
are limited to the reference laboratory setting, and the total
turnaround time will be too long to enable rapid institution of
antimalarial therapy. In such cases, the primary use of NAATs
is for confirmation of infection, assistance in species identifica-
tion, and differentiation of malaria from Babesia.
B. American Trypanosomiasis or Chagas Disease Caused by
Trypanosoma cruzi
American trypanosomiasis may consist of acute, latent, and
chronic phases, and the optimal diagnostic method differs with
each stage. The standard method for diagnosis of American
trypanosomiasis during the acute phase of infection (4–8 weeks
in length) is microscopy of Giemsa stained thick and thin
blood or buffy coat films, since extracellular trypanosomes will
be present at this time (Table XV-3). As with blood films for
malaria and Babesia, a minimum amount of resources (staining
materials and high quality microscopes), as well as proficient
Table XV-3. Laboratory Diagnosis of Trypanosomes
Diagnostic Procedures Optimum Specimen Transport Considerations
Estimated
TATa
Microscopy of Giemsa stained
thick and thin peripheral blood
films in fresh and stained
preparations.
Drop of blood from finger stick or
venipuncture needle placed directly on
glass slides and blood films made
immediately
Slides and wet preps should be made
from blood within 1 h. If transport time
is longer, blood films should be made




Buffy coat concentrate from
anticoagulated venous blood in EDTA
tube (thin smear or fresh wet prep for
motile organisms)
Thick blood films dry slowly and should
be protected from inadvertent
smearing or spillage and dust.
Microscopic examination of tissue
aspirates/biopsies by Giemsa/
hematoxylin & eosin (H&E)
stains
Fluid from needle aspirate of enlarged
lymph nodes or tissue biopsies from
lymph nodes, skin lesions, heart, GI
tract or other organ
Fresh aspirated fluid should be stained
and examined as soon as possible,
preferably within one hour of sampling.
2 h–3 d
Tissues may require 1–2 d of fixation
before staining and examination.




laboratory for availability of
special media.
Anticoagulated blood or buffy coat, tissue
aspirates, and tissue biopsies
Fresh specimens should be inoculated
into culture medium as soon as
possible, preferably within 1 h of
collection for preservation of organism
viability.
2–6 d
Serology 1.0 mL of serum from clotted blood.
Plasma is also acceptable for the Ortho
donor test.
Serum or plasma should be separated
from blood within several hours. Store
serum refrigerated or frozen if not
tested within 4–6 h to preserve
antibody and prevent bacterial growth.
Avoid use of hyperlipemic or
hemolyzed blood.
1 d
Abbreviations: GI, gastrointestinal; TAT, turnaround time.
a Turnaround timewithin laboratory; transportation time is not included in this estimate.
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and experienced technologists, must be available to obtain
maximum accuracy and efficiency. On stained preparations, the
motile trypomastigote forms typically adopt a “C” shape and
can be differentiated from the similar appearing trypomasti-
gotes of T. brucei by the presence in T. cruzi of a large posterior
kinetoplast. In comparison, the kinetoplast of T. brucei trypo-
mastigotes is much smaller. Of course, these infections can also
be likely differentiated on epidemiologic grounds. Motile or-
ganisms can also be observed in fresh wet preparations of anti-
coagulated blood or buffy coat although most U.S. labs are
unfamiliar with this method. Unfortunately, infection is rarely
diagnosed in the acute stage since only 1%–2% of infected indi-
viduals present with symptoms during this time period.
Microscopy is less useful during the latent and chronic stages
of infection when rates of parasitemia are very low. The di-
agnosis in these stages may be established serologically or by
microscopic examination of tissue aspirates or biopsies. The
nonmotile (amastigote) intracellular form of T. cruzi predomi-
nates during this phase of the infection. Culture in easily pre-
pared Novy-MacNeal-Nicolle medium (NNN) or similar
media of any appropriate blood or tissue specimen during the
acute and chronic stages will add to the sensitivity of laboratory
diagnosis. The laboratory should be contacted to assure the
availability of special media. It must be emphasized that live
trypanosomes are highly infectious and specimens must be
handled with care using “standard precautions.” for the han-
dling of blood and body fluids.
Serology by commercially available enzyme-linked immuno-
assay (ELISA) kits is of greatest use during the latent and
chronic stages of disease when parasites are no longer easily de-
tected in peripheral blood preparations by microscopy. Positive
ELISA results are considered evidence of active infection and
would exclude potential blood/tissue donors who test positive
from acting as donors, since the infection has been shown to be
transmitted by transfusion and transplantation. A somewhat
unusual situation has developed for serologic testing for Ameri-
can trypanosomiasis where the FDA has approved two com-
mercial assays for blood or organ donor screening and a
different commercial assay for patient diagnostic testing. Each
assay cannot be used for the nonapproved purpose even though
they are supposed to be detecting the same antibodies. An
ELISA (Ortho-Clinical Diagnostics, Raritan, NJ) and an auto-
mated method (Abbott Prism Chagas, Abbott Park, IL) have
been approved for blood, organ, cell, and tissue donor screen-
ing whereas a different ELISA test (Hemagen Diagnostics, Co-
lumbia, Md) is approved for diagnostic testing. Donor
screening test positives may be tested by an FDA approved sup-
plemental test (ABBOTT ESA Chagas) and/or submitted to a
reference laboratory for confirmatory testing by a radioimmu-
noprecipitation assay (RIPA). The Hemagen assay measures
IgG and does not require confirmatory testing. Both ELISAs
provide only qualitative positive or negative results without in-
formation regarding antibody titer.
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